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ABSTRACT 
 Replication of HIV-1 requires the assembly and release of mature and 
infectious viral particles.  In order to accomplish this goal, HIV-1 has evolved 
multiple methods to interact with the host cell.  HIV-1 recruits the host cell 
ESCRT machinery to facilitate the release of nascent viral particles from the host 
cell membrane.  Recruitment of these cellular factors is dependent on the 
presence of short motifs in Gag referred to as Late-domains.  Deletion or 
mutation of these domains results in substantial decrease in the release of 
infectious virions.  However, previously published work has indicated that over-
expression of the E3 ubiquitin ligase, NEDD4.2s is able to robustly rescue 
release of otherwise budding-defective HIV-1 particles.  This rescue is specific to 
the NEDD4.2s isoform as related E3 ubiquitin ligases display no ability to rescue 
particle release.  In addition, rescue of particle release is dependent on the 
presence of the partial C2 domain and a catalytically active HECT domain of 
NEDD4.2s.  Here I provide evidence supporting the hypothesis that a partial C2 
domain of NEDD4.2s constitutes a Gag interacting module capable of targeting 
the HECT domains of other E3 ubiquitin ligases to HIV-1 Gag.  Also, by 
generating chimeras between HECT domains shown to form poly-ubiquitin 
chains linked through either K48 or K63 of ubiquitin, I demonstrate that the ability 
of NEDD4.2s to catalyze the formation of K63-polyubiquitin chains is required for 
its stimulation of HIV-1 L-domain mutant particle release.  In addition, I present 
findings from on-going research into the role of the HIV-1 accessory protein Nef 
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during viral replication using the culture T-cell line, MOLT3.  My current findings 
indicate that downregulation of CD4 from the host cell membrane does not solely 
account for the dramatic dependence of HIV-1 replication on Nef expression in 
this system.  In addition, I present evidence indicating that Nef proteins from 
diverse HIV-1 Groups and strains are capable of enhancing HIV-1 replication in 
this system.  Analysis of a range of mutations in Nef known to impact interaction 
with cellular proteins suggest that the observed replication enhancement requires 
Nef targeting to the host cell membrane and may also require the ability to 
interact with select Src-kinases.  Lastly, we find that the ability of Nef to enhance 
replication in this system is separate from any increase in viral particle infectivity, 
in agreement with current literature. 
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CHAPTER I 
Rationale and Introduction 
Rationale and Objectives of Thesis Research 
Human Immunodeficiency Virus type I (HIV-1), the etiological agent of 
AIDS, is responsible for approximately 34 million current infections worldwide, 
and in 2010 contributed to the deaths of 1.8 million infected individuals (2011 
UNAIDS report).  While this figure is staggering, the number of AIDS related 
deaths has fallen in recent years due to improvements in antiretroviral therapies 
as well as increased dissemination of treatments.  However, this information is 
tempered by the fact that more than 2.7 million new infections were reported for 
the same year (2011 UNAIDS report).  This statistic, as well as the proven ability 
of HIV-1 to circumvent multiple retroviral treatments, highlights the continued 
need for scientific research in this field. Without pharmaceutical intervention to 
limit virus production, individuals infected with HIV-1 often develop Acquired 
Immune Deficiency Syndrome (AIDS) (205).  This disease is characterized by a 
decrease in CD4+ T-cells over the course of infection due to various cytopathic 
mechanisms, reducing the ability of the immune system to recognize and contain 
other pathogens, often resulting in opportunistic infection and death (205).  CD4+ 
T-cells are one of the earliest populations of cell affected, as they are the cells 
initially infected upon exposure to the virus, either through mucosal transfer or 
direct introduction of the virus into the blood stream through transfusion.  
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Depletion of CD4+ T-cells is the result of directed cell killing by cytotoxic T-
lymphocytes, increased levels of apoptosis in HIV-1 infected cells, and defective 
regeneration of new T-cells (205).  Additional cell types such dendritic cells and 
macrophages are also targeted by HIV-1 due to their expression of CD4 and the 
viral co-receptor, the chemokine receptor CCR5 (205).  During the course of 
infection, mutations in the viral envelope alter the cell preference from CCR5 
expressing cells to CD4+ cells that express CXCR4, an indicator of T-cell 
activation, further depleting the CD4+ T-cell population (57).  Ultimately, this 
attack on the CD4+ cells leaves the infected individual susceptible to 
opportunistic infections otherwise contained by a healthy immune system (205).  
 Symptomatically, the initial exposure to HIV-1 results in normal flu like 
symptoms as the immune system fights to keep the virus infection in check (205).  
During this time the first noticeable T-cell decrease is observed as infected cells 
are cleared by the immune system, or die due to virus-induced cytopathic effects 
(205).  Cells infected during this time may also return to a resting state as the 
viral genome enters a state of latency, where the viral genome has integrated 
into the host cell genome, but no active viral replication is detectable (274).  
These latently infected cells, containing an integrated but epigentically silenced 
viral genome, can serve as reservoirs for the virus, capable of replicating and 
releasing virus upon appropriate cell stimulation (142, 274).  Currently, no 
therapeutic intervention is available to clear these reservoirs. 
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 Current therapies are directed against the activity of the HIV-1 enzymes - 
reverse transcriptase, integrase and protease- each of which are necessary for 
HIV-1 replication (11).  However, due to the high mutation rate of the HIV-1 
genome, the virus has shown a remarkable ability to circumvent directed 
therapies (11).  Current treatment protocols call for a combination of drugs that 
target one or more of these enzymes simultaneously, but the regiment is difficult 
to maintain and can adversely affect patients, leading to discontinuation of 
treatment and return of high viral titers (11).  Thus, continued investigation into 
the replication cycle of HIV-1 may provide new targets for antiviral agents. 
While the devastation caused by the HIV-1 epidemic is clear, it must be 
remembered that the negative effects HIV-1 has on an infected individual are not 
the goal of the virus per se.  Although HIV-1 has debilitating effects on the host in 
terms of immune suppression, the virus evolved these mechanisms for one 
purpose, to enable it to replicate and infect new hosts/cells.  In truth, the virus 
exists solely to copy and transfer its genome to a new host; any other deleterious 
effects in the cell or host are corollary to this end. 
 In order to transfer its genome to another host, the virus must package it 
into a delivery system capable of protecting the genome and targeting it to 
another host.  HIV-1 has developed multiple strategies to not only create this 
delivery system, the virus particle, but to optimize the assembly, release and 
infectivity of the particle to maximal efficiency.  In doing so, HIV-1 has evolved to 
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utilize host cell machinery not just to transcribe and translate the viral genome, 
but also to shuttle viral proteins to assembly sites, create virus particles of the 
correct stoichiometry for release, and enhance the ability of these particles to be 
taken up by the next host (80, 283). 
 In this thesis I address several mechanisms by which HIV-1 interacts with 
the host cell to generate maximally infectious particles.  In the first chapter, I 
introduce general strategies that HIV-1 uses during the course of the viral 
replication cycle from initiation of transcription, trafficking of viral components and 
assembly of viral particles, to release and particle maturation.  In the second 
chapter, I discuss the role that the host cell Endosomal Sorting Complex 
Required for Transport (ESCRT) machinery plays in the release of viral particles 
from the host cell, with particular emphasis on my research investigating the 
mechanism of Nedd4 E3 ubiquitin ligases in rescuing the release of otherwise 
defective viruses.  Previously publications reported that over-expression of the 
NEDD4.2s E3 ubiquitin ligase demonstrated a specific ability to rescue the 
release of Late-domain deficient HIV-1 particles (56, 292).  The focus of my 
research was directed at investigating the role of NEDD4.2s in this release, o  
I then address on-going research into the role that the HIV-1 protein Nef 
plays in enhancing the infectivity and replication of HIV-1 in a specific cultured 
cell line.  Experiments performed in the Gottlinger lab previously demonstrated 
that HIV-1 replication in the MOLT3 cell line, a T-cell line derived from a leukemia 
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patient, is highly dependent on the expression of the lentiviral Nef proteins, in 
stark contrast to HIV-1 replication in other cultured T-cell lines as well as primary 
blood mononuclear cells (PBMCs).  The focus of on-going research is directed at 
determining the role that Nef plays in the replication of HIV-1 in this system, with 
the intent to identify a restriction factor present in these cells that maybe 
functionally counteracted by Nef.  Lastly I discuss how the activities of Nef and 
ESCRT recruitment by HIV-1 may perform similar function in the production of 
infectious viral particles. 
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INTRODUCTION 
 
Hiv-1 Virus and Replication Cycle 
 Replication and transmission of the HIV-1 genome requires timely and 
specific interactions with proteins and other components of the host cell.  In this 
chapter, I discuss several interactions between HIV-1 proteins and host cell 
factors that occur during the course of the HIV-1 replication cycle.  The HIV-1 
replication cycle can be divided into two distinct stages often referred to as the 
early and late events, which together compose the complete cycle.  The early 
events can be considered as those interactions between the components of the 
infecting virus particle and the host cell, and originate with the recognition of host 
cell CD4 by the virion, and end with integration of the viral genome into the 
genome of the host cell.  Those activities considered to be part of the late events 
of the replication cycle include interactions between viral proteins and the host 
cell required for the production of the mature viral particle.  These activities 
include, transcription of the viral genome, translation of viral proteins, processing 
of viral RNA, trafficking of viral particle components and genomes to the plasma 
membrane, assembly and release of the viral particle, and finally, maturation of 
the particle into an infectious virion. 
 A brief summary of the viral genome and proteins is necessary to provide 
an introduction into the relevant molecules discussed in more detail in the 
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following sections reviewing the early and late stages of replication. However, as 
the early events can be considered as interactions that occur between the virion 
and the host cell, an introduction into the morphology and components of the 
mature and infectious virus is also appropriate.   
 
Introduction to HIV-1: Viral Genome and Structure 
Mature HIV-1 virions average 145 nm in diameter and are characterized 
by multiple electron dense layers when visualized by electron microscopy 
(schematic Fig. 1.1) (33).  An electron dense ring of viral envelope supported by 
viral matrix protein (MA) can be seen, from which extend  8-10 trimers of the viral 
Env protein composed of non-covalently interacting gp120 and gp41 proteins 
(326).  The interior of the virus is dominated by another electron dense cone 
structure composed primarily of capsid (CA) proteins.  Biochemical studies have 
shown that this cone structure, referred to as the viral core, contains molecules of 
the viral proteins Vpr (33), Nef (151), and the HIV-1 integrase and reverse 
transcriptase enzymes, which are required by the virus for initiation of the next 
round of infection (33).  In addition, condensed within the viral core are two 
copies of the HIV-1 genome bound to the viral nucleocapsid protein (194). 
The HIV-1 genome consists of a single-strand positive sense RNA 
molecule of approximately 9kb, with two molecules being packaged into each 
virus (194).  This genome contains coding information for only 15 genes with  
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several arising from multiply spliced transcripts (Fig. 1.1, (82)). Each gene plays 
an important role during the course of the infection, and a partial summary of 
those roles is enumerated below. 
    
Introduction to HIV-1:Viral Proteins 
 Gag polyprotein:  The Gag polyprotein contains the structural proteins 
required to form a new virus particle.  Expression of Gag alone is sufficient to 
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produce non-infectious virus-like particles (VLP), indicating that all of the 
information required for virus formation is contained within the sequences of this 
protein (95).  The components of Gag (matrix-MA, capsid-CA, nucleocapsid-NC, 
p6 as well two spacer peptides SP1 and SP2 the flank the NC protein) are 
responsible for interaction with the host cell membrane, formation of higher order 
Gag multimers through self interaction, recruitment and packaging of the viral 
genome and recruitment of cellular factors involved in particle release (41, 67, 
68).  These components are cleaved by the HIV-1 protease to generate the 
subunit proteins that form the mature viral particle (283).     
 Gag-Pol polyprotein:  The Gag-Pol polyprotein arises from a -1 shift in the 
reading frame of Gag that occurs approximately once out of every 15 -20 
translation events (125).  Gag-Pol contains all of the enzymes required by the 
virus to reverse transcribe the viral RNA genome into DNA (Reverse 
Transcriptase-RT), and integrate the viral cDNA into the host cell genome 
(Integrase-IN). Also contained in this coding sequence is gene encoding the viral 
protease (PR), which is required to cleave the viral Gag structural proteins during 
particle maturation.  These enzymes, RT, IN and PR, are the primary targets for 
most current antiviral therapies (11).     
 Envelope glycoprotein:  HIV-1 envelope is responsible for initiating the 
next round of virus infection through recognition of CD4 and the chemokine 
receptors CCR5 and CXCR4.  Also transcribed as a polyprotein, the HIV-1 
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envelope glycoprotein (Env-gp160) is cleaved by cellular furin-like proteases 
during trafficking through the secretory system resulting in a membrane 
anchoring subunit, transmembrane –TM, referred to as gp41, as well as a 
surface exposed glycoprotein, SU-gp120 (48).  In addition, the HIV-1 envelope 
protein has also been shown to play a role in downregulating CD4 from the host 
cell surface, thus playing a role in preventing superinfection of the host cell and 
potentially enhancing particle infectivity (19, 312). 
 Tat: Transcription of the HIV-1 genome by cellular RNA polymerase II is 
one of the first rate-limiting steps to infection.  Basal levels of transcription from 
the promoters contained within the 5’ UTR of the integrated HIV-1 genome are 
inefficient due to cellular regulation of RNA Pol II (254).  However, Tat, one of the 
first viral gene products produced and absolutely required for replication, helps 
the virus overcome this limitation, by recruiting cellular transcription factors 
CycT1 and CDK9 to increase the processivity of the polymerase (254).  Tat 
interacts with a three dimensional motif found within the mRNA of the stalled 
transcript and helps to increase the processivity of Pol II, resulting in an increase 
of full length viral RNA (142). 
 Rev:  Similarly to Tat, the HIV-1 Rev protein is also essential for 
replication.  Full length viral RNA serves not only as a template for production of 
viral proteins, but is also required to be the genome of the progeny virions.  The 
Rev protein encoded by HIV-1 recognizes and binds to full-length RNA through a 
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region of the viral genome termed the Rev Response Element (RRE) and directs 
it, and other RRE containing viral mRNA out of the nucleus (26).  Levels of this 
protein play a role in determining the translation of other retroviral proteins that 
rely on interaction with Rev for nuclear export (142). 
 Accessory proteins (Vif, Vpr, and Vpu):  In addition to the structural and 
regulatory proteins listed above, HIV-1 encodes a series of other proteins which 
have been termed accessory, because they are not needed to productively infect 
most cultured cells.  However, in the natural targets of HIV-1, these proteins 
perform several necessary functions that assist in productive replication.  For 
instance, the Vif accessory protein protects the viral genome from cell directed 
mutation by counteracting a specific innate immune mechanism, the cytidine 
deaminase APOBEC3G which packages into viral particles and stimulates 
hypermutation of the package viral genome (103, 149).  The Vpr protein assists 
in targeting the viral genome to the nucleus of non-dividing cells following 
infection, and a role for G2 arrest has been proposed (103).  The protein Vpu 
disrupts multiple interactions between viral and cell host proteins that would 
otherwise impact particle infectivity and release, by down regulation cell surface 
tetherin and CD4 (103, 149).   
Nef:  An additional accessory protein, transcribed early in HIV-1 infection, 
is Nef, which performs a myriad of tasks throughout the course of replication.  A 
partial list of functions attributed to this protein include: 1) down-regulating of cell 
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surface molecules such as CD4 and MHC-I (80, 161); 2) lowering the threshold 
of activation of infected CD4+ T-cells (294); and 3) increasing the infectivity of 
viral particles (201).  This protein will be discussed in greater detail in Chapter III 
of this thesis.   
 
HIV-1 Replication Cycle  
 To appreciate the complexities of the interactions the HIV-1 makes with 
the host cell, it is necessary to provide background regarding the viral replication 
cycle.  The viral replication cycle can divided into two stages: the first stage 
encompasses the period from interaction of the virus with the host cell and 
culminates with the insertion of the viral genome into that of the host cell; the 
second stage is initiated by the transcription of the integrated viral genome 
ultimately resulting in the formation and release of the next round of virus.  These 
two stages are also referred to as the early and late events of HIV-1 replication. 
 
Viral infection-Early Events 
The early events of HIV-1 infection consists of interactions between the 
host cell and the invading HIV-1 virion (Fig. 1.2).  Infection of the target cell by 
HIV-1 can occur via two separate mechanisms: either virus-cell transmission or 
cell-cell transmission (50).  Infection of target cells from free-floating virus is 
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inefficient, and requires an infectious particle release from the producer cell into 
the extracellular space where it is exposed to immune cells and antibodies 
generated by the host’s adaptive immune system.  By contrast, cell-to-cell 
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transfer occurs when an infected cell makes physical contact with a target cell 
either through formation of filopodia, cytonemes, or nanotubes, and transmits 
virus directly to the uninfected cell (50).  Cell to cell transmission is suggested to 
be more efficient than virus to cell transfer as indicated by the results of one 
study that reported a 100-1,000 fold increase in transmission (70).  Regardless, 
both transmission methods are mediated by HIV-1 Env glycoproteins which 
recognize and bind to the CD4 receptor on the surface of the target cell (57).  
Interaction between the CD4 receptor and the Env protein occurs in a cleft within 
the globular head of the gp120 subunit, initiating a conformational change in the 
molecule that unmasks a CCR5 or CXCR4 co-receptor binding domain (48, 158). 
Reliance on CD4 and CCR5/CXCR4 receptors for infection limits the target 
population, at least initially, to cells of the immune system, specifically, CD4+ T-
helper cells, macrophages and dendritic cells (48).  Upon binding with the co-
receptor, the transmembrane gp41 subunit of Env inserts a hydrophobic fusion 
peptide into the plasma membrane of the target cell.  Structural rearrangements 
of a 6 heptad repeat bundle in gp41 serve to bring the viral envelope into close 
proximity with the cell membrane, and subsequently, fusion of the two 
membranes occurs (57).    
The infection scheme detailed above, fusion of the viral particle to the 
plasma membrane, has until recently, been believed to be the method used by 
HIV-1 to access target cells, based on previous studies reporting that 
endocytosis of virions fails to elicit productive infection (264). Several lines of 
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evidence support this belief.  For example, it has been shown that entry of HIV-1 
into target cells is a pH independent process, suggesting that viral entry via 
acidified endosomes is not required (192).  Additionally, cells in culture infected 
with HIV-1 virions are prone to fusion-from-without, a process that is the result of 
two cell membranes being fused together through a viral particle being held 
between them (58).  Also, the use of membrane impermeable recombinant 
peptides of the gp41 heptad repeat, which block formation of the heptad bundle 
required to bring the two membranes into apposition, inhibit virus-cell fusion and 
prevent delivery of the viral core into the cytoplasm of target cells (193).  Lastly, 
and most germane to this thesis,  the well characterized enhancement of 
infectivity observed when Nef is expressed in donor cells is obviated when 
particles are pseudotyped with an envelope that directs entry to endosomes (61, 
192, 238).  However, recent evidence provided by the Melikyan group strongly 
argues for an endosomal method of virus entry (66, 193).  Using a temperature 
block approach to retard endocytosis, they demonstrated that the HIV-1 envelope 
fuses with the plasma membrane without releasing contents of the viral particle 
into the cell, failing to productively infect the cell (66).  In a subsequent report, 
they also demonstrated fusion of the viral envelope with endosomal membranes 
in a dynamin-dependent manner by imaging fluorescently labeled endosomes 
and viral Gag proteins (193).  Lipid mixing at the endosome membrane was 
followed by deposition of the viral core into the cytoplasm, and resulted in 
productive infection (193).  Interestingly, they also reported no difference in entry 
16 
 
of HIV-1 variants regardless of Nef expression status, consistent with previous 
reports of a lack of Nef-stimulated entry enhancement with virus pseudotyped to 
enter cells via endocytosis.  However, as disease progression in infected 
individuals has been associated with a functional nef allele, it is unclear whether 
an endocytic route of entry is physiologically relevant or rather an interesting 
experimental finding.        
To replicate within the infected cell, the positive sense RNA genome must 
be converted to cDNA, integrate into the host cell genome and access the host 
cell transcriptional machinery (82).  During the process of particle assembly and 
maturation, the viral genome becomes condensed through interactions with 
multiple copies of the viral NC to form a ribonucleoprotein complex (RNP) (7).  
This RNP is then encapsulated by a protective shell generated from viral CA 
protein which is referred to as the viral core.  The core, which is a lattice-like 
structure composed of approximately 1500 CA subunits arranged into 250 
hexamers and 12 pentamers (33), disassociates in the cytoplasm allowing the 
RNP complex to traffic to the nucleus (7).  The dissolution of the capsid core is 
thought to occur because of a reduced concentration of free CA molecules as the 
core transitions from the particle interior to the cytoplasm.  The exact time and 
location of uncoating remains controversial (7).  Several groups have reported 
that the viral core also contains measurable amounts of MA and Nef, which may 
be required to destabilize the core, facilitating uncoating, or assist in transporting 
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the core through the cytoplasm by interacting with host cell motor proteins (79, 
151, 309).   
 Disassembly of the core, or uncoating, coincides with a rearrangement of 
the core components to form the structure referred to as the reverse transcription 
complex (RTC).  The RTC traverses the length of the cell using the cellular 
microtubule network and dynein to migrate to the nucleus (191). During this 
transition, the process of reverse transcription, the conversion of the viral RNA 
genome to cDNA, is initiated prior to insertion of the cDNA genome in the host 
cell.  These two steps, reverse transcription and integration, are accomplished by 
the actions of two viral enzymes (reverse transcriptase-RT and integrase-IN, 
respectively) that are contained within the RTC (7). Reverse transcription 
requires the priming of the RNA genome with a lysyl-tRNA provided by the 
producer cell (7).  This process is believed to be initiated by exposure of the RTC 
to free deoxynucleotides in the cytoplasm (7).  Following completion of reverse 
transcription, the DNA product (provirus) and associated proteins-now referred to 
as the pre-integration complex (PIC) - is imported into the nucleus and inserted 
into the host genome by the viral IN.   
 Although HIV-1 is able to infect resting T-cells, infection of activated T-
cells is generally more efficient (142).  Interestingly, Stevenson et. al. reported 
that infection of resting T-cells by HIV-1 results in production of viral cDNA that 
fails to integrate into the host cell genome (277).  The extra-chromosomal 
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proviral cDNA is transcriptionally active, and able to produce Nef, which has 
been shown to lower the activation threshold of resting T-cells (17, 277).  Thus 
early production of Nef proteins, even before integration of the viral genome, may 
play a significant role in enhancing replication.  
Although beneficial to viral replication, activation of resting T-cells 
presents a risk for the virus.  Activated and infected T-cells often die rapidly due 
to cytopathic effects induced by the virus or targeting by the immune system 
(205).  However, some of these activated-infected CD4+ T-cells may survive the 
initial infection and revert back to a resting state (142, 274).  As HIV-1 gene 
transcription requires recruitment of cellular transcriptional factors produced only 
during activation, the viral genomes in these infected cells become latent (274).  
Viral genomes present in latently infected cells have been shown to be 
transcriptionally silenced through epigenetic modification, and overcoming this 
silencing requires the cells become activated. (290).    
 
 
 
 
 
 
 
19 
 
Viral Infection - Late Stage 
 
 The late stage of HIV-1 replication starts with transcription of the 
integrated retroviral genome and ends with the release of infectious virus (Fig. 
1.3).  During this stage HIV-1 proteins are expressed from unspliced, singly or 
multiply spliced viral transcripts (26).  Following translation, components of the 
virion migrate to the plasma membrane where they assemble into a progeny 
virus particle.  Trafficking of viral components, assembly, and release of virus 
particles are dependent on interactions with the host-cell.  These processes, as 
well as virion maturation, will be described in this section.   
 
Transcription of viral proteins 
Transcription of the HIV-1 genome is regulated by the presence of multiple 
transcription factor recognition start sites present in the 5’ LTR of the integrated 
viral genome (142).  Although the 5’ LTR contains elements for multiple cellular 
transcription factors (NFκB, NFAT, SP1, AP-1 etc), basal transcription from these 
factor-binding sites mostly fail to produce full-length transcripts, because RNA 
polymerase II pauses early in the process of elongation which results in 
truncated viral transcripts (254).  Initial transcripts which are synthesized to full-
length are spliced by the cellular mRNA processing machinery to produce the 
HIV-1 Tat, Rev and Nef mRNAs (26).  Tat protein recognizes and binds to an 
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RNA stem-loop structure present in the viral mRNA (TAR) and recruits P-TEFb, a 
complex of Cyclin T-1 (CycT1) and Cyclin-dependent kinase 9 (CDK9), which 
hyper-phosphorylates RNA pol II to increase its processivity (142, 221, 254).  
Synthesis of additional full-length transcripts leads to increased production of Tat 
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mRNAs, generating a positive feedback loop and overall, an increase in full-
length viral mRNA (254).  This full length viral RNA can be spliced to generate 
the mRNA for selected HIV-1 proteins, or left unspliced or partially spliced to 
generate Gag, Gag-Pol and Env mRNA (26).  Full length viral RNA is also 
required as genomes for the next round of virus particles.  Export of Gag-Pol and 
Env mRNAs, as well as viral genomes, requires the activity of the highly 
conserved HIV-1 Rev protein. 
 The Rev protein binds to a cis-active RNA element termed the Rev-
response element (RRE) within the env coding region of unspliced or partially 
spliced HIV-1 mRNAs, and directs their export from the nucleus in a CRM1-
dependent manner (26).  The requirement of mRNA encoding Gag, Gag-Pol and 
Env on HIV-1 Rev for nuclear export and  translation has a direct effect on when 
viral proteins are translated (142).  Similar to Tat mRNA, fully spliced RNA 
encoding Rev is one of the first species generated from the initial full length viral 
transcripts (26).  Lacking an RRE itself, Rev mRNA is exported from the nucleus 
through interaction with the host cell mRNA splicing pathway components and 
subsequently translated in the cytoplasm (Fig. 1.4(172)). The presence of a 
nuclear localization signal in Rev targets the protein back to the nucleus (172).  
From there, it interacts with viral mRNAs containing an RRE to shuttle them out 
of the nucleus in a GTP-dependent fashion, for translation in the cytoplasm or via 
the endoplasmic reticulum (172).  An important implication in this process is that 
through dependence on Rev-mediated mRNA nuclear export, HIV-1 is able to  
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exert translational control of viral proteins that may trigger adaptive immune 
responses, and ensure that a minimal supply of viral proteins is available to form 
an infectious particle before stimulating the adaptive immune system (142).       
It should also be noted that the accessory protein Nef is produced at the 
same time and same manner as Rev (26).  Early expression of Nef prevents 
super-infection of the host cell by stimulating CD4 downregulation (19, 312).  Nef 
is also important early in infection for immune evasion as Nef downregulates 
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Major Histocompatibility Complex Class I molecules from the surface, preventing 
the infected cell from displaying any HIV-1 antigens for immune recognition by 
the host (167, 170, 214).  Additionally, through interactions with subunit proteins 
of the T-cell receptor, Nef is able to reduce the threshold of T-cell activation of 
infected cells (106, 207).  Again, the findings of Stevenson et al indicated that the 
non-integrated cDNA of HIV-1 was transcriptionally active and suggest that early 
Nef expression is vital to lower the activation threshold of the infected cell leading 
to viral genome integration (277). 
  
Trafficking of HIV-1 proteins 
 After exiting the nucleus, viral mRNA must be translated and viral 
component proteins must traffic to the site of particle assembly (Fig. 1.3).  
Transcripts containing the coding information for Env glycoproteins are translated 
at the rER as a polyprotein, where they are simultaneously glycosylated with the 
addition of mostly N-linked oligosaccharides (48).  It is at this point that the HIV-1 
Env gp160 (glycoprotein) assembles into trimers that traffick to the Golgi, where 
the oligosaccharides obtained in the rER are further modified in the trans-Golgi 
network by the addition of high molecular weight mannose side chains producing 
a shield which blocks Env from immune recognition (48).  It is also in the trans-
Golgi network that gp160 polyproteins are cleaved into gp41 (transmembrane 
domain) and gp120 (surface exposed) subunits by a cellular furin-like protease 
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(48).  After proteolysis, gp41 and gp120 proteins associate via non-covalent 
interactions, and are shuttled to lipid rafts in the plasma membrane (48).  HIV-1 
Env proteins become incorporated into virus particles through interactions with 
the MA protein and the long cytoplasmic tail of gp41(73, 83).   
All other viral components such as Gag are translated on soluble 
polysomes in the cytoplasm and traffick to the site of particle assembly (36, 48, 
303).  The mechanism by which soluble Gag trafficks to the plasma has yet to be 
clearly elucidated, as fluorescent microscopy and biochemical approaches have 
often provided conflicting results.  Biochemical studies indicated a role for the 
cellular microtubule network, and the motor protein kinesin KIF-4  in the 
trafficking of Gag (285).  Martinez, et. al. reported the co-immunoprecipitation of 
KIF-4 with HIV-1 Gag, and that the interaction required the C-terminal portion of 
KIF-4, previously shown to interact with MoMLV Gag in a similar fashion (187, 
285). Subsequent analysis using RNAi directed against KIF4 confirmed its role in 
HIV-1 Gag trafficking as depletion of the kinesin resulted in perinuclear 
accumulation of Gag rather than plasma membrane localization (187). Movement 
of newly translated Gag from a perinuclear region to sites of particle assembly 
was confirmed by Perlman and Resh who followed Gag trafficking in several cell 
types using live-imaging techniques and reported that newly translated Gag 
trafficked from a perinuclear region to the plasma membrane forming a transient 
association with multivesicular bodies (MVB) during the process (227).  This 
finding is consistent with other studies investigating HIV-1 Gag interactions with 
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viral genomes.  These studies reported a perinuclear localized interaction 
between newly transcribed viral genomes and Gag, suggesting that HIV-1 Gag 
may associate with MVB prior to assembly at the PM (6, 129, 156).  Interestingly, 
several of these investigations have reported that the interaction of MA-RNA 
plays a direct role in targeting Gag to the appropriate membrane; interaction 
between MA and the viral genome increases the affinity for MA with 
phosphatidylinositol 4,5 bis-phosphate in the PM (5, 129).  This explanation may 
account for the reports of several labs that soluble Gag localizes to endosomal 
membranes which serve as either intermediary platforms or the sites of particle 
assembly, and traffick to the PM for release (72, 132, 134). 
However, these results differ dramatically from labs who used real-time 
imaging of Gag-GFP constructs which demonstrate that Gag initially assembles 
at the plasma membrane from a cytoplasmic pool, but may then associate with 
internal membrane-bound structures such as endosomes (124, 135-137). A 
decrease in the availability of unbound vRNA may account for this difference, as 
Gag that is actively interacting with viral RNA would be less likely to diffuse from 
the assembly site.  The observations of the real-time imaging studies would 
seem to indicate that the observed deposition of HIV-1 Gag on endosomal 
membranes results following saturation of the suitable interaction partners at the 
plasma membrane, either RNA scaffolds or lipid microdomains (124, 135-137).  
Of particular interest is a report by Jouvenet and Bieniasz, who confirmed Gag 
clustering at the PM before observing any localization of Gag-GFP to endosomes 
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(136).  In addition, by treating the cells with nocodazole, they illustrated that 
trafficking along microtubules played no role in their system, further reinforcing 
the theory that Gag trafficks to the PM via passive diffusion through the 
cytoplasm (136).  Taken together, the current literature suggests that newly 
translated Gag is maintained at a perinuclear location, perhaps via interaction 
with early endosomes, until it binds to viral genomic RNA.  Monomers and dimers 
of Gag-RNA complexes travel to the cell periphery via passive diffusion and bind 
to the inner leaflet of the PM due to the higher affinity of the MA-RNA complex. 
 
Viral particle assembly 
HIV-1 viral particles assemble on the inner leaflet of the plasma 
membrane at specific microdomains known as lipid rafts (302).  These rafts, also 
sometimes referred to as detergent-resistant membranes (DRM), are high in 
cholesterol, sphingomyelin and the phospholipid, phosphatidylinositol-4,5-
bisphosphate (303).  While the existence of lipid rafts has been controversial for 
some time (isolation of lipid rafts required extensive biochemical extraction which 
could be prone to generating artifacts), current analysis of the HIV-1 envelope 
indicates it shares many of the components of the DRM, including the presence 
of raft-associated proteins such as GM1, increased cholesterol and 
sphingomyelin relative to the content of the PM, and the exclusion of non-raft 
targeted molecules such as CD45 (36, 153, 210).   
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Interaction with the plasma membrane is driven by the MA subunit of Gag 
via attachment of a basic stretch of amino acids present in the N-terminus of MA 
(HBR) and acidic side chains of phospholipids (55).  The HBR of MA has a 
specific and high affinity for the plasma membrane component 
phosphatidylinositol-(4,5)-bisphosphate (PI [4,5] P2), and Gag can be re-directed 
from the plasma membrane to intracellular membranes if the PM levels of PI [4,5] 
P2 are decreased (54, 55). For example, Ono’s group observed accumulation of 
Gag on endosomal membranes by treating infected cells with 5-phosphatase IV 
which specifically reduced membrane PI [4,5] P2 levels (54).  In contrast, higher 
levels of cholesterol have been reported to increase the affinity of MA for PI [4,5] 
P2 (5).  Association of Gag with the plasma membrane is strengthened by the 
insertion of the myristic acid anchor of MA into the PM, which occurs after 
interaction between the MA HRP and the PM (259).  The N-terminal myristic acid 
is sequestered into a cleft in monomeric MA, and becomes available for insertion 
into the membrane upon binding of MA to PI [4,5] P2 (55, 222, 259).   
 Formation of HIV-1 virus is a Gag-driven process; expression of Gag 
alone in cells is sufficient to generate non-infectious virus-like particles (95).  
Upon localization at the plasma membrane, neighboring Gag molecules begin to 
form higher order multimers.  Multimerization of Gag is the result of interactions 
between the Gag subunit proteins and interactions with the viral genome (89, 
113, 204).  Following MA association with the PM, Gag forms trimers which 
associate into hexameric rings driven by interactions between the CA-CTD-SP1 
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regions of proximal Gag molecules (1, 67, 88).  Additional higher order structure 
develops as the NC subunit interacts with the viral genome, which some suggest 
acts as a scaffold to drive Gag-multimerization (204, 220).  At this time, the 
assembled Gag lattice assumes a dome-like structure, as CA-CA and NC-RNA-
NC forces begin to pack Gag closer together, creating voids within the 
hexameric-Gag sheet (41).  Crystallographic imaging of Gag displays a tapering 
molecule wider at MA and narrowing after the CA-CTD, which may account, in 
part, for the membrane curvature (89).  Recent imaging studies using 
cryoelectron tomography (cET) with subtom averaging to analyze immature 
particles show that the interior of the budding dome is supported by a continuous 
lattice of Gag hexamers, which transition to an incomplete shell with irregularly 
spaced ‘holes’ following release (32).  The authors of this report hypothesize that 
the irregularly spaced holes are necessary to support the curvature required for 
viral budding (32). A separate group reported that the Gag shell, though 
incomplete, forms a continuous lattice and attributes the membrane deformation 
that accompanies budding to the presence of Endosomal Sorting Complex 
Required for Transport (ESCRT) proteins which, when recruited by the p6 region 
of Gag, induced formation of the bud neck of the nascent viral particle (42).   
 It should be noted that while our focus has been on the activities of Gag 
with regard to particle assembly, the Gag-Pol polyprotein behaves very similarly 
with regard to trafficking, membrane binding and interactions with Gag, as it also 
contains MA, CA and NC domains, and thus is capable of forming interactions 
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with the PM and adjacent Gag molecules.  However, as mentioned previously, 
the ratio of Gag to Gag-Pol is approximately 20:1, and this ratio has profound 
effects on the maturation of the viral particle (283).  The transition from immature 
to mature HIV-1 virus is characterized by complete cleavage of the Gag 
polyprotein by the viral protease (PR) contained in the pol region (310).  Only one 
subunit of PR is present in Gag-Pol, and it must dimerize with another PR 
molecule to become active (82).  At this point, the importance of the 20:1 
Gag:Gag-Pol ratio becomes apparent as interactions between PR monomers 
lead to dimerization and enzyme activation, thus resulting in cleavage of Gag 
prematurely (141).  This observation has been verified in multiple studies 
examining not just the Gag:Gag-Pol ratio, but also mutations in Gag-Pol that 
affect Gag:Gag-Pol interactions and have deleterious effects on particle 
assembly and release, and both effects can be ameliorated by mutations that 
inactivate PR (109, 141, 244).   
Formation of the fully infectious HIV-1 particle is contingent on the process 
of maturation, which is discussed in more detail below.  Maturation occurs either 
concurrent with, or just after, release of the budding viral particle from the plasma 
membrane, which is regulated by cellular proteins known as the ESCRT 
machinery (283).  Viruses that are defective for recruitment of ESCRT proteins 
fail to release from the host cell plasma membrane, and display defects in Gag 
cleavage associated with an intermediate stage of maturation (42, 98).  The 
ESCRT machinery is recruited by interaction with the p6 domain of HIV-1 Gag 
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(186), and is responsible for localized membrane deformation (curvature) and the 
membrane scission event that liberates the nascent virus (313).  Interestingly, a 
recent structural study using cryoelectron tomography (cET) has suggested that 
recruitment of the ESCRT machinery may also play an important role not only in 
particle release, but also in determining the amount of Gag present in the viral 
particle by the formation of a bud neck, which limits incorporation of additional 
Gag molecules (42).  This finding implies that ESCRT recruitment can profoundly 
affect the process of particle assembly in addition to its well characterized role in 
stimulating release of viral particles (42). 
Structure and contents of the Mature HIV-1 Virus  
 Maturation is the final step required for formation of an infectious viral 
particle and occurs either immediately after or concomitant with release.  This 
process is characterized by a major re-arrangement of Gag proteins driven by 
Gag subunit interactions and the activity of the viral protease (PR) (283, 310).  
The immature particle consists of a lattice-like arrangement of Gag molecules 
beneath the viral envelope (formerly the inner leaflet of the host cell plasma 
membrane) centered on CA-CA and NC-RNA interactions (67, 68).  This lattice is 
composed of hexameric subunits which comprise an incomplete Gag shell with 
the C-terminus of Gag (and Gag-Pol) molecules directed inward (67, 68).  
Activation of the viral PR results in an ordered cleavage of Gag molecules due to 
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different affinities of PR and cleavage sites, and a subsequent cascade of 
protein-protein interactions ensues (67, 310).  The RNA- NC complex is removed 
from the Gag lattice to form a condensed viral RNP (7).  Cleavage of CA-SP1 
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from MA allows MA to remain bound to the viral envelope while releasing CA to 
form the conical viral core (89, 310).   
The viral capsid or core (core will be used to avoid confusion with the CA 
protein) is an electron dense structure with the predicted form of a fullerene cone 
(90), made up of ~250 CA hexamers and 12 pentameric defects (5 at narrow tip, 
7 at wider cap, Fig. 1.5)(88).  Retroviral capsid proteins, which are structurally 
conserved despite significant sequence variability, contain two globular domains 
composed of 7-helices (NTD) and 5 helices (CTD) connected by a flexible linker 
(67).  In HIV-1, interactions between adjacent NTD form either a hexameric or 
pentameric ring structure with six- or five-fold symmetry, while the CTD forms a 
‘belt’ surrounding the subunit (87, 246).  Non-covalent interactions between the 
CTD ‘belts’ of adjacent CA subunits act to stabilize the formation of the Gag 
lattice (246).  A similar orientation of CA molecules within the context of the Gag 
polyprotein has been observed in imaging studies of immature virus particles, 
suggesting that the formation of the CA hexamers may be determined prior to 
release/maturation (87, 246).   
At present, it is unclear whether core formation is the result of high local 
concentration of CA within the particle, or whether formation of the core is the 
result of CA hexamer multimerization following nucleation events.  Several 
reports have provided evidence for either mechanism (12, 18, 34).  For example, 
spontaneous formation of CA tubes that resemble authentic HIV-1 cores is 
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possible in vitro under the right conditions with concentrated CA monomers (12).  
A recent cET study by Briggs, et. al. quantified the number of Gag molecules in 
the purified immature particle at ~5,000, which by association suggests that the 
immature viral particle contains almost 2.5 times more CA than the amount 
present in the mature core.  This estimate brings the internal viral CA 
concentration to ~40mM, a more than 4.0x104 increase in concentration from that 
used the in vitro assay (18, 34).  However, the consistent observation of 
authentic viruses and VLP with multiple cores argues against a strictly 
concentration driven reaction as formation of the first core would substantially 
reduce the concentration of CA subunits within the virus (18, 34).  It has been 
argued that the presence of multiple cores is indicative of growth from either one 
or multiple nucleation points (30).  Using an in vitro fluorescent microscopy 
approach, one study reported that formation of CA tubes occurred both uni- and 
bi- directionally following a rate-limiting nucleation step (12).  The finding is 
consistent with the work of Briggs, et. al., who reported results of an in vivo study 
of viral core formation (30).  Using cET, they found that the larger cone end of the 
viral core closely matched the curvature of the envelope in that location.  They 
hypothesized that core formation initiated via a nucleation event at the narrow 
end, perhaps from the budding scar or a localized deposition of CA pentamers, 
and radiated to the far end of the particle, where elongation is halted by the viral 
envelope and the cone was capped (30). 
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 In addition to the cleavage and re-arrangement of Gag, particle maturation 
has effects on the extracellular domain of the Env protein (73, 83, 84).  Previous 
studies indicate an interaction between Gag (MA) and the transmembrane 
domain of the gp41subunit of HIV-1 Env during particle formation.  It has also 
been reported that point mutations in the MA core interfere with the ability of Env 
to associate with viral particles, but such interference could be abrogated by 
removal of the cytoplasmic tail of gp41, or the complete removal of gag (83, 84, 
203, 253).  Data from the Aiken laboratory suggests that the structural 
rearrangements of Gag occurring during particle maturation affect the display of 
surface epitopes of gp41(139).  Using a panel of fluorescently-tagged antibodies, 
they show that maturation of HIV-1 viruses can mask regions of gp41 that were 
otherwise surface-exposed, and thus recognized by their panel of antibodies 
(139).  Collectively, these findings indicate that maturation of the viral particle can 
affect other aspects of the virion structure in addition to Gag re-arrangement.   
 In addition to incorporation of Env glycoproteins into viral particles, other 
HIV-1 proteins required for nascent infection are also packaged into virions, and 
in most cases, into mature viral cores.  Based on previous studies which 
correlated the levels of specific viral proteins to Gag, recent work suggests there 
may be 700 molecules of Vpr, and 250 molecules of both HIV-1 integrase and 
reverse transcriptase (18, 33).  The accessory protein Nef is also present in the 
mature viral particle (151).  Nef associates with the membrane site of assembly 
through an N-terminal myristic anchor and is cleaved during maturation.  What 
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possible role Nef plays during the subsequent round of infection is the subject of 
much debate, and will be considered in significant detail in Chapter III.     
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CHAPTER II 
 
Rescue of HIV-1 Release by Targeting Widely Divergent NEDD4-type  
Ubiquitin Ligases and Isolated Catalytic HECT domains to Gag 
 
SUMMARY 
 
Retroviruses engage the ESCRT pathway through late assembly (L) 
domains in Gag to promote virus release. HIV-1 uses a PTAP motif as its primary 
L domain, which can interact with the ESCRT-I component Tsg101. In contrast, 
other retroviruses use PPxY-type L domains, which constitute ligands for 
NEDD4-type ubiquitin ligases. Surprisingly, although HIV-1 Gag lacks PPxY 
motifs, the release of HIV-1 L domain mutant viruses is potently enhanced by 
ectopic expression of NEDD4-2s, a native isoform of NEDD4-2 containing a 
truncated C2 domain.  The basis of the unique potency of the NEDD4-2s isoform 
has remained to be determined. We show that the truncated C2 domain of 
NEDD4-2s functions as an autonomous Gag-targeting module that can be 
functionally replaced by the unrelated Gag-binding protein cyclophilin A (CypA). 
The residual C2 domain of NEDD4-2s was sufficient to transfer the ability to 
stimulate HIV-1 budding to other NEDD4 family members, including the yeast 
homologue Rsp5, and even to isolated catalytic HECT domains. The isolated 
catalytic domain of NEDD4-2s also efficiently promoted HIV-1 budding when 
targeted to Gag via CypA. We conclude that the regions typically required for 
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substrate recognition by HECT ubiquitin ligases are all dispensable to stimulate 
HIV-1 release, implying that the relevant target for ubiquitination is Gag itself or 
can be recognized by divergent isolated HECT domains. However, the ability to 
ubiquitinate Gag was not solely sufficient to stimulate HIV-1 budding. Rather, our 
results demonstrate that the preference of NEDD4.2s to synthesize polyubiquitin 
chains formed through K63-linkages is critical for the ubiquitin ligase-mediated 
virus release. 
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INTRODUCTION 
 
 Assembly of HIV-1 particles at the plasma membrane results in the 
formation of a budding virus composed of a spherical Gag shell surrounded by a 
viral envelope that is still contiguous with the plasma membrane (307).  This 
structure must separate from the cell to initiate infection in a new target cell.  
Release is accomplished by recruitment of the host cell’s Endosomal Sorting 
Complex Required for Transport (ESCRT) machinery (22, 85, 190, 199, 233, 
307), which promotes the final membrane scission event that separates the viral 
envelope from the PM.  The ESCRT machinery is used by the host cell in the 
formation of multivesicular bodies (MVB) in late endosomes, in cytokinesis to free 
the daughter cell and has been implicated in autophagy (43, 190, 197, 226, 251, 
261).  These processes all contain events of similar topology to virus budding, 
that is membrane curvature away from the cytoplasm followed by scission.    
 Access to the ESCRT machinery is mediated by interactions between 
ESCRT subunits and short motifs in retroviral Gag molecules known as Late (L)-
domains (23, 69, 307).  The first indication that HIV-1 contained a site for host 
cell protein recruitment came from deletions of the p6 region of Gag (98, 115), 
which, when expressed, forms particles at the PM that fail to release, and soon 
after, similar regions were found in other retroviruses (69).  It has been observed 
that these regions can be moved to different areas of the Gag molecule, or used 
interchangeably between different viruses, suggesting that they behave as 
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recruitment domains for cellular factors (224).  Analysis of the amino acid 
sequences of these regions has lead to the identification of three common L-
domain motifs, often found in combination, which each interact with a different 
cellular protein (69).  The PS/TAP motif, the dominant L-domain in HIV-1 as well 
as in MLV and the Filovirus Ebola, recruits the ESCRT-I subunit Tsg101 (185, 
269).  The YPxL motif, an auxiliary L-domain in HIV-1 but the only one present in 
Equine Infectious Anemia Virus (EIAV), recruits the ESCRT accessory protein, 
ALIX.  The third style of L-domain, not present in HIV-1 but found in both MLV 
and Ebola, is the PPxY motif which interacts with E3 ubiquitin ligases of the 
Nedd4 family (269).  Each cellular host factor provides access to the ESCRT 
pathway in different fashions, but all result in the same process, scission of the 
plasma membrane and release of the virus. 
 
The ESCRT pathway 
 The ESCRT machinery exists in all eukaryotes and consists of five hetero-
oligomeric complexes, ESCRT-0, ESCRT-I, ESCRT-II, ESCRT-III and VPS4, as 
well as accessory proteins such as ALIX (Table 2.1) (117).  ESCRT complexes 
are thought to be recruited sequentially to endosomal membranes, although 
there is evidence that upstream ESCRT complexes may act in parallel (120).  
ESCRT-0, ESCRT-I and ESCRT-II are recruited as pre-formed complexes, 
whereas the ESCRT-III complex transiently assembles on endosomes from  
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Table 2.1: ESCRT proteins involved in HIV-1 release
ESCRT Complex Subunit Required for HIV-1 release? ESCRT related interaction partners Role Citation
ESCRT - 0 HRS No Ubiquitin, STAM1/2, Tsg101 Interact with Ub 247
STAM Not determined Ubiquitin, HRS Interact with Ub 
ESCRT-I Tsg101 Yes Ubiquitin/Hrs/ ESCRT-I subunits Interact with p6 PTAPP motif; interact with ubiquitin 91, 185
Vps37 Yes ESCRT-I subunits required as ESCRT-I component 76,282
Vps28 Yes Eap45/ESCRT-I subunits Structural component of ESCRT-I complex 184, 282
Mvb12a/b No ESCRT-I subunits Structural component of ESCRT-I complex 196
ESCRT-II Eap20 No ESCRT-II subunits Structural component of ESCRT-II complex 162
Eap30 No CHMP6/ESCRT-II subunits Interacts with ESCRT-III through Chmp 6 162
Eap45 No Vps28/ESCRT-II subunits Interacts with ESCRT-I through Vps28 162
ESCRT-II Chmp 3 No CHMP2A/B, CHMP4 Formation of ESCRT-III, Membrane Scission 198, 301
Chmp 6 No Vps28/ESCRT-II subunits, CHMP4A/B Vps4 Formation of ESCRT-III, Membrane Scission 198
Chmp 2 Yes CHMP4A/B Formation of ESCRT-III, Membrane Scission 43, 198, 282
Chmp 4 Yes ALIX, CHMP6, Vps4 Formation of ESCRT-III, Membrane Scission 198
Accessory proteins Alix Sometimes CHMP4 (A-D) Interact with HIV-1 p6 and NC 184, 279
 Nedd4 Sometimes Unknown Interact with HIV-1 CA 56, 292, 308
Vps4 A/B Yes CHMP2A/B ESCRT complex recycling 91, 301
LIF1 Yes ESCRT- II subunits, VPS4A/B ESCRT complex recycling 190
 
soluble cytosolic components (307).  Mammalian ESCRT-III is formed by 
charged multivesicular body proteins (CHMPs), a family of structurally related but 
highly divergent α-helical proteins that has 12 known members in humans (307).  
A recent report by Wollert and Hurley demonstrated that the individual ESCRT 
complexes perform discrete functions (313).  Using purified ESCRT components 
and giant unilamellar vesicles, they showed that 1) the ESCRT-0 complex 
functions to concentrate ubiquitinated cargo on endosomal membranes, 2) the 
ESCRT-I and ESCRT-II complexes together induced bud formation without 
themselves entering the lumen of the budding vesicle, and 3) the ESCRT-III 
complex mediates membrane scission from the cytosolic side of the bud (313).  
Rather than being consumed, ESCRT-III is disassembled and recycled by the 
VPS4-VTA1 complex, enabling further rounds of sorting (16).  Thus, in the MVB 
pathway, all of the ESCRT complexes are required.  Intriguingly, only certain 
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ESCRT complexes (Table 2.1) have been shown to be required for the budding 
and release of HIV-1 (190). 
 Although the ESCRT machinery was first characterized based on its 
requirement for MVB biogenesis, it has recently emerged that the ESCRT system 
is also involved in membrane remodeling and fission events that lead to midbody 
abscission during the final stages of cytokinesis (43, 44, 197).  Additionally, the 
ESCRT machinery controls earlier stages of cell division.  At least a subset of 
ESCRT proteins is required for the proper function of centrosomes, and it has 
been noted that certain ESCRT-III components localize to kinetochores (195).  
Interestingly, ESCRT-III and Vps4 homologs are also key components of the cell 
division system of certain archaea (173, 262).  Since eukaryotes and archaea 
diverged at least a billion years ago, the promotion of cell division is likely to be 
the ancestral function of the ESCRT machinery. 
 
ESCRT-I 
 The PTAP L domain of HIV-1 Gag binds directly to TSG101, the central 
component of ESCRT-I, a stable cytosolic heterotetramer formed by one copy 
each of TSG101, VPS28, VPS37 and MVB12 (117, 196).  Human cells express 
four versions of VPS37 (VPS37A-VPS37D) and two versions of MVB12 (termed 
MVB12A and MVB12B), which are encoded by different genes (76, 196, 282).  
Thus, eight combinations of TSG101, VPS28, VPS37 and MVB12 are 
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theoretically possible, and all of these can indeed form stable ESCRT-I 
complexes in cells (196).  The ESCRT-I heterotetramer consists of a core formed 
by a headpiece and a long stalk, and of conformationally dynamic TSG101 UEV 
and VPS28 C-terminal domains that are appended to opposite ends of the 
extended core (150). 
 The flexible attachment of the UEV domain of TSG101 to the ESCRT-I 
core is thought to facilitate binding of ligands, such as the PTAPP L domain in 
HIV-1 p6.  In the endocytic pathway, the TSG101 UEV domain binds to PSxP 
motifs in the ESCRT-0 component HRS (27, 247), which has led to the proposal 
that HIV-1 Gag mimics the ability of HRS to recruit TSG101 (247).  In support of 
this notion, an HRS fragment capable of recruiting TSG101 rescues virus-like 
particle production when fused to an active HIV-1 Gag construct that lacks its 
native PTAPP L domain (247). 
 The role of the TSG101 UEV domain in HIV-1 budding is limited to the 
recognition of the PTAP L domain since the N-terminal UEV domain is 
dispensable for the rescue of L domain defective HIV-1 when TSG101 is 
artificially recruited to assembly sites (185).  However, under these artificial 
conditions, a C-terminal region of TSG101 that binds to VPS28 remains 
necessary to confer budding activity (186, 282).  Interestingly, the VPS28 C-
terminal domain, which is attached to the ESCRT-I core via a flexible tether 
(150), is sufficient to rescue budding when appended to an L domain defective 
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Gag construct, apparently by serving as an adaptor for the ESCRT-III component 
CHMP6 (234).  TSG101 also interacts with VPS37 proteins, which again can 
provide L-domain function when fused directly to Gag (76, 282).  Furthermore, 
binary TSG101-VPS37 complexes interact with MVB12 (196), which is thought to 
stabilize the extended stalk of the ESCRT-I core (150).  Nevertheless, MVB12 
does not appear to play a central role in HIV-1 release (196).  However, the 
depletion of MVB12 proteins induces aberrant virion morphologies and inhibits 
infectivity (196). 
 
 
ESCRT-II  
 Together with ESCRT-I, ESCRT-II mediates the deformation of 
endosomal membranes into buds during MVB biogenesis (9, 313).  Yeast 
ESCRT-II binds to the ESCRT-I component Vps28 and to the ESCRT-III 
component Vps20 and thereby links ESCRT-I to ESCRT-III (119).  Human 
ESCRT-I and ESCRT-II also interact, albeit in a different manner (162), and 
human ESCRT-II binds directly to the ESCRT-III component CHMP6 (162, 317).  
Together, these observations indicate that ESCRT-II also connects ESCRT-I to 
ESCRT-III in humans.  Just as one might expect, human ESCRT-II transiently 
associates with endosomal membranes like its yeast counterpart and functions in 
receptor downregulation (162).  However, human ESCRT-II is dispensable for 
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HIV-1 budding (162), indicating that HIV-1 p6-associated ESCRT-I recruits 
ESCRT-III membrane scission machinery in some other way. 
 
ESCRT-III 
 The ESCRT-III complex is the main engine that carries out membrane 
scission in the ESCRT pathway (313, 314).  The core ESCRT-III complex is 
formed by Vps20, SNF7, Vps24 and Vps2 in yeast and by their homologues 
CHMP6, CHMP4A-CHMP4C, CHMP3, and CHMP2A and CHMP2B in humans.  
As it yeast ortholog Vps20, human CHMP6 is N-terminally myristoylated and 
thought to nucleate the oligomerization of CHMP4 proteins on membranes (286, 
287, 317).  The remaining ESCRT-III core components CHMP3 and CHMP2 
appear to function as termination factors that cap CHMP4 filaments and recruit 
VPS4 for ESCRT-III disassembly (286). 
 An essential role for the membrane fission activity of ESCRT-III in HIV-1 
release is strongly implied by the fact that various dominant-negative versions of 
VPS4 (the ATPase that disassembles ESCRT-III) arrest the budding of HIV-1 
and other retroviruses (91, 97, 268).  HIV-1 budding is also strongly inhibited 
when both human VPS4 proteins are depleted simultaneously via siRNA (145).  
Moreover, individual ESCRT-III components, which are autoinhibited to prevent 
premature polymerization, can be activated to become extremely potent 
inhibitors of HIV-1 budding (10, 163, 184, 206, 273, 279, 301, 318).  For 
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instance, CHMP6 fused to RFP strongly inhibits HIV-1 release in a dominant 
negative manner.  It therefore comes as a surprise that CHMP6, the ESCRT-III 
subunit activated by ESCRT-II to trigger ESCRT-III assembly (287), is not 
required for HIV-1 budding (162).  CHMP3 is also dispensable for HIV-1 budding, 
leaving only the core ESCRT-III components CHMP2 and CHMP4 as potential 
players in HIV-1 release.  Indeed, a recent study demonstrates that the co-
depletion of CHMP2 and CHMP4 family members profoundly impairs HIV-1 
release, whereas other CHMPs are not required (198). 
 When overexpressed, human CHMP4A and CHMP4B polymerize into 
circular filaments that deform the plasma membrane into buds and tubules 
emanating from the cell surface (108).  Filament formation by SNF7, the yeast 
homolog of the three human CHMP4 proteins, is required to sequester 
endosomal cargo (286) and appears to be the critical event during ESCRT-III 
catalyzed membrane scission (314).  Indeed, when recruited via ESCRT-II and 
the nucleation factor Vps20 (CHMP6), SNF7 (CHMP4A-C) was sufficient to 
catalyze the scission of bud necks in an in vitro reaction (313).  Thus, during HIV-
1 assembly, the formation of circular CHMP4 polymers within Gag-induced bud 
necks could, in principle, lead to membrane constriction and drive virus release 
(226).  CHMP4-mediated membrane constriction in concert with Gag may also 
explain the observation that HIV-1 virions are often released before the Gag shell 
is completely assembled (42).  In one model (77), which is based on the dome 
shape of certain CHMP2/CHMP3 copolymers (164), the assembly of dome-
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shaped CHMP4 polymers within HIV-1 buds would tighten the neck, owing to an 
affinity of CHMP4 for membranes, ultimately causing spontaneous fission.  
However, the critical role of CHMP2 proteins, which recruit VPS4, also suggests 
an active participation of VPS4-VTA1 complex in HIV-1 release (198).  Recent 
cell imaging studies reveal that ESCRT-III and VPS4 are rapidly and transiently 
recruited before HIV-1 particle release, supporting the notion that VPS4 has a 
direct role in budding (16, 138). 
 
ALIX:  
 Although HIV-1 relies predominantly on a PTAPP type L domain to recruit 
the CHMP4 fission factor via ESCRT-I, it can also engage CHMP4 in an 
alternative manner.   As noted earlier, HIV-1 p6 harbors a secondary L domain of 
the LYPxnL type, which functions as a docking site for ALIX, another early-acting 
factor in the ESCRT pathway (184, 279, 301).  ALIX is composed of a banana-
shaped Bro1 domain, a V-shaped middle domain, and a presumably 
unstructured proline-rich C-terminal domain (PRD) that harbors binding sites for 
various interaction partners.   Through its Bro1 domain, ALIX interacts with C-
terminal residues of the human CHMP4 proteins (78, 184, 189, 279, 301).  ALIX 
thus directly links HIV-1 Gag to ESCRT-III. 
The central V domain of ALIX harbors the binding site for the LYPxnL-type 
L domains in HIV-1 p6Gag and EIAV p9Gag (78, 169).  Interestingly, the LYPxnL 
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motif in HIV-1 p6Gag (n=3) adopts a helical main-chain conformation when bound 
to ALIX, whereas the EIAV L domain (n=1) is bound in an extended conformation 
(321).  Although the conserved residues in the LYPxnL-type L domains of HIV-1 
and EIAV make equivalent interactions with ALIX, HIV-1 p6Gag has a significantly 
lower affinity for ALIX than EIAV p9Gag (321).  Presumably, the difference in 
affinity is related to the fact that HIV-1 p6Gag also has a docking site for ESCRT-
I, whereas EIAV relies solely on ALIX for budding. 
HIV-1 budding can be potently inhibited by dominant-negative ALIX 
fragments, as long as a V domain capable of mediating ALIX dimerization is 
maintained (202, 235, 279).  Dominant-negative ALIX fragments also induce Gag 
processing defects resembling those seen in the absence of a functional L 
domain (202, 279). However, mutations in the ALIX binding site of HIV-1 p6Gag 
generally have more modest effects on HIV-1 release and replication than 
mutations that disrupt the TSG101 binding site (78, 86).  Also, HIV-1 p6Gag-
mediated budding was significantly less affected by ALIX depletion than EIAV 
p9Gag-mediated budding (184).  Overall, these findings are consistent with the 
notion that HIV-1 p6Gag contains a bipartite L domain in which the TSG101 
binding site predominates but does not account for all of the budding activity 
(182).   
Remarkably, the release and infectivity of HIV-1 mutants that lack the 
PTAPP L domain can be dramatically stimulated by overexpressing ALIX (78, 
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291).  This implies that ALIX, if expressed at sufficiently high levels, can 
essentially fully substitute for TSG101 in HIV-1 budding. As expected, the ALIX-
mediated rescue is dependent on a V domain capable of binding to LYPxnL (78).  
Moreover, the presence of an intact LYPxnL motif in p6Gag is required, confirming 
that this motif constitutes a genuine L domain that functions through ALIX (78, 
291).  The activity of ALIX also depends on the ability of its Bro1 domain to 
interact with CHMP4, implying that the recruitment of this fission factor is crucial 
for ALIX-mediated HIV-1 budding. In contrast, interaction sites for TSG101, 
endophilin, CIN85, CMS/CD2AP, and CEP55 in the PRD of ALIX are 
dispensable for its function in HIV-1 budding (43, 78, 291).  Nevertheless, the 
very C-terminus of the PRD is essential (43, 78, 291), apparently because PRD-
dependent ALIX multimerization is required to promote HIV-1 budding (43). 
It has recently been revealed that HIV-1 Gag harbors a second binding 
site for ALIX in the NC domain (74, 243), in addition to the LYPxnL ALIX binding 
site in p6.  ALIX interacts with HIV-1 NC via its N-terminal Bro1 domain (74, 243), 
and the widely divergent Bro1 domains of other human proteins share an affinity 
for HIV-1 NC, indicating that NC recognizes a structural feature of the Bro1 
domain rather than a specific sequence (242).  The ability of NC to interact with 
Bro1 domains depends on two conserved CCHC-type zinc finger motifs in NC 
that are also required for the selective packaging of genomic viral RNA during 
assembly (242, 243).  Nevertheless, nucleic acid does not appear to be involved 
in the ALIX–NC interaction because the interaction was maintained in the 
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presence of nuclease (243).  Interestingly, mutations that disrupt the ALIX 
binding site in NC cause defects in Gag processing and HIV-1 release 
resembling those typically seen with HIV-1 L domain mutants (243).  
Furthermore, electron microscopy analyses of Rous sarcoma virus and HIV-1 NC 
mutants have revealed budding defects similar to those of L-domain mutants (75, 
168).  Together, these observations suggest that NC may play a role in ESCRT 
engagement and virus release, in addition to its previously documented role in 
virus assembly (322). 
NEDD4 E3-ubiquitin ligases:   
 The Nedd4 family of ubiquitin ligases serves as the ESCRT access point 
for viruses that contain the PPxY L-domain (24, 39, 100, 110, 183, 315).  There 
are nine members of this family found in humans (122), and a number of them 
have been implicated in the release of a range of viruses, all in an ESCRT 
dependent manner (190).  All family members share a common modular 
architecture with an N-terminal C2 domain, multiple WW domains, and a catalytic 
Homologous to E6-AP Carboxyl Terminal (HECT) domain (122).  Recognition of 
the PPxY motif is determined by the ligase’s WW domain, and a recent study has 
shown that affinity is determined by residues adjacent to the PPxY sequence 
(183).  The C-terminal HECT domain is responsible for the addition of ubiquitin to 
substrate lysine residues, although in the case of viral budding the ubiquitination 
target has not yet been determined (56, 308, 320).   
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 Ubiquitin-a surrogate Late-domain? 
 The importance for ubiquitin in viral particle release is well established, 
although the exact role that it plays remains controversial (219, 249).  Almost 
twenty years ago, it was reported that the concentration of free ubiquitin in the 
viral particles of ALV were about 10-fold higher than the concentration of 
ubiquitin in the cytoplasm, suggesting specific incorporation of that molecule into 
virions (249).  This finding (249) was soon followed by another reporting the 
presence of free ubiquitin in the particles of HIV and MLV, further reinforcing the 
idea that ubiquitin enrichment in virus particles was a conserved process (219).  
It has since been demonstrated that treatment of cells producing HIV-1 with 
proteasome inhibitors, which reduce cytoplasmic levels of free ubiquitin, resulted 
in a release defect typically observed with L-domain mutants (225, 265, 270).  
This observation clearly indicated a role for ubiquitin in the release of retroviral 
particles.   
Not surprisingly, studies of retroviruses that utilize a PPxY motif to recruit 
members of the Nedd4 E3 ubiquitin ligase family have provided some additional 
insight into the relationship between ubiquitin and particle release.  Over-
expression of Nedd4 family members in cell lines transfected to express MLV, 
HTLV-1 or RSV all show an increase in the levels of Gag ubiquitination 
accompanied by a commensurate increase in particle release (24, 146, 269, 278, 
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315).  A mutational analysis of HTLV-1, in which 4 Lys residues present in the 
MA subunit of that Gag molecule were mutated to Arg, illustrated that 
ubiquitination of Lys74 of MA was required for particle release (111).  A similar 
result was obtained from a mutational analysis of HIV-1 Gag, in which the 17 Lys 
residues of SP1, NC, SP2 and p6 were changed to Arg, indicating that at least 
mono-ubiquitination of Gag was required for particle release (102, 127).  
Interestingly, an L-domain phenotype appeared only after all ubiquitin acceptor 
sites were mutated (101, 102), implying that while Gag-ubiquitination served a 
functional purpose, in the case of HIV-1, no specific site of ubiquitin attachment 
was required.  It has been hypothesized that the addition of mono-ubiquitin to 
HIV-1 Gag may enhance recruitment of ESCRT proteins by providing additional 
interaction sites for Tsg101(245).  Tsg101can bind ubiquitin via an Ubiquitin E2 
Variant domain while simultaneously interacting with the HIV-1-p6 PTAPP motif, 
thus increasing the affinity of Tsg101 for Ub-Gag (245).  Other labs have found 
that late domain deficient versions of Equine Infectious Anemia Virus (EIAV) or 
Prototypic Foamy Virus could be rescued by the fusion of a mono-ubiquitin 
molecule to the C-terminal of both Gag molecules, indicating that ubiquitin itself 
could serve as a surrogate L-domain in this context (133, 320).   
While the attachment of ubiquitin to Gag has been shown to be sufficient 
to drive recruitment of ESCRT proteins (133, 320), a question still remains as to 
whether retroviral Gag is the relevant substrate for ubiquitination.  A recent report 
by Zhadina et al demonstrated that mutation of the sole ubiquitin acceptor site in 
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PFV Gag had no effect on the release of viral particles if the native Nedd4-
recruitment site remained intact (320).  Release of particles bearing this mutation 
still relied on an active E3 ubiquitin ligase, suggesting that ubiquitination of a 
separate protein may be necessary (320).  A similar result was reported by 
Chung et al who demonstrated that in the presence of overexpressed Nedd4.2s, 
the ESCRT-I subunit, MVB12 was also ubiquitinated (56).   
Participants in protein ubiquitination 
 Ubiquitination is a post-translational modification of a protein by the 
covalent attachment of one or more ubiquitin molecules (257).  Substrate 
proteins may be ubiquitinated at their N-terminal amines or at specific amino 
acids such as cysteine, serine and lysine (257).  By far the most common site of 
attachment is lysine with a covalent bond being formed between the C-terminal 
Glycine residue of ubiquitin and the ε-amide of the target Lysine (257).  In 
addition to modifying target proteins with mono-ubiquitin, ubiquitin can also be 
attached to itself, forming chains built upon linkages with 7 of the available Lysine 
residues present in ubiquitin  (228).    
The covalent addition of ubiquitin to target proteins requires the function of 
a series of proteins that operate in a process commonly referred to as the 
ubiquitin cascade (257).  This process is initiated by the formation of a thioester 
intermediate formed between ubiquitin and the E1 protein in a process that 
requires ATP (Fig. 2.1)(257).  The ‘charged’ molecule is then passed from the E1 
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 to the E2 protein, through the formation of a second thioester intermediate (257).  
Attachment of ubiquitin to the target molecule requires the activity of the E3 
ubiquitin ligase.  Several hundred of E3 ubiquitin ligases have been found to be 
expressed in mammalian cells, where they participate in multiple processes such 
as protein turnover, receptor downregulation, and transcriptional regulators (257).  
Although there are hundreds of these enzymes, E3 ubiquitin ligases have been 
broadly grouped into two subsets based on the structures used to transfer 
ubiquitin from the charged Ub-E2 to the substrate. 
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Members of the RING family (Really New Interesting Gene) of E3 ubiquitin 
ligases serve as intermediates during the ubiquitination process (130).  While 
these proteins are required for the formation of the amide bond between ubiquitin 
and the substrate, ubiquitin-substrate bond formation is the result of transfer from 
the charged E2-Ub to the substrate without the formation of an E3-Ub 
intermediate (130).  This method of substrate ubiquitination differs greatly from 
that observed with the second group of E3s, those containing a HECT domain 
(130, 257). 
HECT (Homologous to E6AP Carboxyl Terminus) domain E3 ubiquitin 
ligases direct the ubiquitination of target Lysines through the formation of a high 
energy thioester intermediate, directly interacting with ubiquitin at a Cys residue 
present in the enzyme’s active site.  Interestingly, it has been reported in the 
literature that specific E2 molecules are utilized by specific E3 ligases and that 
E2-E3 combinations may play a functional role in determining polyubiquitin chain 
linkages (154), although HECT E3 ligases have been shown to specify ubiquitin-
linkage directly (147).  Unlike RING containing E3 ubiquitin ligases, HECT 
domain containing E3s generally contain recognition sites within the enzyme for 
direct interaction with substrates (181).  The type of substrate recognition site 
present in the enzyme has been used to organize these ligases into three distinct 
families (181).  One family, the NEDD4 family of E3s, contains enzymes that 
possess multiple WW domains used to bind to substrates containing the PPxY 
recognition motif (122, 181).  The second family contains two groups referred to 
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as the Large and Small HERC E3s; members of this group are designated by the 
presence of at least one RLD domain (Recognizer of Chromatin Condensation 
Like Domain) and based on cellular localization have been implicated in 
endosomal activity (112, 181, 257), although a role in innate immunity has also 
been reported (64).  Finally, the family of HECT domain-containing ubiquitin 
ligases (SI) is comprised of all other HECT E3s (181).  Members of this family 
are classified by the presence of multiple different substrate recognition domains, 
or in certain cases, no domain at all (257).  For example, while HUWE1 ligase 
contains 5 different domains, the ubiquitin ligase E6AP contains none (257). 
In addition to the varieties of substrate recognition domains, structural 
differences in the catalytic HECT domains themselves have been observed.  The 
crystal structures of the HECT domains of E6AP, HUWE1 (SI family), Nedd4, 
WWP1 and ITCH (NEDD4 family) have all been reported allowing for their 
comparison (71, 114, 188, 223, 298).  All 5 reported structures display overall 
similar tri-lobal arrangement with N-terminal and C-terminal lobes of the HECT-
domain flanking the catalytic cysteine residue.  However, the orientation of the 
lobes relative to each other differs between the two families; HECT domains of 
E6AP and HUWE1 have their lobes oriented in a T shape (114, 223), while the 
HECT domains of NEDD4 family members are oriented in more of an L shape 
(71, 166, 188, 298).  This difference in HECT domain structure may account for 
the observed preferences in ubiquitin chain specificity, although is possible that 
the chain-type specificity is dictated at the level of E2 interaction as well, and this 
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would make sense considering the catalytically inactive nature of the RING finger 
E3s (130).  However, a recent study indicated that the C-lobe of HECT domain 
E3 ubiquitin ligases plays an important role in determining ubiquitin chain-type 
specificity (147).     
Mono- and Polyubiquitin as recognition motifs 
Recognition and interaction of ubiquitinated proteins of the cell are the 
result of hydrophobic interactions between ubiquitin and specific domains 
referred to here as ubiquitin binding motifs (241).  The hydrophobic region of 
ubiquitin, termed the hydrophobic patch, is centered around three key residues, 
Leu 8, Ile44 and Val70, and mutation of these regions can result in variable 
recognition defects with cellular binding partners (166).  Attachment of a single 
ubiquitin molecule to a substrate, monoubiquitination, is sufficient to target 
cellular receptors for internalization from the plasma membrane (272, 281).  
However, direction to other cellular pathways is based upon the recognition of 
polyubiquitin chains, formed by the attachment of one ubiquitin molecule to any 
of the seven Lys residues found in ubiquitin (13).  Two of the most studied forms 
of polyubiquitin chains are those formed through linkages between Lys 48 or Lys 
63 (respectively referred to as K48 or K63 chains)(13, 166). 
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Generation of either of these two polyubiquitin chains results in the 
formation of specific secondary structures (65) which serve as a different 
recognition motif for cellular proteins, and the formation of these chains is 
determined by at the level of the E3 ubiquitin ligase (147, 306) or at the level of 
E2 recruitment others (154).  As Fig. 2.2 illustrates, the resulting structure of K48 
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linkages sequesters the hydrophobic patch of ubiquitin into a cleft formed 
between the two adjacent ubiquitin molecules (65).  In contrast, the linear 
structure formed by K63-linked ubiquitin chains results in a repetitive structure of 
unobstructed hydrophobic patches (65).  The more open structure of the K63-
linked chain allows for recognition by molecules that contain only one ubiquitin 
interaction motif, such as Tsg101, as well as proteins that contain multiple sites 
capable of recognizing the specific pattern of hydrophobic patches (Fig. 2.2) 
(284, 295).  Thus, it can be seen how the attachment of polyubiquitin chains 
formed through different linkages can add functional complexity to ubiquitin 
recognition and result in different downstream effects than monoubiquitin alone. 
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Research Aims  
As mentioned previously, deletion or mutation of the endogenous PTAPP 
L-domain of HIV-1 results in a release defect characterized by viral particles that 
fail to mature and remain tethered to the plasma membrane (69).  Particle 
release and infectivity could be rescued by overexpression of ALIX, which 
interacts with the less effective YPxL motif to recruit the ESCRT machinery (78, 
291).  Interestingly, two labs recently reported that overexpression of a Nedd4 
isoform, NEDD4-2s, was able to potently rescue release of the same PTAPP 
deficient virus (HIV-1ΔPTAPP) (56, 292).  In addition, siRNA mediated knockdown 
of endogenous NEDD4-2s decreased the already limited release observed with 
this mutant, suggesting that NEDD4-2s accounted for the majority of released 
particles, and not ALIX (56).  Interestingly, siRNA mediated knockdown of 
endogenous Tsg101 abrogated the rescue phenotype, although expression of 
dominant negative fragments of Tsg101 indicated that neither the UEV nor the 
PRD of the protein was required for NEDD4-2s stimulated rescue, implying that 
ubiquitin recognition or ALIX interaction was not a major contributor to this 
activity (56).  It was determined that this rescue was dependent on both the N-
terminal portion of NEDD4-2s and a catalytically active HECT domain (292).  
While most other Nedd4 family members contain a complete C2 domain, 
NEDD4-2s, a naturally occurring isoform of Nedd4.2, contains only a residual C2 
domain due to alternative exon usage (123).  The previous finding that this partial 
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C2 domain was required for the observed rescue activity of NEDD4.2s suggests 
that it may constitute a functional domain.  
In light of these findings, we determined what roles the required partial C2 
domain and HECT domain of NEDD4.2s play in the rescue of HIV-1ΔPTAPP 
release.  We hypothesized that the partial C2 domain constituted a Gag-targeting 
motif, and to test this we replaced it with a molecule known to interact with HIV-1 
Gag, Cyclophilin A.  We also sought to determine if the required HECT domain of 
NEDD4.2s could be replaced by other functional HECT domains that were either 
closely or distantly related.  Finally, based on these findings, we investigated the 
role that the formation of K63-polyubiquitin chains played in rescuing the release 
of the L-domain-defective HIV-1 construct.  The results of these experiments are 
presented here. 
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Results 
   
Targeting of the catalytic HECT of NEDD4-2s to HIV-1 Gag is sufficient to 
rescue HIV-1ΔPTAPP release 
 It was previously determined that the residual C2 domain of NEDD4-2s 
was required for the ability of NEDD4-2s to rescue HIV-1ΔPTAPP release (292).  
We hypothesized that the partial C2 domain of NEDD4-2s constituted a Gag 
interaction motif, and to test this decided to replace it with a protein known to 
interact with Gag.  For this purpose we chose the human protein Cyclophilin A 
(CypA), which has been shown to interact with the CA domain of HIV-1 Gag (81, 
289).  We replaced the partial C2 domain of NEDD4-2s, residues 1-31, with 
CypA followed by HA and FLAG tags, fused to the remaining region of NEDD4-
2s (CypA-NΔ1-31).  The presence of the CypA molecule was expected to target 
the construct to HIV-1 Gag.   
 Consistent with previously published results (292), co-transfection of 293T 
cells with vectors encoding HIV-1ΔPTAPP and FLAG-tagged NEDD4-2s robustly 
rescued particle release as measured by the amount of extracellular CA (Fig 
2.3).  NEDD4-2s also corrected the Gag cleavage defect of HIV-1ΔPTAPP, which 
leads to the accumulation of CA-p2 at the expense of mature CA in virus-
producing cells (Fig. 2.3). Although the mechanistic basis for this cleavage defect 
remains unknown, impaired processing at the CA-p2 site is considered a 
hallmark of late assembly defects.  Also as expected, removal of the first 31  
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amino acids of NEDD4-2s, containing the partial C2 domain (NΔ1-31), completely 
abrogated the rescue effect (Fig. 2.3 (292).  In contrast, expression of the protein 
containing CypA in place of the partial C2 domain (CypA-NΔ1-31) with the HIV-
1ΔPTAPP construct was able to rescue viral particle production to levels 
comparable to that observed with WT NEDD4-2s (Fig. 2.3).  In addition, CypA-
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NΔ1-31 was able to correct the intracellular Gag cleavage defect of HIV-1ΔPTAPP 
(Fig. 2.3).  These results demonstrated that the CA-binding protein Cyclophilin A 
can be used in place of the native partial C2 domain of NEDD4-2s to stimulate 
release of HIV-1ΔPTAPP particles. 
 The partial C2 domain of NEDD4-2s is separated from the catalytic HECT 
domain by a region that contains four WW domains that take part in substrate 
recognition (Fig. 2.3).  To determine whether these domains played any role in 
the rescue of HIV-1ΔPTAPP, we fused CypA followed by HA and FLAG epitopes to 
truncated version of NEDD4-2s that lacked the first two (CypA-NΔ1-275) or all four 
(CypA-HECT) WW domains.  As shown in Fig. 2.3, both chimeric constructs 
were highly active in the ΔPTAPP rescue assay.  Both constructs stimulated the 
release of particle-associated CA, and exhibited modest effects on intracellular 
Gag cleavage.  Of note, it was previously shown that truncated mutants that lack 
both the N-terminus and CypA displayed no activity in this assay (292).  We thus 
conclude that the targeting of the isolated HECT domain of NEDD4-2s to Gag via 
CypA is sufficient to rescue release and correct HIV-1 budding defects. 
Transfer of the residual C2 domain of NEDD4-2s confers the ability to 
rescue HIV-1 release to a yeast homologue 
 Previous results generated by our lab indicated that overexpression of 
Nedd4 ubiquitin ligase family members Nedd4, WWP1, WWP2 and ITCH had no 
significant effect on the release of HIV-1ΔPTAPP (292).  Since all of these proteins 
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possess an intact C2 domain, a variant of WWP1 was generated that lacks the 
exact portion of the C2 domain which is naturally absent from NEDD4-2s.  The 
resulting WWP1s mutant remained inactive in the ΔPTAPP rescue assay, 
indicating that the robust activity of NEDD4-2s is not simply due to its naturally 
truncated C2 domain (292).  To determine what region of NEDD4-2s accounts for 
its unique ability to rescue HIV-1ΔPTAPP release, we generated FLAG-tagged 
chimeras between N-terminal portions of Nedd4.2.s and WWP1 as illustrated in 
Fig. 2.4.  Interestingly, while full length WWP1s displayed no ability to rescue 
release of HIV-1ΔPTAPP budding (292), a fusion protein containing the first 245 
residues of NEDD4-2s in place of the endogenous region of the protein (N1-
245/WWP1), displayed a robust rescue phenotype with particulate CA levels at 
least as high as WT NEDD4-2s (Fig. 2.4).  In addition, this chimera was also able 
to correct the characteristic Gag cleavage defect to levels similar to those 
observed with WT NEDD4-2s (Fig. 2.4).  Quantitation of virion-associated CA in 
this experiment indicated that NEDD4-2s increased release 25-fold compared to 
empty vector, while the N1-245/WWP1 construct demonstrated a 43-fold effect.  
Additional fusion proteins were generated to remove portions of NEDD4-2s to try 
and arrive at a minimal portion required for activity.  The first 245 residues of 
NEDD4-2s contain the first WW domain as well as a long, non-interacting  
65 
 
 
segment (Fig. 2.4).  A construct that lacked this long intervening segment was 
generated (N1-110/WWP1), and co-transfected with HIV-1ΔPTAPP; this construct 
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was able to rescue release to levels 20-fold higher than vector, despite being 
poorly expressed (Fig. 2.4).  Finally, a construct containing N-terminal portions of 
NEDD4-2s up to, but not including, first WW domain was created and stimulated 
a 40-fold increase in particulate CA, indicating that only sequences upstream of 
the NEDD4-2s WW domain were required for activity in this assay (Fig. 2.4). 
 The results above strongly suggested that the partial C2 domain of 
NEDD4-2s was specifically required for activity.  To test this, we tried to confer 
the rescue ability of NEDD4-2s to the Nedd4 family member AIP4/ITCH by 
replacing its complete C2 domain with the first 37 amino acids of NEDD4-2s, 
which contain only the partial C2 domain of that molecule.  As shown in Fig. 2.4, 
co-expression of this NEDD4-2s/ITCH chimera (N1-37/ITCH) rescued the release 
of HIV-1ΔPTAPP and corrected Gag cleavage to levels equal to that of WT NEDD4-
2s.  Although it has recently been reported that overexpression of WT ITCH is 
able to rescue release of a murine leukemia virus that lacks a functional Late 
domain (126), previous results from our lab have demonstrated that 
overexpression of WT ITCH shows no activity in the rescue of HIV-1ΔPTAPP (292).  
Together, these findings indicate that the partial C2 domain of NEDD4-2s is both 
required and sufficient to transfer the ability to rescue HIV-1 budding to other, 
previously non-functional, ubiquitin ligases. 
 To determine the generality of these findings, we tested whether we could 
use the partial C2 domain of NEDD4-2s to target a yeast ubiquitin ligase to 
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rescue HIV-1ΔPTAPP budding defects.  The E3 ubiquitin ligase Rsp5 is the sole 
Nedd4 homologue encoded by Saccharomyces cerevisiae, and it contains the 
similar modular structure of an N-terminal C2 domain, three WW domains, and a 
C-terminal HECT domain.  As illustrated in Fig. 2.4, we replaced the full-length 
C2 domain of Rsp5 with the N-terminal 37 amino acids of NEDD4-2s containing 
its partial C2 domain (N1-37/Rsp5).  When co-expressed in 293T cells with the 
vector encoding HIV-1ΔPTAPP, the N1-37/Rsp5 fusion protein displayed an almost 
identical ability to rescue particle release compared to WT NEDD4-2s, even 
though it was expressed at lower levels (Fig. 2.4).  In contrast, the parental, full-
length Rsp5 displayed only a minimal ability to rescue particle release and did 
not noticeably affect Gag cleavage defects (data not shown).  These findings 
indicate that the residual C2 domain of NEDD4-2s is sufficient to confer the 
ability to function in HIV-1 budding to widely divergent Nedd4 family members 
from different species. 
 
The residual C2 domain of NEDD4-2s confers the ability to associate with 
HIV-1 Gag 
 It was previously demonstrated that the residual C2 domain of NEDD4-2s 
is required for its ability to induce Gag ubiquitination, and for its incorporation into 
virus-like particles (VLP) (292).  To examine those parameters, a Gag construct 
referred to as ZWT was used.  The Gag ZWT construct contains a foreign 
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dimerization domain in place of HIV-1 NC-p6 and efficiently produces VLP in an 
ESCRT-independent manner (1).  Furthermore, ZWT Gag exhibits less baseline 
ubiquitination than authentic HIV-1 Gag.  This construct was used to determine 
the levels of ubiquitin ligase incorporation into VLP as well as to determine the 
formation of Gag-ubiquitin conjugates, independent of VLP production. 
 Previous observations from our lab found that co-expression of ZWT with 
FLAG-tagged NEDD4-2s resulted in the appearance of additional Gag species in 
ZWT VLP that migrated slower than the ZWT precursor, and it was determined that 
these slower migrating species represent Gag-ubiquitin conjugates (1, 292).  
These conjugates were not observed in ZWT VLP that were obtained from 
samples co-expressed with either catalytically inactive FLAG-NEDD4-2s or active 
FLAG-WWP1s (292).  Also, only WT NEDD4-2s was shown to incorporate into 
ZWT VLP; no FLAG signal was observed with either inactive NEDD4-2s or 
WWP1s in ZWT VLP (292).  These findings were in agreement with a lack of 
activity for both of these constructs in the HIV-1ΔPTAPP rescue assay.  In contrast 
to this result, when ZWT was cotransfected with FLAG-tagged versions of N1-
245/WWP1, N1-110/WWP1, or N1-73/WWP1- all of which rescued HIV-1ΔPTAPP 
release- all were found to be incorporated into VLP (Fig. 2.5).  In addition, all 
three constructs induced a similar pattern of Gag-ubiquitin conjugation to that 
observed with WT NEDD4-2s (Fig. 2.5).  Results similar to those observed with 
the WWP1 chimeras were observed with the N1-37/ITCH and N1-37/Rsp5 chimeras  
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 (Fig. 2.5).  We found that both N1-37/ITCH and N1-37/Rsp5 induced very similar 
levels of Gag ubiquitination as NEDD4-2s (Fig. 2.5).  Further, particularly with 
regard to N1-37/Rsp5 construct, the pattern of Gag ubiquitination was virtually 
identical to that observed with NEDD4-2s (Fig. 2.5).  In addition, both N1-37/ITCH 
and N1-37/Rsp5 were incorporated into VLP at levels even greater than those 
observed with NEDD4-2s (Fig. 2.5).  Taken together, these results indicate that 
the residual C2 domain of NEDD4-2s is sufficient to transfer the ability to 
associate with HIV-1 Gag to other Nedd4 family members, which thereby gain 
access to VLP and the ability to ubiquitinate Gag. 
 
Isolated HECT domains differ in their ability to rescue HIV-1 budding when 
fused to the residual C2 domain of NEDD4-2s 
 As described above, we found that the isolated HECT domain of NEDD4-
2s is sufficient to rescue the release of HIV-1ΔPTAPP particles if fused to a Gag 
interacting protein such as Cyclophilin A.  Furthermore, our results suggested 
that the residual C2 domain of NEDD4-2s can serve as a Gag-binding module.  
We therefore asked whether the isolated HECT domains of other human HECT 
ubiquitin ligases can promote HIV-1ΔPTAPP budding if fused to the residual C2 
domain of NEDD4-2s.  Among the HECT domains selected for this analysis were 
those belonging to Nedd4 family members SMURF1, HECW1 and HECW2, 
which were derived from different ancestral genes than NEDD4-2s, WWP1 or 
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ITCH (181).  We also included the HECT domains of E6-AP and HERC6, which 
are members of the SI-HECT domain and HERC families, respectively (20).  All 
selected HECT domains were directly fused to a FLAG-tagged construct 
containing the partial C2 domain of NEDD4-2s, and the fusion proteins were 
expressed in 293T cells with a plasmid encoding the PTAPP- deficient HIV-1 
construct.  Two of the HECT domain constructs (N1-37/HECW1 and N1-
37/HECW2) displayed the ability to rescue particle release and to correct the 
Late-domain-associated Gag cleavage defect (Fig. 2.6).  Release of particulate 
CA and intracellular conversion of CA-p2 to CA stimulated by both HECT E3 
domains was similar to that observed with WT NEDD4-2s (Fig. 2.6).  In contrast, 
constructs containing the HECT domains of SMURF1, E6-AP and HERC6 failed 
to rescue particle release to any noticeable extent, despite being expressed at 
comparable levels (Fig. 2.6). 
 As shown in Fig. 2.6, only the two constructs containing the HECT 
domains of HECW1 and HECW2 displayed the ability to induce formation of ZWT 
Gag ubiquitin conjugates to levels similar to those observed with NEDD4-2s.  In 
contrast, the constructs containing the HECT domains of SMURF1, E6-AP or 
HERC6 failed to induce any Gag ubiquitination.  It is possible that these 
constructs were not catalytically active since no evidence of autoubiquitination 
was observed.  Also, HERC6 is an interferon-induced protein that, based on 
similarity with human HERC5 and mouse HERC6, may be a ligase for ISG15 and 
not ubiquitin (64, 299).  However, it did appear that the construct containing the  
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SMURF1 HECT domain was catalytically active, based on the presence of a 
slower migrating molecular weight band which was also observed in the 
constructs that were able to rescue HIV-1ΔPTAPP release (Fig. 2.6). 
 To more directly determine whether the HECT domain constructs were 
capable of associating with HIV-1 Gag, we also examined their incorporation in 
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ZWT VLP.  The two active HECT domain constructs were readily detectable in 
VLP.  In fact, relative to their expression levels, N1-37/HECW1HECT and N1-
37/HECW2HECT were incorporated at 14- and 46-fold higher levels that NEDD4-
2s, respectively (Fig. 2.7).  In contrast, two of the three inactive constructs (N1-
37/SMURF1HECT and N1-37/E6-APHECT) were not incorporated, even though they 
were expressed as well or better than the constructs that were taken up into VLP 
(Fig. 2.7).  The third inactive construct (N1-37/HERC6HECT) was incorporated at 
about 4-fold higher levels that NEDD4-2s, normalized for expression levels (Fig. 
2.7).  The N1-37/HECW2HECT construct exhibited the lowest level of expression but 
the highest level of VLP association, which suggested that the HECT domain of 
HECW2 in particular contributed to the association with HIV-1 Gag (Fig. 2.7).  
However, a version of N1-37/HECW2HECT that lacked the residual C2 domain of 
NEDD4-2s did not induce Gag ubiquitination, was not incorporated into VLP, and 
was inactive in the ΔPTAPP rescue assay (Fig. 2.7) 
 Taken together, these results show that the residual C2 domain of 
NEDD4-2s is sufficient to target a subset of isolated HECT domains to HIV-1 
Gag.  They also show that the isolated HECT domain of NEDD4-2s is not unique 
in its ability to rescue HIV-1 budding when targeted to Gag.  Rather, this ability is 
shared by the HECT domains of the two human Nedd4 family members that are 
overall most divergent from NEDD4-2s. 
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Induction of Gag ubiquitination is not sufficient to rescue the release of 
HIV-1ΔPTAP budding 
 The apparent inability of the N1-37/SMURF1HECT construct to associate with 
HIV-1 Gag offered a possible explanation for its failure to rescue HIV-1ΔPTAPP 
budding and to ubiquitinate ZWT Gag, despite being able to auto-ubiquitinate.  We 
therefore examined the effect of targeting the SMURF1 HECT domain to HIV-1 
Gag via CypA.  As shown in Fig. 2.8, fusing the HECT domains of SMURF1, E6-
AP and HERC6 directly to CypA did not confer the ability to rescue HIV-
1ΔPTAPP.  In contrast, the equivalent CypA-NHECT construct, which instead 
contains the HECT domain of NEDD4-2s, did rescue nearly as well as WT 
NEDD4-2s, as expected.  Although all CypA-HECT domain fusion proteins were 
incorporated into ZWT VLP, those containing the HECT domain of E6AP of 
HERC6 did not ubiquitinate ZWT Gag, consistent with the possibility that these 
HECT domains are catalytically inactive in isolation (Fig. 2.8).  Surprisingly, the 
CypA fusion proteins with the NEDD4-2s and SMURF1 HECT domains induced 
comparable level of Gag-ubiquitin conjugates (Fig. 2.8), even though only the 
former was active in the ΔPTAPP rescue assay (Fig. 2.8).  Moreover, although 
the CypA fusion protein with the NEDD4-2s HECT domain (Cyp-NHECT) and WT 
NEDD4-2s exhibited comparable activities in the ΔPTAP rescue assay (Fig. 2.8), 
the former induced a much lower level of ZWT Gag ubiquitination (Fig 2.8).  These 
results demonstrate that the mere ability to ubiquitinate Gag is not sufficient to 
rescue HIV-1 budding.  Furthermore, if the ubiquitination of Gag is necessary to  
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promote budding, then only relatively low levels of Gag ubiquitination are 
required. 
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Rescue of HIV-1 budding correlates with ubiquitin chain-type specificity 
 The lack of correlation between the rescue of HIV-1 budding and the 
overall levels of Gag ubiquitination led us to investigate the possible role of the 
type of ubiquitin chain that can be formed.  It was recently shown that ITCH, 
which potently rescues HIV-1 budding when targeted to Gag (Fig. 2.4), has a 
very high preference for the synthesis of K63-linked polyubiquitin chains (147).  
However, the replacement of the C-lobe of the HECT domain of ITCH with that of 
E6AP caused a complete switch to K48 chain type specificity (147).  On the other 
hand, an ITCH-HUWE1 C-lobe chimera produced both relatively short K48 
chains and even shorted K63 chains (147).  HUWE1 is a large HECT domain 
ubiquitin ligase that does not belong to the Nedd4 family, but is relatively closely 
related in its HECT domain (257). 
 To examine the role of chain type specificity in the rescue of HIV-1 
budding, we replaced the C lobe of N1-245/ITCH with that of E6AP or HUWE1, as 
illustrated in Fig. 2.9. N1-245/ITCH rescues HIV-1ΔPTAPP as potently as N1-37/ITCH, 
and thus was used here because HECT C lobe chimeras based on this construct 
were relatively stable (data not shown).  The N1-245/ITCH E6AP C lobe chimera 
appeared to have no effect on HIV-1 budding, but was too poorly expressed to 
yield reliable results (data not shown).  In contrast, the N1-245/ITCH HUWE1 C 
lobe chimera was expressed at higher levels.  However, even at expression  
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levels similar to or higher than those obtained with the parental N1-245/ITCH 
construct, N1-245/ITCH-HUWE1 had at most a small effect on the release of HIV-
1ΔPTAPP, whereas N1-245/ITCH potently rescued budding (Fig. 2.9).  Nevertheless, 
the parental N1-245/ITCH construct and N1-245/ITCH-HUWE1 induced comparable 
levels of ubiquitination both of ZWT Gag (Fig. 2.9) and of authentic HIV-1 Gag 
expressed by a proviral protease mutant (Fig. 2.9).  
 Interestingly, the pattern of ZWT Gag ubiquitination seen with N1-245/ITCH-
HUWE1 differed slightly from that obtained with N1-245/ITCH (Fig 2.9), consistent 
with the possibility that these two proteins catalyze different chain linkages, as 
previously shown for ITCH-HUWE1 and ITCH in vitro (147).  To examine this 
possibility directly, we made use of the linkage-specific antibodies Apu3 and 
HWA4C4, which exhibit high selectivity for K63-linked ubiquitin chains (209, 305).  
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In the experiment shown in Fig. 2.9, N1-245/ITCH-HUWE1 was more highly 
expressed that N1-245/ITCH, and induced higher overall levels of ZWT Gag 
ubiquitination as detected by immunoblotting of ZWT particles with anti-CA 
antibody (left panel).  Nevertheless, when the same samples were examined by 
Western blotting with the K63-linkage specific Apu3 antibody, only the parental 
N1-245/ITCH construct yielded three prominent bands (right panel).  The mobility 
of these three bands was as expected for ZWT Gag modified with di-, tri-, or tetra-
ubiquitin chains.  Equivalent results were obtained with HWA4C4, another K63-
linkage specific antibody (data not shown).   
In order to verify these findings, we attempted to return K63-linked chain 
specificity to the N1-245/ITCH-HUWE1 construct.  Previous work by Kim et al. 
reported that the chain-type specificity of HECT E3 ubiquitin ligases could be 
altered by exchanging portions of their C-lobes with that of another HECT 
domain (147).  The C-terminal 57 amino acids of the ITCH HECT domain were 
fused in place of the equivalent region of the HECT domain of N1-245/ITCH-
HUWE1 – replacing the C-terminal 67 amino acids of that protein, generating the 
construct we refer to here as N1-245/ITCH-HUWE-ITCH.  While this construct was 
less well expressed than the parental N1-245/ITCH protein, it was expressed at 
high enough levels for us to compare its activities to N1-245/ITCH-HUWE1.  As 
Fig. 2.10 demonstrates, replacement of the C-terminal portion of HUWE1 with 
that of ITCH resulted in release of HIV-1ΔPTAPP particles at levels similar to those 
observed with N1-245/ITCH.  As before, rescue of HIV-1ΔPTAPP by N1-245/ITCH- 
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Figure 2.10. Rescue of HIV-1 release correlates with chain type specificity.
(A) Schematic illustration of chimeric ubiquitin ligase constructs. Residues from 
HUWE1 are indicated in yellow. (B) Replacement of the C lobe of the ITCH HECT 
domain by that of HUWE1 greatly impairs the rescue of HIV-1ΔPTAPP by a NEDD4-
2s/ITCH chimera . Restoring the C-terminus of the ITCH C-lobe restores the ability 
to rescue HIV-1ΔPTAPP release.  (C) Restoration of release correlates with the 
restoration of  K63 polyubiquitin chain specificity.  293T cells were transfected with 
HXBH10ΔPTAPP or the ZWT Gag construct and empty vector, or vectors expressing 
FLAG-tagged versions of the indicated HECT domain constructs. Gag proteins 
from released HXBH10ΔPTAPP and VLP samples were analyzed by Western blotting 
with anti-CA to detect : Gag and Gag cleavage products (panel B) as well as 
unmodified and ubiquitinated versions of ZWT Gag, and in parallel with Apu3 to 
detect K63-linked ubiquitin chains conjugated to ZWT Gag (panel C). The cell 
lysates from both experiments were also examined with anti-FLAG to detect 
expression of HECT domain constructs.
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HUWE1 showed hardly any effect, even when compared to a lower concentration 
of the parental construct.  Analysis of the ubiquitination pattern of ZWT particles 
by immunoblotting with the K63-specific Apu3 antibody demonstrated that the 
partial C-lobe of ITCH was sufficient to return K63-chain specificity to this 
chimera.  We conclude that the chain type specificities of N1-245/ITCH and N1-
245/ITCH-HUWE1 in living cells differ considerably, and that the ability to catalyze 
K63-linked chains is of critical importance for the rescue of HIV-1 release. 
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Discussion 
 We show here that widely divergent human and yeast ubiquitin ligases of 
the Nedd4 family, and even a subset of isolated HECT domains, possess the 
intrinsic ability to function in HIV-1 release.  The truncated C2 domain of NEDD4-
2s provides a natural Gag-targeting module, which accounts for the unique ability 
of authentic NEDD4-2s to rescue HIV-1 budding defects.  However, other Nedd4 
family members, including yeast Rsp5, and in some cases even isolated catalytic 
HECT domains, acquire the same ability if targeted to HIV-1 Gag.  A common 
property that is shared by widely divergent Nedd4 family members is the 
preferential catalysis of K63-linked ubiquitin chains, and at least in the case of 
yeast Rsp5, the isolated HECT domain is sufficient to synthesis such chains 
(147).  Our data support a model in which the ability to conjugate K63 chains to a 
viral or cellular substrate in the immediate vicinity of the emerging bud is central 
to the ability to stimulate virus release. 
 In a previous study, the unique potency of NEDD4-2s in the ΔPTAPP 
rescue assay did depend on its C2 domain being truncated, and was not shared 
by several other Nedd4 family members with intact C2 domains (292).  One 
possible explanation for these observations was that the natural truncation of the 
C2 domain in NEDD4-2s relieves an auto-inhibition, which would be consistent 
with a study showing that catalytic activity of a subset of C2-WW-HECT E3s is 
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regulated through an inhibitory interaction between their C2 and HECT domains 
(311).  On the other hand, the residual C2 domain of NEDD4-2s was essential for 
activity in the ΔPTAPP rescue assay (292).  This finding raised the possibility that 
the C2 domain remnant of NEDD4-2s, which corresponds to β-strands 7 and 8 of 
the intact domain, constitutes a functional domain on its own that plays an active 
role in the rescue of HIV-1 budding (311).  The present study supports this notion 
by demonstrating that the residual C2 domain of NEDD4-2s is sufficient to 
transfer the ability to rescue HIV-1 budding defects to other Nedd4 family 
ubiquitin ligases, and even to a subset of isolated HECT domains. 
 Previous results suggested that the C2 domain remnant of NEDD4-2s is 
required for the activity on the ΔPTAPP rescue assay, because it mediates the 
association of the ubiquitin ligase with HIV-1 Gag (292).  In support of this 
concept, we now show that other Nedd4 family members, and some isolated 
HECT domains, associate with HIV-1 Gag if tagged with the residual C2 domain 
of NEDD4-2s.  Additional strong support is provided by the fact that we were able 
to functionally replace the C2 domain remnant of NEDD4-2s with CypA, an 
entirely unrelated protein that has long been known to specifically interact with 
HIV-1 Gag (81, 289).   
 HECT E3s contain two broad functional regions: a large N-terminal region 
required for substrate recognition, and a C-terminal region (the HECT domain) 
which catalyzes the ubiquitination of bound substrates (304).  Apart from the C2 
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domain, the N-terminal regions of Nedd4 family members harbor multiple WW 
domains, which were previously found dispensable for the rescue of HIV-1 
budding by NEDD4-2s (292).  In the present study, essentially the entire N-
terminal substrate recognition portion of NEDD4-2s became dispensable in the 
presence of CypA, which served as a Gag-targeting module.  The simplest 
interpretation of this result is that no substrate other than Gag needs to be 
recognized to stimulate virus release.  However, if a transacting factor rather than 
Gag is the relevant substrate for ubiquitination as proposed (320), then the 
isolated catalytic HECT domain of NEDD4-2s must be sufficient to recognize that 
factor. 
 One potential transacting factor is ESCRT-I, because Sundquist and 
colleagues have demonstrated that the stimulation of HIV-1ΔPTAPP release by 
NEDD4-2s depends on Tsg101/ESCRT-I (56).  Furthermore, these authors 
showed that the NEDD4-2s overexpression induces the ubiquitination of ESCRT-
I complexes, particularly of those that contain MVB12B.  They also reported that 
a PPQY sequence in MVB12B, which constitutes a potential binding site for WW 
domains, contributes to the ubiquitination of MVB12B/ESCRT-I complexes by 
NEDD4-2s.  Based on these results, it was suggested that NEDD4-2s-mediated 
ubiquitination may activate ESCRT-I to function in HIV-1 release (56).  If this 
hypothesis is correct, then our observations imply that NEDD4-2s must remain 
capable of recognizing ESCRT-I as a substrate even in the absence of its N-
terminal substrate recognition domain. 
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 It has also been suggested that Nedd4 family E3s interact through their 
HECT domains with as yet unknown components of the ESCRT pathway, 
because several Nedd4 family members, and the isolated HECT domain of 
WWP1, localized to aberrant endosomal class E compartments induced by 
dominant-negative VPS4 (183).  We have now observed that Rsp5, the single 
C2-WW-HECT E3 of Saccharomyces cerevisiae, can strongly stimulate HIV-
1ΔPTAPP release and Gag processing when its C2 domain is replaced.  Thus, if an 
interaction with an ESCRT pathway component is required for activity in the 
ΔPTAPP rescue assay, such an interaction and the interfaces involved must be 
conserved between yeast and man.  One reported interaction that potentially 
meets these criteria is that between Nedd4 and ALIX or their yeast homologues 
Rsp5 and Bro1 (212).  Notably, the protein regions involved in the interaction 
appear conserved, because yeast Rsp5 co-immunoprecipitated with mammalian 
ALIX (212).  However, the Nedd4-ALIX interaction may depend on the WW 
domains of Nedd4, which are dispensable for the ability of NEDD4-2s to rescue 
HIV-1ΔPTAPP (212, 292). 
 In principle, ESCRT pathway components could also be recruited via 
ubiquitinated Gag, because the upstream ESCRT complexes each possess at 
least one component that binds ubiquitin (165, 251).  For instance, the human 
ESCRT-I components Tsg101 and VPS37A contain ubiquitin-binding domains 
(120).  It was also recently reported that the ESCRT-associated protein ALIX 
specifically binds to ubiquitin (133).  However, at least the ubiquitin-binding 
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activity of Tsg101 is not required for the rescue of HIV-1 budding by NEDD4-2s 
(56).  Also, there is evidence that the ubiquitination of Gag is dispensable, 
because the PPxY-dependent budding of a foamy virus Gag protein completely 
devoid of ubiquitin acceptors could be stimulated by catalytically active WWP1 
(183).  However, in the latter case, Gag-associated WWP1 could have served as 
an alternative ubiquitin acceptor, since the enzyme is capable of 
autoubiquitination. 
 K63-linked ubiquitin chains are required for the transport of at least some 
cargo into MVB (165), and have also been implicated in the function of PPxY-
type L domains (280), which act by recruiting Nedd4 family members (23).  
Several Nedd4 family members have indeed been shown to preferentially 
synthesize K63-linked ubiquitin chains, including mammalian Nedd4.1 and ITCH 
(147, 148, 267), as well as yeast Rsp5 (147).  In contrast, E6AP, another HECT 
domain E3, preferentially synthesizes K48-linked chains, which provide a signal 
for proteasomal degradation (143, 148).  At least in the case of ITCH, chain type 
specificity is determined that the C lobe of the HECT domain (147).  For instance, 
the replacement of the C lobe of ITCH with that of HUWE1 considerably reduces 
the preference for the synthesis of K63 chains.  In the present study, we 
observed that an ITCH/HUWE1 C lobe chimera did not efficiently rescue HIV-1 
budding.  Interestingly, the C lobe chimera retained the ability to efficiently 
ubiquitinate Gag, but lacked the ability of the parental ITCH construct to induce 
the attachment of K63-linked ubiquitin chains to Gag.  Taken together, these data 
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indicate that the ability to synthesize K63 chains is crucial for the stimulation of 
HIV-1 budding. 
 Structural studies indicate that the conformations of K63- and K48-linked 
chains are markedly distinct (65).  Specifically, K63-linked di- or tetraubiquitin 
chains exhibit an extended conformation in which the functionally important 
surface hydrophobic residues are constitutively exposed, whereas K48-linked 
chains can adopt a closed conformation in which these hydrophobic surface 
residues are sequestered (65, 288, 295, 296).  It is thus likely that linkage-
specific conformations provide a basis for the recruitment of distinct cellular 
recognition factors.  Interestingly, it has recently emerged that K63-linked 
ubiquitin chains serve as specific signals for the ESCRT-dependent sorting of 
cargo into MVBs.  For instance, in the case of the yeast membrane protein Gap1, 
monoubiquitination is sufficient for its efficient endocytosis (166).  However, the 
presence of short K63-linked chains is required for the entry of the Gap1 into the 
MVB pathway (166), suggesting preferential recognition of K63-linked chains by 
some component of the ESCRT machinery.  The results presented here imply 
that HECT ubiquitin ligase-stimulated virus budding, which is also ESCRT-
dependent (23, 49), is governed by the same type of ubiquitin modification. 
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UPDATE AND FUTURE RESEARCH 
 Since the publication of this manuscript, several studies have reported 
findings that are relevant to our results (252, 319).  For example, using a 
retroviral Gag molecule (PFV) that was mutated to remove all potential ubiquitin 
acceptor sites, Zhadina and Bieniasz investigated the role of multiple NEDD4 E3 
ubiquitin ligases in budding (319).  As mentioned earlier, this construct, which 
contains an endogenous PPxY motif used to recruit NEDD4 family members, 
buds and releases efficiently when co-expressed with a broad range of NEDD4 
ubiquitin ligases (319, 320).  Interestingly, release of this construct required both 
the presence of the PPxY motif in the viral Gag molecule and a catalytically 
active HECT domain, in spite of the fact that the PFV Gag contained no ubiquitin 
acceptor sites, suggesting that either ubiquitination of some other ESCRT related 
protein was required or that the HECT domains themselves could be used as 
ESCRT recognition domains (319).  This latter point was underscored by the 
correlation they observed between auto-ubiquitination of these HECT domains 
and release; those HECT domains which showed a high level of auto-
ubiquitination also demonstrated an increase in particle release (319).  Using 
RNAi they also demonstrated that release of PFV Gag under these 
circumstances required the presence of ALIX and Tsg101 (319).  It has been 
shown previously that the UEV domain of Tsg101 is capable of binding to 
ubiquitin and recruiting ESCRT complexes to facilitate release (133, 245), and a 
similar interaction between ALIX and ubiquitin has been shown (133).  In light of 
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the results we have obtained it is worth investigating whether the recruitment of 
Tsg101 and ALIX observed by Zhadina are related to the ability of the tested 
HECT domains to form K63-linked polyubiquitin chains.   
 A similar relationship between HECT domains and ALIX recruitment has 
also been reported by the Martin-Serrano group, which recently demonstrated 
that Arrestin-related proteins (ARTs) are involved in the release of viral particles 
that utilize PPxY L-domains, and thus recruit NEDD4 family members (252).  
Overexpression of ART proteins results in an inhibition of MLV particle release, a 
defect commonly observed when overexpressing ESCRT proteins (183, 252).  
Also, expression of dominant-negative VPS4, which also acts as an ESCRT 
pathway inhibitor, results in accumulation of ARTs at late endosomes, a 
phenotype often seen with ESCRT pathway subunit proteins (183, 252). 
  Using a yeast 2-hybrid (Y2H) approach they demonstrated interactions 
between Arrestin domain-containing proteins (ARRDC1-3) and NEDD4 ubiquitin 
ligases as well as ubiquitin, Tsg101 and ALIX (252).  These proteins all contain 
either multiple PPxY motifs or in one case, ARRDC1, a Tsg101 binding site in 
addition to two NEDD4 binding sites (252).  Predictably, the interactions between 
ARTs, NEDD4 family members and Tsg101could be abrogated by removal of the 
C-terminal portion of the ARRDC1 protein, which contains the NEDD4 and 
Tsg101 recognition sequences (252).   Interestingly, removal of these recognition 
sequences also prevents the interaction of ALIX with these proteins as 
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demonstrated by Y2H (252).  As no LYPxnL sequence was observed in these 
proteins the lack of ALIX recruitment under these conditions suggests either the 
presence of a cryptic ALIX recruitment site, or that recruitment of ALIX is 
mediated by interaction with Tsg101 or NEDD4 family members (252).  Using co-
immunoprecipitation, the authors demonstrated an interaction between ARRDC1 
and ALIX and mapped this interaction to the Proline Rich Repeat (PRR) of the 
ALIX protein using Y2H (252).  Their data clearly provide additional evidence 
suggesting that NEDD4 recruitment of ESCRT is an ALIX meditated process. 
Lastly, and perhaps most importantly, at the 2011 Cold Spring Harbor 
Conference on Ubiquitin a poster was presented by a member of Ron Kopito’s 
group from Stanford University.  In this poster, the author’s described results 
obtained from investigating cellular proteins that bind specifically to K63-
polyubiquitin chains.  One of their principle findings was that ALIX was able to 
recognize and bind to K63-linked polyubiquitin chains through the V-domain of 
the ALIX protein (unpublished data).  While this paper has yet to be published, 
and thus peered reviewed for content, this finding may indicate how PPxY-motif 
L-domains access the ESCRT pathway to promote viral release. 
 While recruitment of ALIX by K63-polubiquitin chains formed by 
expression of NEDD4 family members answers the question of how these E3 
ubiquitin ligases stimulate particle release, this idea remains unproven.  A series 
of experiments would need to be undertaken to directly show that this suggested 
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recruitment is indeed the mechanism by which PPxY-containing viruses access 
ESCRT.  Fortunately, the constructs that we have already used and published 
would be extremely beneficial in investigating this hypothesis.  Using the 
previously described ZWT Gag construct, which buds in an ESCRT independent 
manner while serving as a suitable substrate for ubiquitination (1), we would be 
able to definitively show recruitment of ALIX to HIV-1 Gag in response to K63-
polyubiquitination by quantifying the amount of ALIX incorporated into these 
particles upon expression of our E3 ubiquitin ligase chimeras.  Based on our 
previous results, we would also be able to use other HECT domain constructs 
that do not form K63 chains as controls.  Also, this technique would allow us to 
map ALIX to determine the relevant domain required for interaction for both K63-
recognition and ESCRT access.  An additional line of investigation that has yet to 
be fully elucidated in the literature is whether retroviral Gag or the NEDD4 
ubiquitin ligase itself is the relevant substrate for K63-polyubiquitination (56, 319, 
320).  Generation of chimeric E3-ubiquitin ligases capable of attaching K63-
chains to substrates, but which are not NEDD4 family members, could be used to 
determine if ALIX recruitment is limited specifically to recognition of K63-chains 
or if it is mediated by the presence of the highly conserved HECT domains of 
these ligases.   
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Materials and Methods 
Proviral constructs 
 HXBH10ΔPTAPP is a mutant of HXBH10, a vpu-positive version of the 
infectious HXB2 proviral clone of HIV-1, with an in-frame deletion of codons 7 
though 11 of p6.  The ZWT variant of HXBH10 encodes a chimeric Gag precursor 
that has NCp1p6 replaced by a leucine zipper dimerization domain. 
 
Expression vectors 
 Plasmids expressing NEDD4-2s, NΔ1-31 (residues 32-834 of NEDD4-2s), 
or WWP1s (residues 110-922 of WWP1) with an N-terminal FLAG tag have been 
previously described, and are based on the mammalian expression vector pBJ5.  
Vectors expressing CypA-HA/FLAG-NEDD4-2s fusion proteins were created 
using an overlap extension technique.  First, DNA fragments with overlapping 
ends were amplified in separate PCR reactions, suing previously described 
vectors encoding CypA-HA and FLAG-tagged NEDD4-2s truncation mutants as 
templates.  The two fragments were then recombined in a second PCR reaction 
as described, and inserted into pBJ5.  The resulting CypA-NΔ1-31, CypA-NΔ1-275, 
and CypA-NΔHECT constructs encode CypA followed by HA and FLAG epitopes, 
which in turn are followed by NEDD4-2s residues 32-834, 276-834, and 432-843, 
respectively.  Vectors expressing CypA-HA/FLAG fused to the isolated HECT 
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domains of SMURF1 (residues 366-757), E6AP (residues 462-852), or HERC6 
(residues 637-1014) were made in an analogous manner using CypA-NΔ1-31 and 
cDNA clones encoding SMURF1 (KIAA1625), E6AP (BC009271), or HERC6 
(BC042047) as templates.  Overlap extension PCR was also used to generate 
pBJ5-based vectors expressing FLAG-tagged residues 1-73, 1-110, or 1-245 of 
NEDD4-2s fused to residues 383-922 of WWP1 (yielding N1-73/WWP1, N1-
110/WWP1, and N1-245/WWP1), using previously described vectors expressing 
FLAG-NEDD4-2s and FLAG-WWP1s as templates.  Furthermore, over extension 
PCR was used to generate pBJ5-based vectors expressing FLAG-tagged 
residues 1-37 of NEDD4-2s fused to residues 142-862 of ITCH (yielding NΔ1-
31/ITCH), residues 138-809 of yeast Rsp5 (yielding NΔ1-31/Rsp5), residues 366-
757 of SMURF1 (yielding NΔ1-31/SMURF1HECT), residues 1207-1606 of HECW1 
(yielding NΔ1-31/HECW1HECT), residues 1162-1572 of HECW2 (yielding NΔ1-
31/HECW2HECT), residues 462-852 of E6AP (yielding NΔ1-31/E6APHECT), or 
residues 637-1014 of HERC6 (NΔ1-31/HERC6HECT).  The templates used included 
previously published plasmids and cDNA clones KIAA1625 (SMURF1), 
KIAA0322 (HECW1), KIAA1301 (HECW2), BC009271 (E6AP), and BC042047 
(HERC6).  The cDNA clones were provided by Kazusa DNA Research Institute 
or purchased from Open Biosystems.  Of note, each HECT domain construct 
includes the N-terminal H1’ helix of the HECT domain.  An expression vector for 
full-length Rsp5 with an N-terminal FLAG tag was generated using standard 
PCR.  Finally, overlap extension PCR was used to generate pBJ5-based vectors 
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expressing FLAG-tagged residues 1-245 of NEDD4-2s fused to residues 142-
862 of WT ITCH (NM_031483), or to versions of ITCH in which the C lobe of the 
HECT domain has been replaced with to the corresponding region of E6AP or 
HUWE1. 
Assays for viral particle production and Gag ubiquitination 
 293T cells (1.2x106) were seeded into T-25 tissue culture flasks 24 hrs 
prior to transfection.  A calcium phosphate precipitation technique was used to 
transfect cell with HXBH10ΔPTAPP (between 0.5 and 2 µg) or ZWT proviral DNA 
(2µg), along with expression vectors encoding the indicated E3 constructs 
(between 1 and 6 µg) or empty vector.  Total DNA transfected was normalized to 
8 µg by the addition of carrier DNA (pTZ18U).  At 24 hrs post-transfection, cell 
culture supernatants were removed and clarified by low-speed centrifugation and 
passage through a 0.45 µm filter.  Clarified supernatants were layered on to 20% 
sucrose, and viral particles were separated using high-speed centrifugation 
(27,000 rpm, 2 h, 4ºC).  Cells were lysed using 1x RIPA buffer with protease 
inhibitors.  Virus pellets and cell lysates were analyzed by SDS-PAGE and 
Western blotting.  The anti-HIV CA antibody 183-H12-5C was used to detect 
Gag, Gag cleavage products, and Gag-ubiquitin conjugates.  Ectopically 
expressed ubiquitin ligase constructs were detected using anti-FLAG (M2; 
Sigma) or anti-HA (HA.11; Covance).  The K63-linkage specific antibodies Apu3 
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and HWA4C4 were purchased from Millipore.  Western blots were quantified with 
the ImageJ software. 
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CHAPTER III  
Analysis of Nef activity in the replication enhancement of HIV-1 in the 
MOLT3 System 
 
 Summary 
 
The role of Nef in the virus life cycle is certainly of clinical importance, as 
the presence of a functional nef allele in the HIV-1 viral genome impacts disease 
progression in the infected individual.  The effects of Nef on the infected cell, 
although broad in scope, pose multiple opportunities as therapeutic targets, 
particularly in light of the fact that most Nef effects are the result of interactions 
between the viral protein and host cell proteins.  Such targets could potentially be 
more effective than current HAART targets, which are viral proteins and subject 
to high levels of mutation.   
To further investigate the role of Nef in HIV-1 infection, we chose to use 
the MOLT3 cell line, in which we have observed a necessity for Nef for HIV-1 
replication, despite modest levels of CD4 expression.  Our results indicate that 
CD4 downregulation is not the major mechanism by which Nef enhances HIV-1 
replication, contrary to published data.  We also report that in the presence of a 
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CD4 variant incapable of downregulation, expression of Nef in trans is sufficient 
to restore replication of HIV-1that lacks a functional nef allele.  Rescue of HIV-
1Δnef replication in the downregulation-resistant CD4 cell line was accomplished 
by Nef proteins from multiple HIV-1 groups and clades.  We also report that in 
the parental MOLT3 cell line, the presence of nef in the viral genome leads to 
enhanced replication even after maximal stimulation with TNFα.  Lastly, we 
report that enhanced replication stimulated by Nef is not dependent on levels of 
particle infectivity, as indicated by the delayed replication kinetics of HIV-1 
genomes containing a portion of the Murine Leukemia Virus Glyco-Gag in place 
of Nef, which enhances HIV-1 particle infectivity to levels similar to WT Nef.  
While no specific mechanism for the increase in replication stimulated by Nef has 
been determined, the results of these experiments suggest that the MOLT3 cell 
culture system presents an opportunity to study how Nef positively impacts the 
replication of HIV-1. 
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Introduction 
 
 Produced early during viral infection, the lentiviral Nef protein is a crucial 
determinant of infection success.  While an early study initially reported Nef to 
play a negative role in viral infection, (Nef – negative factor (51)) more recent 
research demonstrated just how vital this protein is regarding HIV-1 replication 
(144, 248).  Although Nef is generally not required for replication of HIV-1 in most 
cultured cell lines (62), it plays a significant role in disease progression within the 
context of both HIV-1 and SIV infection in host organisms (144, 201, 248).  
Studies have shown that humans infected with HIV-1 variants that lack a 
functioning nef gene are protected from full progression to AIDS, and generally 
have relatively normal levels of circulating CD4+ cells (144, 248).  Similarly, it has 
been observed that primates infected with SIV strains that have deleted or 
mutated nef alleles also fail to progress to a fully immuno-compromised state 
(201).  It is clear that understanding the role that Nef plays during the course of 
infection is an important area of HIV-1 research. 
 In a perfectly permissive cell line, only a subset of genes contained in the 
HIV-1 genome would be required for productive rounds of infection, and in most 
cell lines this is certainly the case (62).  The structural and enzymatic proteins 
encoded in the Gag and Gag-Pol transcripts provide the means of encapsulating 
and protecting the viral genome, as well as a means to copy and insert it into the 
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host cell genome, while the Env glycoprotein is sufficient to mediate viral entry 
into host cells (82).  HIV-1, however, has devoted part of its limited genome to 
encode factors in addition to the viral structural proteins.  In addition to the 
regulatory factors Tat and Rev (82) HIV-1 encodes genes for other proteins 
referred to as accessory factors.  While these proteins may not be required for 
productive infection in certain cell culture lines, they perform essential functions 
in others, and more importantly, in the target cells of the host organism.  These 
proteins are Vpr, Vif, Vpu and Nef.   
 The primary role for Vpr is to assist in the delivery of the retroviral genome 
into the nucleus of non-dividing cells, a necessary step for HIV which initially 
infects resting T-cells (103).  Vif protects the viral genome from the innate 
immune effector APOBEC3G (A3G), a cytidine deaminase that is packaged into 
viral particles and hypermutates the genome by converting deoxycytosine 
nucleosides into deoxyuracil, thus significantly altering the viral genome (103, 
179).  Vif serves as an adaptor protein between APOBEC3G and a cellular E3-
ubiquitin ligase, resulting in ubiquitination of A3G and proteasomal degradation 
(103, 179).  Vpu assists in release of the viral particle from the surface of the cell 
by downregulating the molecule tetherin, another protein of the innate immune 
system (179).  Vpu also plays a role in reducing the cell surface levels of CD4 by 
interacting with Env-CD4 dimers that form in the ER (179).  These accessory 
proteins play important roles in the replication of HIV by altering the host cell to 
better suit the needs of the virus. In contrast, while expression of Nef in HIV-1 
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infected hosts has such a profound effect on disease progression (144, 248), 
expression of Nef in cultured cell lines appears to have only modest benefits to 
viral replication (62).  
The lentiviral Nef proteins are typically between 26-34 kDa and in addition 
to a high degree of sequence conservation (229), they also share a common 
structure (See Fig. 3.1 and Fig 3.2).  Nef proteins are co-translationally 
myristoylated at their N-terminus, have a unstructured loop connected to a 
conserved globular domain, and a variable-length C-terminus that also lacks a 
defined structure (Fig. 3.1) (92).  The high degree of Nef sequence conservation 
correlates with functional conservation regardless of lentivirus strain or host 
organism (201). These activities can be assigned to several broad categories 1) 
evasion of the host adaptive immune response by downregulating MHC-I 
molecules (167, 170), 2) lowering the threshold for T-cell activation (215), 3) and 
an increase in individual particle infectivity and replication efficiency (53, 192, 
201).  As Nef lacks enzymatic activity, it brings about the changes in the host cell 
by acting as an adaptor, recognizing specific cellular proteins with one portion of 
the molecule and connecting to other cellular proteins such as enzymes and 
endosomal proteins (80, 161, 255).   
Evasion of the host adaptive immune response 
 Nef is one of the first viral proteins to be expressed during infection, being 
transcribed early with the regulatory proteins Tat and Rev (26) and early 
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expression of this viral protein is beneficial for several key reasons.  Initial Nef-
induced downregulation of host cell surface CD4 protects against super-infection, 
ensuring that only one copy of the viral genome is active in the target cell (19, 
312).  Also, Nef induces downregulation of Major Histocompatibility Class-I 
(MHC-I) proteins from the host cell, while simultaneously directing intracellular 
MHC-I molecules in the trans-Golgi network for degradation via the  
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endosomal/lysosomal pathway (80, 161).  MHC-I molecules present peptides 
scavenged from the cytoplasm of cells and will present all peptides to cytotoxic 
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T-lymphocytes (CTL) for recognition (205).  The CTL subset of T-cells is able to 
differentiate between peptides derived from the host cell and peptides that 
originate from pathogens, such as those that are scavenged from HIV-1 proteins.  
Recognition of a cell presenting a foreign antigen results in the destruction of the 
infected cell by CTL, and thus, the invading organism (205).  By interfering with 
this surveillance system, HIV-1 genomes that encode Nef are able to avoid 
detection and propagate (205). 
Nef disrupts MHC-I antigen presentation by recognizing a tyrosine-based 
sorting signal present in the cytoplasmic tail of the MHC-I proteins HLA-A and 
HLA-B. (167)  HIV-1 Nef downregulates surface levels of MHC-I by forming a 
ternary complex between the MHC-I proteins HLA-A or HLA-B and the cellular 
adaptin protein AP-1γ, which induces receptor internalization via a clathrin 
mediated mechanism (14, 128, 167, 176, 214, 275).  In addition to reducing 
surface levels of MHC-I molecules, Nef is also able to induce MHC-I degradation 
while it trafficks through the secretory pathway by interacting with trans-Golgi 
network (TGN) coatomer β-COP and directing MHC-I to lysosomes for 
destruction (263).  The timing of this interaction is important for two reasons: first, 
targeting MHC-I in the secretory pathway prevents any molecules loaded with 
viral antigens from being presented on the cell surface and second, early 
expression of Nef guarantees low levels of MHC-I when the full complement of 
HIV-1 proteins are present in the cytoplasm. 
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Lowering the threshold of T-cell activation 
    Although HIV-1 is capable of infecting resting CD4+ T-cells, viral 
replication is more efficient in activated cells (277).  HIV-1 contains multiple 
binding sites for transcription factors in the 5’ long terminal repeat (LTR) of its 
genome that are recognized by cellular transcription factors such as NFκB, 
NFAT, SP1 and AP1(142).  However, high levels of these transcription factors 
are only produced by the cell in response to T-cell activation, indicating that 
translocation of the viral genome into the host cell nucleus itself is not sufficient 
to drive genome replication (142).  A study by Stevenson et. al. demonstrated 
that infection of resting PBMCs results in delivery of viral cDNA into the nucleus 
of target cells, but that integration of the viral genome occurred only after 
activation of the target cell. The non-integrated viral genome is maintained in an 
extra-chromosomal state, although it is still transcriptionally active (277).  Low 
levels of transcription from the non-integrated viral genome are able to produce 
Tat, Rev and Nef transcripts, in addition to small amounts of Gag.  In this context, 
the early expression of Nef facilitates viral replication by lowering the threshold of 
T-cell activation though interactions with Src-family kinases (SFK) Fyn and Lck 
(105, 207), thus stimulating viral genome integration.  These kinases, which are 
normally auto-inhibited (25), become active during T-cell receptor stimulation 
resulting in their phosphorylation, and initiation of a signaling cascade that results 
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in the production of NFκB, NFAT, SP1 and AP1 transcription factors (205).  HIV-
1 Nef disrupts the auto-inhibition of these SFK molecules by displacing the 
inhibitory region with a higher affinity PxxP motif present in the retroviral protein 
(140).  This displacement activates the kinase activity of the SFK molecule 
resulting in lowering the activation threshold of the T-cell and ultimately 
transcription of the viral genome.  In addition to SFK-mediated activation, Nef has 
also been implicated in an interaction with p21-activated protein kinase 2 (PAK2), 
a downstream effector of T-cell receptor stimulation that plays an important role 
in rearrangement of the cytoskeleton (294) further impacting immune responses 
by interfering with the formation of immunological synapses between immune 
cells.  This interaction has been shown to be genetically separable from that of 
the SFK effects and important in the previously observed replication 
enhancement often seen in Nef-positive viral isolates (215).  
 
Nef-stimulated enhancement of particle infectivity and replication of HIV-1  
Virus to Cell Transmission 
 One of the most intensely studied aspects of Nef function has to do with 
an observed enhancement of HIV-1 particle infectivity in viral isolates that contain 
an intact nef gene (53, 61, 160, 201, 264).  This enhancement is dependent on 
the expression of Nef in the virus producer cell and its mechanism is a matter of 
some debate (53, 201, 264).  Studies have shown that the enhancement occurs 
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sometime after fusion (192, 264) of the virus with the host cell, inviting the 
speculation that Nef by-passes a cytoskeletal barrier facilitating release of the 
viral core into the cytoplasm (250).  This theory is bolstered by the finding that 
treatment of target cells with cytochalasin B, which depolymerizes the actin 
cytoskeleton, can substitute for a lack of Nef in producer cells (40).  Others have 
speculated that Nef participates in the uncoating of the viral RTC which is 
suggested by the incorporation of Nef into viral particles and a reported 
interaction between Nef and the viral core (151).  However, the results of a study 
by Zhou and Aiken showed that post-release incorporation of Nef into viral 
particles also enhanced infection, after the viral core had been formed, arguing 
against a need for Nef interaction with the viral core (325).  This has led some to 
investigate the role that surface CD4 plays on Env incorporation into particles, 
finding that reduced CD4 at the cell surface correlated with an increase in gp120 
in HIV-1 virions (61, 160, 208). 
 Several labs have investigated the activity of Nef on the downregulation of 
the CD4 receptor from the surface of the host cell and how this interaction relates 
to the observed infectivity phenotype (61, 160, 177, 208, 264).  The presence of 
the CD4 glycoprotein on the surface of producer cells presents a problem for the 
virus, as expression of the gp120 HIV-1 envelope protein is capable of interacting 
with it during the process of particle assembly, negatively impacting future 
interactions between Env and CD4 on the target cell (48).  HIV-1 has evolved 
several methods to circumvent this interaction, by downregulating CD4 from the 
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surface of the host cell, and directing its degradation as it trafficks through the 
secretory pathway (96, 231).  Downregulation of CD4 from the cell surface is the 
result of the formation of a ternary complex between CD4, Nef and the µ-subunit 
of the clathrin adaptor protein AP-2 (46, 47, 60, 230), while an additional 
interaction between Nef and β-COP, mediated by cellular V-ATPase, has been 
shown to direct the internalized protein to the endosomal pathway for lysosomal 
degradation (63, 180, 231, 263).  Mutational analysis of Nef has identified 
regions of Nef which are required for the specific interactions with host cell 
proteins.  Notably, a dileucine motif (LL164) found in the globular domain of Nef  
as well as an upstream Glu residue (E160) and downstream diacidic region 
(DD174), have all been shown to direct the interaction of Nef with AP-2 and V-
ATPase (3, 46, 47, 94).  Recruitment of Nef to β-COP is mediated by a 
diglutamate motif (EE154) found upstream of the dileucine motif (231).  Mutation 
of this β-COP interacting motif results in the internalization of CD4 from the cell 
surface, but these molecules are not degraded, and merely recycle back to the 
membrane (231). 
Interaction of Nef with the CD4 cytoplasmic domain is mediated by several 
Nef residues including WL58, D108, and FPD121; although the later region is 
thought to contain a putative dimerization domain which has been shown to be 
important for a number of Nef functions (Table 3.1).  It has been suggested that 
residues comprising this region align to form a dimerization domain as well as an 
interaction site (8, 175), and Poe and Smithgall have presented a model of  
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dimerized Nef based on alignment of the crystal structure (240).  However, it has 
also been reported that Nef proteins from different strains, including SIVs, are 
able to functionally dimerize while lacking structures similar to the HIV-1 Nef 
dimer interface (157).  It was later reported that the dimerization of HIV-1 Nef is 
most likely an artifact that arises during preparation of the protein for analysis 
(29).  Clearly, additional investigation into the role of these residues is required to 
fully understand their importance. 
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The importance of CD4 downregulation to the replication of HIV-1 is 
further illustrated by the functional redundancy exhibited by the virus to achieve 
this goal.  In addition to Nef, HIV-1 disrupts surface levels of CD4 through the 
activities of the Vpu accessory protein (179), and through activity of the HIV-1 
Env molecule itself (48), implying that reduction of CD4 at the cell surface is 
important enough for the virus to devote limited genome space to encode three 
separate methods of achieving this result. 
 Several labs have investigated the relationship between CD4 
downregulation and viral particle infectivity, finding that increased levels of 
surface CD4 in producer cells do indeed correlate with a decrease infectivity of 
viral particles (61, 160, 177, 208).  However, it should be noted that some of 
these results were obtained from studies in cultured cells of epithelial and 
myeloid lineage that were transfected with vectors expressing CD4 in addition to 
HIV-1 constructs (160, 208), which may have resulted in CD4 expression well 
beyond physiological levels.  Conflicting results have been reported by groups 
using CD4+ T-cells derived from primary blood mononuclear cells (PBMCs), 
which can be considered a far more relevant system (61, 177).  These 
experiments, which tested the infectivity of viral particles produced in non-
transformed T-cells, demonstrate that some Nef mutants defective for CD4-
downregulation retain the Nef-induced infectivity enhancement (61, 178, 208), 
although the authors of one study did suggest that late-cycle activities of Vpu 
may have been responsible for reduction of CD4 in their system (208).  
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Interestingly, one study showed a distribution of phenotypes from Nef mutants 
previously shown to be involved in CD4-downregulation at various stages 
ranging from almost completely WT to Nef-deficient (177).  Finally, a separate 
study, also testing the infectivity of particles generated in PBMCs, reported no 
effect of Nef expression regarding HIV-1 Env incorporation or particle infectivity 
(208).  It should also be noted that despite showing no significant difference in 
the infectivity of Nef+ viral particles produced in CD4+ PBMCs, both studies 
reported a significant difference in the replication of HIV-1 in the presence of Nef, 
although this may have been a result of using activated cells (177, 208).   
 Intriguingly, Nef is also able to increase the infectivity of viral particles from 
cells that do not express CD4 (192, 237, 264).  HIV-1 particles generated in cells 
of epithelial lineage, such as HEK293 cells, show a modest increase in infectivity 
when a functional nef allele is present in the provirus or expressed in trans (4, 
192, 237).  This observation suggests that the presence of Nef in the producer 
cell leads to a fundamental difference in the composition of the particle, either at 
the level of assembly or protein content of the virus.  One possible mechanism 
for this observed effect is downregulation of an as yet unidentified PM protein, a 
theory supported by a reported interaction between Nef and the GTPase 
dynamin, a participant in clathrin-mediated endocytosis (237).  However, it is also 
possible that Dyn2 affects the lipid composition of the membrane by facilitating 
the turnover of non-raft membranes, enriching the raft content of the membrane 
which has been shown to enhance virion infectivity (37, 237).  Several studies 
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have found a qualitative difference in the lipid composition of the viral envelope, 
with expression of Nef positively correlating with increased cholesterol levels in 
both viral envelope and host cell PM (36, 37, 323, 324).  This observation may 
suggest a mechanism by which Nef can affect infectivity without altering viral 
protein content.  Previous reports have indicated that reduction of cholesterol 
from both producer cells and virions has a negative effect on particle infectivity 
while increased envelope cholesterol levels seem to promote fusion with the 
target cell plasma membrane (323, 324).  This observation may also explain the 
findings of Pizzato et al, who reported that receptor pseudotyped virus particles 
showed enhanced infectivity in the presence of Nef (238).  Also, it has been 
demonstrated that Nef contains a cholesterol binding motif, and mutation of this 
region results in decreased particle infectivity, further illustrating the importance 
of the lipid composition of the viral envelope (323). 
 It should also be noted that Nef is packaged into viral particles, where it is 
cleaved by the viral protease (38, 151, 309).  Imaging of HIV-1 cores produced in 
the presence or absence of Nef have shown no distinct morphological 
differences (79). Biochemical analyses suggest no significant difference in the 
levels of viral proteins outside of the presence of Nef itself (37, 151, 192).  
However, a report by Forshey et al indicated that Nef associated with the viral 
core, and suggested that Nef may serve to destabilize the core post-fusion (79).  
A separate study by Aiken et al showed that interaction with HIV-1 structural 
proteins was sufficient to induce Nef-associated infectivity enhancement (250) 
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perhaps indicating that effects on the viral core were responsible for Nef 
enhanced infectivity.  However, a different group reported no difference in the 
levels of particle infectivity in producer cells expressing Nef, regardless of 
whether Nef was associated with the virions (159).   
The role of Nef in Cell-to-Cell Transmission of virions 
 In addition to enhancing HIV-1 virion infectivity, it has been previously 
reported that the presence of an intact nef gene also has an effect on the 
replication of virus in vitro (177).  Perhaps counter-intuitively, the enhanced effect 
of Nef on particle infectivity is separate from enhanced replication (177).  For 
example, Nef mutants that have been shown to be defective in enhancing 
infectivity (removing the myristoyl anchor of Nef, or disrupting Nef’s interaction 
with SFKs) can still display activity with regard to enhancing replication in 
activated PBMCs (177).  This discrepancy most likely reflects a difference in 
transmission method with infectivity being considered the transmission of the 
viral genome via particle (virus-to-cell) compared to cell-to-cell transmission of 
the virus by cellular contact through formation of a virological synapse (VS) (50).  
However, both of these methods of transfer have clinical relevance as they 
account for the initial infection of the host (virus-to-cell) and dissemination of 
virus over the course of disease (cell-to-cell) (50).   
 One method by which Nef may enhance cell-cell transfer of virions is 
through actin rearrangement.  Multiple studies have shown that Nef expression in 
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producer cells affects the cytoskeleton (106, 131, 213).  Nef is able to affect actin 
rearrangement by activation of PAK2, replacing the activation of that protein by 
CDC42 and Rho GTPases (213).  Actin restructuring by Nef has been implicated 
in formation of both immunological and virological synapses, which form the cell-
to-cell contacts of APCs and immune cells (IS) and HIV-1 producer and target 
cells (VS) respectively (106, 213).  In addition, expression of Nef has been 
correlated with an increase in filopodia production in T-cells (213).  As filopodia 
are thought to be one of several methods by which HIV-1 infected cells interact 
with target cells (271), expression of Nef in producer cells may enhance viral 
replication by stimulating cell-to-cell contact to form a VS.   
 Another aspect of virological synapses that may be influenced by Nef 
expression is the concentration of HIV-1 Gag and Env proteins to sites of cell to 
cell contact (107, 131).  This concentration may be the result of increased lipid 
raft clustering, due in part to direct activities of Nef which have been shown to 
increase the size of microdomains in infected cells (52).  As both Gag and Env 
associate with lipid microdomains during particle assembly (21, 171), an increase 
in either the size or number of these domains may increase particle assembly 
kinetics.  Alternately, clustering of viral components may facilitate infection of the 
target cell by concentrating virus to one area of the membrane.  Nef-induced 
clustering of microdomains may also rely on actin remodeling (131), suggesting 
that the increase in cell-cell transfer of Nef-positive virions may depend on the 
cooperative effect of both functions.   
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Research Aims Chapter III 
 
 The results of an initial experiment investigating the replication efficiency 
of HIV-1 in the presence or absence of Nef in MOLT3 cells indicated an exquisite 
requirement for this lentiviral protein in replication.  In light of the fact that nef 
expression typically has a limited effect in cultured cells (62), we chose to 
investigate the requirement for Nef expression in the MOLT3 cell line. 
Determination of CD4 expression levels on the cell surface showed that MOLT3 
cells expressed only modest levels of CD4 in comparison to other cultured T-cell 
lines commonly used in HIV-1 research, in which Nef is dispensable for 
replication (62).  Taken together, the modest levels of CD4 in MOLT3 cells and 
the requirement for Nef expression in HIV-1 replication suggested that this cell 
line was ideal to determine how Nef-induced CD4 downregulation impacted viral 
replication.  To investigate this we first sought to observe the replication 
efficiency of HIV-1 viruses that contained mutations in the endogenous Nef 
protein known to interfere with CD4 downregulation.  Results of these 
experiments indicated that HIV-1 was able to replicate in MOLT3 cells when a 
Nef-mutant defective for CD4 downregulation was expressed.  In light of these 
results, we set out to determine how Nef expression enhanced replication of HIV-
1 in the MOLT3 system.  Toward that end we investigated the ability of Nef 
proteins from a variety of HIV-1 groups and clades to enhance replication in the 
MOLT3 system.  We also sought to determine if the Nef-induced replication 
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enhancement could be attributed to any previously published interactions by 
testing the effects of an additional panel of Nef mutants on replication.  Also 
investigated were the role that Nef may play in the regulation of lentiviral 
transcription and the relative contributions of virus to cell and cell to cell 
transmission in the observed phenotype.   
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Results 
   
Nef mutants defective for CD4 down-regulation retain the ability to enhance 
replication of HIV-1 in MOLT3 cells 
 Having observed the profound effect of Nef on the replication of HIV in the 
MOLT3 cell line (data not shown), we set out to determine the mechanism used 
by Nef to achieve this result.  It has previously been reported that one of the 
primary functions of Nef, downregulation of surface levels of CD4, serves to 
prevent interactions between CD4 and viral Env at the cell surface (61, 160, 
208).  Studies using transient transfection of 293T and HeLa cells with vectors 
expressing CD4 have shown that very high cell surface levels of the receptor 
impact particle infectivity, and this infectivity can be restored with Nef expression 
(61, 160, 208).  However, as these cell types are not normal targets for HIV-1 
infection, and the overexpression of CD4 may have been well beyond 
physiologically relevant levels, the results of these studies leave room for 
refinement.  Our previous results demonstrating the complete reliance on Nef for 
the replication of HIV in the MOLT3 cell line despite modest CD4 surface levels 
suggested that these cells may provide a suitable model to test whether Nef-
induced downregulation of CD4 is responsible for the observed enhancement of 
replication.  In order to test this, we chose to infect these cells with HIV-1 that 
expressed Nef mutants known to be defective for CD4 downregulation.  
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 Point mutations were made in the Nef coding region of the full-length NL4-
3 proviral construct to mutate specific residues to Ala, and these constructs were 
transfected into 293T cells in order to produce infectious virus.  Twenty-four 
hours after transfection, the supernatant was removed and the amount of 
released virus was quantified by p24 ELISA.  MOLT3 cells were inoculated for 24 
hrs with equivalent amount of virus as determined by ELISA, washed to remove 
unbound virus, and resuspended in media.  Samples of supernatant were 
periodically removed over the course of the infection for analysis of released 
virus using the same p24 ELISA.  As Fig. 3.3 indicates, infection of MOLT3 cells 
with 25 ng of WT NL4-3 input virus resulted in a 115-fold increase of particulate 
p24 14 days after the initial infection as compared to MOLT3 cells inoculated with 
Nef-deficient virus (FS).  Interestingly, an enhancement of HIV-1 replication was 
observed by several Nef mutants known to be defective for various steps in the 
downregulation of CD4 (Table 3.1)  For example, the viral genome expressing 
the Nef mutation EE155,156QQ replicated almost as well as the HIV-1 virus 
encoding WT Nef.  Previous findings indicate that these two Glu residues are 
responsible for the interaction of Nef with β-COP, which happens after clathrin-
mediated CD4 internalization from the membrane, but prior to CD4 degradation 
(231).  Thus this mutant most likely reduces the amount of surface CD4 to levels 
comparable to WT Nef.  In contrast, mutations of the dileucine motif in Nef 
(LL164,165AA) are known to interfere with CD4 internalization from the plasma 
membrane (46), as are mutations of a di-aspartate motif further upstream  
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(DD174,175AA) (3).  It has been shown that both of these motifs are required for 
interaction with cellular clathrin adaptor protein molecules; AP-1, AP-2 and AP-3 
in the case of the LL164 motif and AP-2 in the case of DD174 (46, 47, 60).  
Interaction with these adaptor proteins is required for both clathrin—mediated 
internalization and downregulation of surface CD4, therefore Nef proteins 
harboring mutations in these residues fail to reduce surface CD4 levels (46, 47, 
60).  As seen in Fig. 3.3, while mutation of these residues to Ala had a significant 
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impact on replication of HIV-1 in MOLT3 cells, both versions still displayed a 
clear Nef-related enhancement of virus replication, particularly compared to Nef-
deficient virus (29-fold increase of released virus for LL164,165AA and over 11-fold 
for DD174,175AA compared to NefFS virus) in samples taken 14 days after 
infection.  Thus, while downregulation of cell surface CD4 molecules may play a 
role in the replication of HIV-1 in MOLT3 cells, the inability to stimulate CD4 
downregulation did not fully account for the Nef-enhanced phenotype observed.  
Alternatively, the inability of the LL164,165AA and DD174,175AA Nef mutants to 
interact with the adaptin complexes suggested a possible role for the endocytosis 
machinery in Nef-induced replication enhancement of HIV-1.  
 
Replication enhancement of HIV-1 by Nef is observed in MOLT3 cells 
expressing a CD4 molecule that is not downregulated by Nef. 
 Based on the results of our mutational analysis, we decided to further 
investigate the role that Nef-induced CD4 downregulation plays in the observed 
replication enhancement in MOLT3 cells.  To that end, we generated a cell line 
that stably expressed a version of CD4 that was incapable of being 
downregulated by Nef.  Nef induced CD4 downregulation requires that the viral 
protein forms a ternary complex between Nef, the host cell AP-2 complexes and 
the cytoplasmic tail of CD4; this interaction between HIV-1 Nef and CD4 is 
mediated by the presence of a dileucine motif present in the cytoplasmic tail of 
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CD4 (2).  Thus, removal of the cytoplasmic tail of CD4 results in the expression 
of CD4 at the plasma membrane that cannot be internalized and degraded via 
Nef (2, 104).  Stable cell lines were made by infecting MOLT3 cells with virus 
containing either a retroviral genome encoding the truncated CD4 molecule or 
empty vector, and transformed cells were expanded under antibiotic selection; 
the MOLT3 cell line expressing the truncated CD4 molecule will be referred to as 
MOLT3CD4ΔCT. 
Detection of the surface CD4 levels of the transfected cells by FACS 
showed an increase in fluorescence by an order of magnitude in the 
MOLT3CD4ΔCT cells, consistent with expression of additional CD4 from the 
integrated CD4ΔCT vector.  (Fig. 3.4, panel A. compare shadowed peak of 
parental MOLT3 cells to the dotted line of MOLT3CD4ΔCT cells).  These cells 
were then infected with 10 ng of NL4-3 WT or NL4-3 NefFS virus and 
supernatant samples were removed periodically for analysis of particulate p24.  
As demonstrated in Fig. 3.4, panel B, an almost 50-fold difference in the 
replication of HIV-1 WT vs. NefFS virus can be observed despite the fact that 
these cells express a CD4 molecule incapable of being downregulated by Nef.  
Also important to note is that the replication of HIV-1 NefFS was as poor in these 
cells as in the parental MOLT3 cell line, indicating that higher levels of CD4 
expression did not increase overall permissiveness of these cells.  These results 
indicate that the Nef-induced enhancement of replication characterized in MOLT3 
cells is not strictly due to the ability of Nef to reduce surface levels of CD4. 
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Enhancement of viral infectivity can be returned to HIV-1 NefFS by 
providing Nef in trans in target cells. 
 We next attempted to determine if we could restore the WT replication 
phenotype to HIV-1 that lacked a Nef-coding region by expressing Nef in trans in 
target cells.  There were multiple reasons to pursue this line of thought: 1) 
expression of Nef in target cells allowed us to determine the effect of ‘adding 
back’ Nef to the virus in a more controlled manner than transient transfection, 2) 
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positive results would enable us to test Nef molecules from multiple lentiviruses 
without having to clone them into a proviral HIV-1 vector, and 3) expression from 
a retroviral vector would allow us to express a Nef protein that could be detected 
by probing for a C-terminal epitope tag.  To this end the MOLT3CD4ΔCT cell line 
was transfected with a Murine Stem Cell Virus vector system (pMSCV) 
containing either empty retroviral vector or a vector containing the WT Nef 
protein from HIV-1LAI (NefLAI) and an HA-tagged version (NefLAI-HA).  As 
anticipated, determination of surface CD4 levels by FACS indicated that 
expression of Nef in trans did not decrease surface levels of CD4ΔCT in these 
cells (Fig 3.5, panel A).  MOLT3CD4ΔCT cells stably expressing NefLAI, NefLAI-HA 
or empty vector were infected with 10 ng of HIV-1 lacking Nef (HIV-1Δnef) for 24 
hrs, washed, and resuspended in fresh media.  Over the following three weeks, 
supernatant samples were periodically removed for detection of p24 via ELISA.  
As Fig. 3.5, panel B indicates, infection of MOLT3CD4ΔCT cells containing the 
empty retroviral vector (Vector) with NL4-3 lacking Nef resulted in a final p24 
concentration of less than 1 ng/ml, similar to infection of the parental MOLT3 
cells infected with the same virus (compare to Fig. 3.4).  However, infection of 
MOLT3CD4ΔCT cells that stably expressed NefLAI (Nef +) in the context of 
pMSCV vector resulted in a final p24 concentration that was 40-fold higher than 
empty vector (Fig. 3.5, panel B).  In addition, comparison of released virus from 
one timepoint indicated that attachment of a C-terminal HA epitope to NefLAI did 
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not severely restrict the ability of this protein to rescue replication of HIV-1Δnef 
virus in this assay (Fig. 3.5, panel E). 
 We next decided to test whether using a different expression system could 
improve the results we obtained in this experiment.  Prior experience in our lab 
indicated that the pCX4 retroviral system would provide increased expression of 
NefLAI compared to that obtained with the pMSCV system (H.G. unpublished 
observation).  Based on that observation, stable cell lines were made as 
described above instead using pCX4-based retroviral vectors in place of pMSCV-
based ones.  Again, following selection, MOLT3CD4ΔCT cells expressing NefLAI 
or empty vector were analyzed for CD4 expression by FACS. As Fig. 3.5, panel 
C demonstrates, expression of NefLAI had no impact on the levels of cell surface 
CD4 compared to MOLT3CD4ΔCT cells transfected with empty vector.  These 
cell lines were then infected with equal titers (10 ng) of HIV-1Δnef virus and 
supernatant samples were removed periodically after infection.  As shown in Fig. 
3.5, panel D, expression of NefLAI from the pCX4 system in MOLT3CD4ΔCT cells 
(Nef +) resulted in a robust rescue of HIV-1Δnef replication (250-fold) as 
compared to that observed from infection of cells containing empty vector 
(Vector).  Together, the results of this experiment prove that Nef can dramatically 
enhance HIV-1 replication even under conditions where CD4 cannot be 
downregulated.  They also indicate that addition of a small epitope, such as the 
HA tag, does not severely inhibit the activity of Nef-enhanced 
infectivity/replication.   
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Replication of Nef mutant viruses in MOLT3 cells 
 Due to its importance in disease progression (144, 248), investigation into 
the functions of Nef is one of the most intensely studied areas of HIV-1 research.  
Multiple labs have looked into interactions between Nef and cell proteins through 
mutational analysis of Nef and have published findings linking residues to 
specific functions (Table 3.1).  In addition to these published mutations, we 
tested mutations in other residues that are conserved in Nefs from various HIV-1 
groups and strains (Fig. 3.1).  The indicated amino acid substitutions and residue 
numbering are based on the sequence for NefNL4-3.  We initially chose to address 
mutations in Nef that have previously been implicated by other labs in specific 
interactions with host cell proteins (Table 3.1).  In order to determine if any of 
these published interactions could be attributed to the enhanced replication 
phenotype we observed in the MOLT3 system, we introduced several of these 
mutations individually into the Nef coding region of the NL4-3 proviral clone.  
Infectious virions containing these mutations were generated by transfecting 
293T cells with the specified proviral construct and equivalent p24 titers were 
used to infect MOLT3 cells.  MOLT3 cells were infected with either 10 or 25 ng of 
input virus for 24 hrs, unbound virus was removed by washing the cells, and 
infected cells were resuspended in fresh media.  Samples of supernatant were 
removed periodically for determination of released virus using the previously  
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mentioned p24 ELISA.  Wild-type NL4-3 (WT) and NL4-3Δnef (FS) were used as 
positive and negative controls for these experiments.   
 Analysis of the replication efficiency of 18 of these mutants can be 
observed in Fig. 3.6.  Mutation of the N-terminal Gly to Ala resulted in an almost 
complete loss of replication (Fig 3.6, panel A).  This mutation removes the 
myristoylation site for Nef that serves to associate the viral protein with host cell 
membranes (237).  It has been previously published that this mutation is 
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sufficient to abrogate most effects of Nef with regard to CD4 and MHCI 
downregulation and enhanced infectivity (178).  We also observed a marked 
reduction in the replication efficiency of HIV-1 virus that contained the double Pro 
mutation PP69,72AA (Fig. 3.6, panel A).  These two residues are part of a highly 
conserved region in lentiviral Nefs (PxxPxxPxR) that have been indicated to 
interact with Src-family kinases such as Fyn and Lck, and actin remodeling 
effectors such as p21 associated kinase -2 (PAK2).  Interaction of Nef with Fyn 
and Lck results in lowering of the activation requirements for T-cells (155, 215, 
255).  In contrast to results obtained with the PP69,72AA mutant, another Nef 
mutant defective for interaction with PAK2,  F191I (215), replicated at levels 
similar to that observed in the presence of WT Nef (Fig. 3.6 panel A).  A mutation 
of Nef which interferes with hTE interaction, and may be part of the Nef 
dimerization domain (D108E), displayed no defect in replication in our assay (Fig. 
3.6, panel A), in contradiction to other published results (59).  Although the exact 
function of thioesterase recruitment in HIV-1 infection has yet to be fully 
elucidated, no effect from disrupting the dimerization domain was observed.  Our 
data also indicate that in the MOLT3 system, the increase in replication induced 
by Nef does not rely on the ability of Nef to interact with AP-1 or AP-3 adaptor 
complexes.  Our initial investigation of CD4 downregulation used the Nef 
dileucine mutant (LL164,165AA) which is defective for interaction with AP-1, AP-2 
and AP-3 adaptor proteins (230) (Fig. 3.3).  However, mutation of the Glu at 
position 160 (E160A) of Nef results in a mutant that is incapable of interacting with 
129 
 
AP-1 and AP-3 complexes, allowing Nef to interact only with AP-2 proteins (60).  
Analysis of the replication of HIV-1 virus containing the E160A mutation, which 
replicated better even than WT HIV-1 (Fig. 3.6, panel A), suggests that the 
interaction with AP-1 or Ap-3 is not required for the Nef-induced increase in 
infectivity in this system (60). 
 Mutation of residues in the highly conserved FPD121 motif (92, 175)(F121A, 
D123A, and FD 121, 123AA) led to dramatic decreases in replication (Fig.3.6 Panels 
C and D), and results of the ELISA used to quantify the p24 concentration 
indicated that these mutations released no more virus than HIV-1 that lacked the 
Nef protein entirely (Fig. 3.6, panel D).  Crystal structures of the Nef protein have 
indicated that these residues are part of a domain which has been suggested to 
be part of the interface for Nef dimerization (157).  It is also important to note that 
mutation of these residues has also been implicated in activity of Nef with regard 
to CD4 and MHCI downregulation, as well as being important for the interaction 
with dynamin2 (237) and hTE (157, 240).  The Leu112 residue, also previously 
indicated to play a role in dynamin2 interaction displayed a significant reduction 
in replication (Fig. 3.6, panel C and D), with supernatant p24 levels being only 
slightly higher than Nef-deficient virus (2.5 fold over Nef-deficient virus) (237, 
240).   
 An additional panel of Nef proteins, containing mutations in residues 
localized to a putative dimerization domain (93, 157), was also tested using the 
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replication assay described above.  The three constructs containing mutation at 
Leu 100 (L100), the double Arg mutation at position 105 (RR105AA), and the 
mutation of Leu 109 (L109) , all demonstrated similar levels of replication, with 
enhancements of 47-, 32- and 36-fold, respectively, over Nef-deficient virus (Fig. 
3.6, panel B).  Again, alignment of the Nef crystal structure has implicated these 
residues to be important for Nef dimerization (8, 157).  Two additional mutations 
of highly conserved residues not reported previously in the literature 
demonstrated opposing effects on replication.  Mutation of the Asn residue at 
position 126 (N126), which is conserved across most Group M HIV-1 strains (Fig. 
3.1), enhanced replication approximately 170-fold compared to cells infected with 
the NefFS virus (Fig. 3.6, panel B).  This increase was in excess of the 
enhancement observed with WT Nef in this assay (137-fold over NefFS).  
Interestingly, a mutation of the Lys 92 (K92A) residue, found in a similar position 
in almost all other Nef molecules (229), displayed an extreme defect in 
replication in comparison to WT Nef, and increased replication only 3-fold above 
HIV-1 NefFS (Fig. 3.6, panel B).  This mutant was proven to be as active in the 
downregulation of both CD4 and MHC-I as WT Nef when assayed in 293T cells 
(data not shown).  Additional replication assays performed to verify this result 
returned similarly low enhancement effects, with the maximum increase being 7-
fold compared to NefFS replication (data not shown).  This observation shows 
that CD4 downregulation and replication enhancement can be genetically 
separated.   
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The Nef proteins of HIV-1 virus from different Groups and Clades display a 
conserved ability to rescue replication of HIV-1 Nef-deficient virus when 
expressed in trans in target cells. 
 In order to determine whether the ability of Nef to enhance replication in 
this system was shared by all Nef molecules, we next chose to investigate the 
activity of Nef proteins from HIV-1 and SIV variants from a range of Groups and 
subtypes using our Nef in trans system.  Based on genetic similarity, strains of 
HIV-1 that have been found circulating in the population have been organized 
into Groups and Clades (45).  The most diverse Group is M, which is believed to 
have arisen from a single chimpanzee to human transmission from after which it 
diverged to generate the various Clades (45).  HIV-1 variants found within each 
Group M clade also show regional bias i.e. Clade A variants predominate in West 
Africa, B variants in North America, etc (45).  Like Group M viruses, Groups N 
and O are thought to have arisen from a separate zoonotic transmission between 
chimp and human (45), while P appear to have originated in gorillas (239).     
 Our previous Nef in trans experiment made use of the Nef protein from the 
HIV-1LAI isolate, a member of Group M, clade B. In order to expand on our 
findings we tested Nef proteins from other Group M variants encompassing 
clades B, C, F, and H, as well as members of Group N and P (Fig. 3.7).  Stable 
MOLTCD4ΔCT cell lines were generated to express the selected Nefs with a  
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C-terminal HA tag so that expression levels could be determined.  Expression 
levels of Nef proteins were similar as determined by Western blot of the epitope 
tag (results not shown).  Analysis of cell surface CD4 by flowcytometry indicated 
that expression of various Nef proteins had no effect on the levels of CD4 
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present on the cell surface (Fig 3.8).  Replication of 10 ng HIV-1Δnef input virus 
was followed as previously reported for the Nef in trans assay described above. 
 As Fig. 3.8, panel A indicates, expression of Nef from the clade B variant 
SF2 was able to restore replication to HIV-1 lacking an intact Nef gene to similar 
levels observed with the LAI construct (25-fold increase in cells expressing 
NefSF2 and 36-fold increase in replication in NefLAI cells, compared to empty 
vector).  It was also observed (Fig. 3.7, panel A) that replication of HIV-1Δnef 
virus in MOLT3CD4ΔCT cells expressing Nef proteins from clades C, F, and H 
was as efficient as that observed with the HIV-1NefLAI construct (41-,36-, and 30-
fold, respectively, over cells expressing empty vector), and in at least one case, 
Clade C 96ZM651, significantly exceeded that of NefLAI and resulted in a 115-fold 
increase in particulate p24 compared to empty vector (Fig. 3.7, panel B).  As 
previously described, no substantial replication of HIV-1Δnef was observed in the 
MOLT3CD4ΔCT cells expressing empty vector (Fig. 3.7, all panels).   
 Investigation of HIV-1 Nef proteins from other Groups showed mixed 
results; as Fig. 3.7, panel C demonstrates, expression of the Group N Nef 
resulted in rescue of replication just slightly less robust than that observed with 
the Group M variant LAI (32-fold increase over empty vector, compared to 50-
fold increase from NefLAI).  However, stable expression of the Group O Nef in the 
MOLT3CD4ΔCT cell line failed to enhance replication to any greater levels than 
those observed from the cell line expressing the empty vector (Fig. 3.7, panel C). 
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A possible reason for the lack of replication in the Group O expressing cell line is 
the down regulation of the HIV-1 CXCR4 co-receptor, required for the replication 
by NL4-3.  It has been reported that the Nef proteins of Simian Immunodeficiency 
Viruses (SIV) also downregulate HIV-1 co-receptors in addition to CD4 (297).  
Analysis of cell surface levels of all stable cell lines used in these experiments by 
flow cytometry indicated that while CD4 surface levels remained unchanged in all 
lines (Fig. 3.8), MOLT3CD4ΔCT cells expressing the Nef protein of Group O did 
indeed significantly downregulate CXCR4 from the cell surface (Fig. 3.9).   
 We also opted to determine if the Nef proteins from selected SIV stains 
could be used in our Nef in trans assay to restore replication to Nef-deficient HIV-
1.  Cell lines were generated to stably express HA-tagged Nef proteins from two 
African Green Monkey variants (SIVagm155, and SIVagm677) as well as the Nef 
protein from SIVmac239 in CD4ΔCT cells.  Again, following selection, cell surface 
levels of CD4 where determined by FACS.  Compared to the parental cell line, 
MOLT3CD4ΔCT cells stably expressing Nef proteins from SIVagm155 and 
SIVagm677 displayed identical levels of surface CD4, while only a modest decrease 
in the surface levels of CD4 were observed in MOLT3CD4ΔCT cells stably 
expressing Nef from SIVmac239 (Fig 3.8). These cell lines expressing the HA-
tagged SIV Nefs, as well as empty vector (negative control) and HA-tagged 
NefLAI (positive control), were inoculated with 10 ng of HIV-1Δnef virus and 
replication was determined by quantifying particulate p24 in the supernatant over 
time.  As Fig. 3.7, panel D demonstrates, none of the cell lines expressing SIV  
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Nef proteins showed significant replication of HIV-1Δnef, although a very slight 
enhancement was observed in the cell line expressing Nefagm155 (a 3-fold 
increase over empty vector, panel D, Fig. 3.7).  FACS analysis of these stable 
lines indicated that expression of the respective Nef proteins resulted in a 
significant downregulation of surface CXCR4, which could account for the low 
levels of replication (Fig. 3.9).  However, no differences in cell surface levels of 
CD4 were observed in any of these stable cell lines.  Thus, we can conclude that 
Nef proteins from Groups M, and N are able to restore replication enhancement 
to HIV-1Δnef in the MOLT3CD4ΔCT cell line.  Conversely, Nef proteins from 
more distantly related viruses, such as those from Group O and SIV strains, are 
unable to rescue HIV-1Δnef replication, although whether this deficiency is the 
result of an inherent Nef defect or CXCR4 down regulation is unclear. 
 
MOLT3 cells maintain a reliance on Nef for replication regardless of cell 
activation  
 Expression of Nef in infected T-cells has been shown to lower the 
activation threshold for these cells and increase NFκB-directed transcription from 
the retroviral 5’LTR (142).  This effect is particularly pronounced in cells that have 
been infected prior to activation, where the presence of Nef can often lead to 
greater than 10-fold differences in replication (215).  Conversely, there is little 
difference in replication observed if the T-cells are infected following activation,  
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as this condition obviates the requirement for Nef in lowering the activation 
threshold of the host cell (215).  In an effort to further elucidate the role Nef plays 
in the replication of HIV-1 in the MOLT3 cell line, we chose to test whether Nef 
offered any replication advantage to virus used to infect activated MOLT3 cells.  
Cells were activated by the addition of tumor necrosis factor-α (TNFα – 100 
ng/ml) to cultured MOLT3 cells 24 hrs prior to infection (290).  Treatment of T-
cells with TNFα initiates a signal cascade that ultimately results in increased 
levels of nuclear NFκB, which is a cellular transcription factor for inflammation 
related genes, as well as a transcription factor for HIV-1 (290).  Twenty-four 
hours after TNFα treatment, MOLT3 cells were inoculated with equal titers of 
either WT or Nef-deficient HIV-1 (10 ng as determined by p24 ELISA) for 24 hrs, 
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washed and resuspended in fresh media containing an additional 100 ng/ml 
TNFα.  Supernatant samples were removed periodically to assay viral replication 
using a p24 ELISA.  Our results indicate that Nef continues to have a profound 
effect on replication even after T-cell activation in the MOLT3 system (Fig. 3.10).  
These results are contrary to published reports (215), and indicate that Nef plays 
a role in HIV-1 replication in the MOLT3 cell line even after activation of host T-
cells.     
 
Expression of Nef does not affect viral replication at the level of 
transcription 
 In an effort to further investigate the role of the endocytic pathway in Nef-
induced replication enhancement, we decided to generate stable cell lines in 
which we separately knocked down expression of clathrin heavy chain protein, 
the enzyme dynamin2, and the µ-adaptin subunit of AP-2.  Previous reports by 
our lab and others have implicated these proteins in Nef-associated functions 
such as increased infectivity and replication, and our hope was that an inducible 
siRNA-mediated knock-down of these proteins would provide insight into Nef’s 
activity in the MOLT3 system (46, 47, 170, 230, 237).  In order to accomplish this 
goal, we opted to use a lentiviral based vector (TRIPZ, Open Biosystems) that 
would stably integrate the shRNA element into the genome of infected MOLT3 
cells, which could then be selected for by the addition of antibiotics.  Interestingly, 
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we failed to observe any cells resistant to selection following infection with the 
TRIPZ system, despite the fact that this same virus preparation was able to 
transform MOLT4 cells, a cell line derived from the same donor as MOLT3.  As 
the lentiviral system chosen to create these stable cells was derived from HIV, 
this observation suggested that MOLT3 cells may contain a restriction against 
lentiviral activity that may be alleviated by expression of Nef.  We postulated that 
in the MOLT3 system, integrated viral genomes are transcriptionally silenced, 
and the presence of Nef may prevent this silencing from occurring.   
 We initially chose to test our hypothesis by infecting MOLT3 cells with 
VSV-G pseudotyped, envelope deficient HIV-1 containing either wt Nef or the Nef 
frameshift mutation.  VGV-G pseudotyping of HIV-1 virus particles removes any 
effect of Nef infectivity enhancement on particles, and allowed us to ensure that 
target cells were infected equally (61). This was intended to limit the infection to a 
single round and allow us to observe the effects of Nef expression on 
transcription by measuring the levels of newly translated HIV-1 Gag proteins in 
infected cells.  The results of our initial investigation showed no difference in the 
production of viral proteins in MOLT3 cells regardless of whether a functional nef 
gene was present in the viral genome (Fig. 3.11, panel A).  Comparison of 
samples taken from the infections at two different timepoints indicated that the 
intracellular viral proteins could be “diluted out” by the addition of fresh media, 
indicating that active translation of the viral genome was no longer occurring (Fig. 
3.11, panel B).   
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However, it has been reported that several Nef functions, e.g. increased 
infectivity, are only observed when the HIV-1 envelope is expressed (61, 178).  It 
seemed possible that an interaction between the viral envelope protein and a 
component of the host cell produced a restriction that was alleviated by the 
expression of full-length Nef, so we chose to repeat this experiment with a 
different pair of proviral constructs.  In order to ensure that we were observing 
single cycles of infectivity, we generated nef+ and nef- HIV-1 vectors that 
142 
 
contained a mutation in the HIV-1Env (D368R) that blocks recognition of CD4 by 
HIV-1 Env (216).  It was our belief that these constructs would accurately reflect 
the intracellular effect of Env expression, while simultaneously limiting HIV-1 
replication to a single cycle.  VSV-G pseudotyped, full-length and nef-deficient 
HIV-1 virus, containing the D368R mutation in env, were generated in 293T cells 
and equal titers (100 ng p24) were used to infect MOLT3 cells.  Samples of 
infected cells were removed and lysed for determination of Gag levels by 
Western blot.  As can be seen in Fig. 3.11, panel C, comparison of Gag 
expression in the cells expressing Nef to cells infected with Nef-deficient virus 
display only a modest difference in the intracellular levels of Gag at the initial 
time point of 5 days post infection.  This slight difference in Gag levels hardly 
accounted for the robust replication difference observed between Nef containing 
and Nef deficient HIV-1 in MOLT3 cells.  It should also be noted that samples 
obtained two days later (7 days post infection) showed similar levels of 
intracellular Gag, regardless of Nef expression (Fig. 3.11, panel C).   
This result further indicates that the presence of Nef offers no advantage 
at the level of viral protein production.  In addition, a Western blot of released 
viral particles from these samples demonstrated no difference in p24 levels (Fig. 
3.11, panel C) or envelope incorporation (results not shown).  These results 
suggest that in the MOLT3 system, expression of viral proteins is limited to a 
short time just after infection, and after this time -approximately 2-4 days post-
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infection, transcription of viral proteins is silenced.  Expression of Nef from the 
provirus did not extend the window of viral protein expression. 
 
Nef-induced enhancement of HIV-1 replication in the MOLT3 system does 
not positively correlate with an increase in viral particle infectivity. 
 Viruses come into contact with target cells in two different ways, either 
through diffusion of the virus through some extracellular medium (virus-cell 
transfer) or through directed contact between the producer and target cell (cell-
cell transfer).  Cell-to-cell transfer can occur following the formation of a so-called 
virological synapse, named for its resemblance to an immunological synapse, 
and benefits the virus by limiting diffusion of virions into the extracellular space, 
directing them instead to the membrane of the target cell (50).  Several studies 
have reported that Nef plays a role in increasing cell-cell transfer of virus by 
clustering viral proteins and cellular receptors on the membranes of the 
respective cells through rearrangement of the actin cytoskeleton and lipid raft 
clustering (131, 276).  In addition, several studies have indicated that expression 
of Nef in producer cells correlates with an increase in filopodia formation, as well 
as encouraging actin rearrangements that benefit viral delivery (107, 200, 213, 
276).   
 In order to determine if the expression of Nef in the MOLT3 system 
enhanced replication by means of an increase in individual particle infectivity 
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(virus-to-cell) or instead enhanced transmission of virus from infected cell to 
target cell, we chose to compare the infectivity and replication of virus particles 
produced in the presence of HIV-1 NefNL4-3 to that of HIV-1 produced in the 
presence of an active portion of the Murine Leukemia Virus (MLV) protein Glyco-
Gag (236).  MLV Glyco-Gag is produced occasionally during translation of the 
MLV Gag molecule due to transcription initiation from a cryptic start codon 
upstream of the normal start codon (236).  In addition to enhancing infectivity of 
MLV particles, expression of this glycoprotein has also been shown to increase 
the infectivity of HIV-1 virions in a manner similar to Nef expression (236).   
 Infectious viruses expressing full-length HIV-1, HIV-1 NefFS, or HIV-1 in 
which the nef gene was replaced by a sequence encoding a short, active portion 
of Glyco-Gag were generated by transfection of HEK293T cells.  Following p24 
determination, this virus was then used to infect MOLT3 cells to determine the 
effects of Nef and Glyco-Gag expression on replication and infectivity.  Virus 
used to determine particle infectivity was generated by infecting MOLT3 cells 
with either HIV-1 WT (10 ng of p24) or 100 ng of either HIV-1Nef FS or HIV-1-
Glyco-Gag.  Due to the limited replication of both HIV-1 NefFS and HIV-1 Glyco-
Gag (HG unpublished observation), increased virus titers were used to ensure 
production of enough output viruses to measure infectivity.  Viruses produced in 
MOLT3 cells were then harvested, and their single cycle infectivity was 
determined using the TZMbl reporter cell line, which has been described 
previously (244).  Briefly, a HeLa derived cell line, TZMbl cells stably express 
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CD4, CCR5 and CXCR4 receptors as well as β-galactosidase in a Tat dependent 
manner.  As Fig. 3.12, panel A indicates, no significant difference in the infectivity 
of virus expressing either Nef or a portion of Glyco-Gag was observed, in line 
with previous reports (236).  However, both of these viruses showed a dramatic 
increase in particle infectivity when compared to HIV-1 that lacked functional Nef.  
(The infectivity experiment detailed above was conducted by E. Popova)   
 We next sought to determine if the activity of Glyco-Gag could replace that 
of Nef with regard to enhancing HIV-1 replication in MOLT3 cells.  Infectious HIV-
1 virions expressing either: Nef, the NefFS mutant, or Glyco-Gag in place of Nef 
were generated in 293T cells as described above.  Virus was quantified via p24 
ELISA and MOLT3 cells were inoculated with HIV-1 encoding Nef (2 ng or 10 
ng), HIV-1 Nef FS or HIV-1 Glyco-Gag (10 ng or 100 ng).  At multiple timepoints 
following infection, supernatant samples were removed for determination of 
released virus as a measure of virus replication over time.  As Fig. 3.12, panel B 
demonstrates, infection of MOLT3 cells with 10 ng of Nef expressing HIV-1 WT 
resulted in a 40 –fold increase in the levels of released virus compared to Nef-
deficient virus 14 days after inoculation.  Interestingly, infection of MOLT3 cells 
with virus expressing an active portion of Glyco-Gag failed to enhance replication 
of HIV-1 to any significant level when compared to Nef-deficient virus (Fig. 3.12, 
panel B).  Infection with 100 ng of input HIV-1 Glyco-Gag demonstrated only a 3-
fold increase over HIV-1Δnef (FS) (both 10 and 100 ng input, Fig. 3.12, panel B).  
In fact, a 50 fold difference in input virus between HIV-1 WT (2 ng) and HIV-1  
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Glyco-Gag (100 ng) resulted in higher levels of p24 in the HIV-1 WT sample than 
with the HIV-1 Glyco-Gag sample (Fig. 3.12, panel B).  Together with the results 
of the infectivity assay, these results demonstrate that the effect that Nef has on 
enhancing the replication of HIV-1 in the MOLT3 cell system is not due to 
enhancement of individual particle infectivity. 
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Discussion: 
 The lentiviral Nef protein is a critical determinant in the progression of HIV-
1 infected individuals to fully immune-compromised status (144), playing a 
number of roles in both transmission and replication (80, 161, 255).  Due to the 
functional complexity of this viral protein, studies focused on understanding its 
contributions to particle infectivity and replication often conflict based on the 
nature of the system being used, i.e. cultured cell lines vs. PBMCs (61, 177, 
208).  In general, Nef is largely dispensable for replication of HIV-1 in cell lines, 
and replication in PBMC is only delayed if these cells are infected prior to 
stimulation.  In contrast, we now report a cell culture system in which Nef is 
essentially required for HIV-1 replication.   
It has been previously reported that the Nef-induced downregulation of cell 
surface CD4 plays a major role in determining particle infectivity in both virus-cell 
and cell-cell transmission, potentially by interacting with viral envelope at the cell 
surface, prior to particle release (61, 160, 177).  This finding has been supported 
by the observation that Nef mutants unable to interact with CD4, or to direct it to 
the endosomal pathway for degradation, often display reduced infectiousness in 
reporter cell lines and modestly reduce replication (177).  Our results suggest 
that downregulation of CD4 by Nef does not account for the reduced replication 
of HIV-1 observed in the absence of Nef.  HIV-1 viral genomes containing 
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mutations in nef known to be required for CD4 downregulation remained 
replication competent and produced significantly higher amounts of virus 
compared to a Nef deficient mutant.  In addition, expression of Nef in producer 
cells transfected to stably express high levels of CD4 resistant to Nef-induced 
downregulation was still required for HIV-1 replication, regardless of whether Nef 
was expressed from the provirus, or provided in trans.  This rescue effect was 
able to be replicated by Nef proteins from a broad range of HIV-1 clades 
indicating that the replication enhancement is a conserved function of Nef.  
Interestingly, the activities of the Nefs used in this in trans assay seem to reflect 
with the world-wide spread of HIV-1 (45), with Group M Nefs displaying the 
greatest rescue effect and Group O being fairly modest in activity.  The results 
obtained from expressing Nef proteins from SIV are far less conclusive and 
hampered by the downregulation of the co-receptor for the NL43 envelope, 
CXCR4.  In order to determine if SIV Nefs are active in this assay additional 
CXCR4 will need to be expressed in these cells; this experiment has already 
been planned and will be undertaken soon.  Alternatively, replication of a CCR5 
tropic virus could be tested in this system provided that CCR5 levels are 
adequate.   
Nef is a functionally complex molecule, possessing several reported 
effects on the host cell during particle formation and infection (80, 161, 255).  We 
attempted to determine the relative contributions of several of these reported 
effects by analyzing the replication of viruses containing point mutations in Nef 
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that disrupted previously reported protein-protein interaction motifs.  The results 
of our comprehensive, although not exhaustive, mutational analysis indicate that 
many of the reported interactions between Nef and host cell proteins do not play 
a significant role in Nef-induced replication enhancement.  Nef mutants lacking 
residues known to be crucial for downregulation of MHC-I (14, 128, 214), 
interaction with PAK2 (215) or interaction with hTE (59) displayed no adverse 
effects on replication.  Mutations of some residues found within the hydrophobic 
pocket/dimerization domain of Nef, which have been implicated in almost all Nef-
related activities (8, 175), essentially abrogated the effect of expressing Nef and 
led to levels of replication similar to those obtained with an HIV-1 provirus lacking 
an intact nef gene.  This result may indicate that an interaction between Nef and 
a host cell protein present in MOLT3 cells is required for the observed 
dependence of HIV-1 replication on Nef in this cell line, although we cannot 
definitively rule out a defect in Nef dimerization.  While it has been proposed that 
residues which constitute this hydrophobic pocket also contain a significant 
portion of the Nef dimerization domain (8, 240), we do not attribute our 
observations to a dimerization defect for several reasons.  First, additional 
mutants used in this assay are also part of the reported dimerization domain 
(RR105 AA, Y115A), and their activity in supporting HIV-1 replication was 
significantly higher than that observed for the F/D mutants (Fig. 3.8, panels B and 
C)(8, 240).  Second, almost none of the Nef molecules expressed in cells have 
been shown to be present in dimers provided they retain their myristoyl anchor 
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(29).  This suggests that if dimerization of Nef were required for activity, the 
greatest portion of Nef present in the infected cell is inactive (240).  Lastly, Nef 
molecules from SIV and HIV have been shown to form heterodimers in solution 
despite lacking a structurally similar dimerization interface (157).  In light of this 
information, we hypothesize that the F/D mutation results in a Nef protein 
incapable of binding with a MOLT3 protein. 
In addition to the mutations disrupting the hydrophobic binding pocket, two 
additional point mutations in Nef also severely impacted replication in the MOLT3 
cell line.  The amino terminus of Nef is co-translationally modified by the addition 
of a myristic acid moiety which drives association of Nef with the plasma 
membrane (93).  Mutation of the amino terminal Gly residue to Ala removes the 
site of myristoyl attachment (99), and the resulting Nef molecule is unable to 
interact with the membrane.  As most of the interactions between Nef and the 
host cell are localized to membranes, removal of the membrane anchor of Nef is 
associated with phenotypes that mirror a complete lack of Nef (92, 93).  We 
report similar effects with regard to viral replication in the MOLT3 system.  
Interestingly, Lundquist and colleagues reported near wildtype levels of 
replication in PBMCs that had been infected with HIV-1 with a similar mutation in 
Nef (177).  This discrepancy could be explained by the fact that Lundquist used 
activated PBMCs, which have been shown to be less dependent on Nef for 
replication (177, 215).  Whether the difference between the two studies reflects a 
difference in experimental methodologies or indicates a specific role for 
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membrane associated Nef in the MOLT3 system, will need to be determined.  
However, the near-absolute dependence of HIV-1 on Nef for replication in 
MOLT3 cells indicates that the MOLT3 system is significantly more robust, and 
likely to reflect differences in Nef activity accordingly.   
A similar result was observed regarding the PP69,72AA mutant.  Again, 
Lundquist and colleagues reported no significant difference in the replication of 
an HIV-1 construct containing this mutation compared to HIV-1 NefWT in 
activated PBMCs (177).  However, in our hands, infection of MOLT3 cells with 
provirus containing this mutation resulted in reduced replication efficiency when 
compared to HIV-1 encoding WT Nef.  Our results show replication at levels 
more similar to virus lacking a functional nef allele (Fig. 3.8, panel A).  The 
polyproline motif of Nef has been shown to be an essential factor for lowering the 
threshold of T-cell activation by interacting with Src-family kinases such as Fyn 
and Lck, as well as with p21-associated protein kinase (PAK2), and a separate 
role for downregulation of CD4 has been indicated (105, 155, 215).  It is 
surprising that any mutation that affects the T-cell activation threshold is relevant 
in our replication studies, as MOLT3 cells infected with Nef mutants were not 
intentionally stimulated during the course of investigation. Based on previously 
published reports, it seems more likely that the results we obtained during testing 
of this mutant reflect an inability of Nef to affect actin rearrangement in non-
activated cells (105-107, 213).  A recent study by Haller et al. indicated a defect 
for actin rearrangement in Jurkat T-cells expressing Nefs in which either the 
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myristoylation site (G2A) or the PxxP motif (PP69,72AA) had been mutated (106).  
Using fluorescent microscopy they observed a ring of actin in TCR stimulated 
Jurkat T-cells that was disrupted upon expression of Nef and demonstrated that 
this defect was dependent on the actin polymerizing protein, N-WASP (105).  
The demonstrated defect of these two Nef mutants in promoting actin 
rearrangement may negatively impact the clustering of Gag and Env proteins at 
the virological synapse, a process previously shown to be actin-dependent (131).  
Disruption of VS formation would certainly explain the reduction in replication in 
the MOLT3 system.  Whether the suspected decrease in clustering of Gag and 
Env disrupts formation of the virological synapse or the assembly of viral 
particles at this site will need to be further investigated.      
Previous studies have reported that the presence of Nef provides the 
infected HIV-1 genome with a replication advantage in non-activated cells (215, 
277).  This advantage is directly related to the lowering of the activation threshold 
and results in increased expression of NFκB and other HIV-1 transcription 
factors, which in turn favor production of virus in these cells.  However, the 
advantage provided by Nef is ameliorated if the T-cells are activated prior to 
infection as both Nef-expressing  and Nef–deficient  virus have access to 
sufficient transcription factors (215).  We have found that HIV-1 containing a 
functional nef retains a profound replication advantage over Nef-deficient virus 
following infection of MOLT3 cells stimulated by the addition of TNFα (Fig. 3.10).  
This advantage is evident by the difference in replication kinetics observed 
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between stimulated MOLT3 cells infected with authentic HIV-1, HIV-1NefFS, or 
HIV-1 expressing Glyco-Gag in place of Nef (data not shown).  This replication 
advantage is separate from any difference in particle infectivity, as we have 
demonstrated that Glyco-Gag increases HIV-1 particle infectivity at levels 
comparable to those observed with bona fide Nef, and yet offers almost no 
advantage to replication in MOLT3 cells.     
In addition, we report that expression of HIV-1 in MOLT3 appears to be 
transient, and limited to a narrow timeframe of approximately 2-4 days 
immediately after infection; expression of Nef had no apparent effect on 
extending the period of viral expression.  Comparison of intracellular Gag levels 
from cells infected with either Nef-expressing or Nef-deficient virus displayed 
similar levels of the Gag polyprotein when analyzed by Western blot (Fig. 3.11).  
Analysis of lysates from a later timepoint showed no increase in Gag expression.  
Rather, a clear decrease in signal was observed compared to samples taken at 
an earlier timepoint, suggesting that transcription of Gag had ceased.  Taken 
together, we conclude that expression of HIV-1 in MOLT3 cells occurs for a 
limited time following infection, after which it is transcriptionally silenced by the 
host cell.  Although transcription of viral proteins from non-integrated HIV-1 
genomes has been reported (277), and integration was not confirmed for these 
experiments, we don’t believe that an integration defect explains our results.  
While it has also been reported that expression of Nef increases the success of 
viral integration into host genomes (277), we failed to observe any differences in 
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the level of transcription, as measured by Gag expression, between WT and Nef-
deficient strains 
The results of our various replication studies are generally consistent with 
previously published results regarding an increase in replication efficiency by 
HIV-1 in the presence of Nef (177).  However, in the MOLT3 system the 
requirement for Nef is far more pronounced.  The difference in replication 
efficiency observed between authentic HIV-1 and HIV-1 expressing Glyco-Gag in 
place of Nef, despite the similar infectivity of individual particles, suggests Nef 
alone is able to enhance the spread of HIV-1 via cell-cell transmission.  
Expression of Nef has previously been shown to increase cell-cell transmission 
by stimulating actin arrangement, clustering of lipid raft microdomains, as well as 
increasing the formation of filopodia and nanotubes (131, 200, 213).  The results 
of our mutational analysis of Nef are compatible with a role for actin remodeling, 
raft clustering and formation of cellular processes in the MOLT3 system.  As any 
of the Nef-associated activities listed above could individually explain our 
findings, additional investigation to determine the specific mechanism will need to 
be undertaken. 
In light of the limited time frame of viral expression observed in this cell 
line, an increase in cell-cell transmission efficiency also provides a suitable 
explanation for the results we have observed.  In our replication assays, MOLT3 
cells infected with Nef-deficient virus often display their highest level of virus 
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release within 2-4 days after the initial infection, followed by a decrease in viral 
particle release over the duration of the respective experiments.  This could 
indicate that Nef-deficient virus is less efficient at spreading from cell-cell than is 
WT, and that once this initial transmission opportunity is missed, not enough viral 
proteins are being produced for continued replication.  As cell-to-cell transfer of 
HIV-1 is considered the primary mode of HIV-1 viral dissemination, we submit 
that the MOLT3 cell line provides an excellent system to study this phenomenon. 
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Future Directions 
 
While the data we have obtained to date investigating the role of Nef in the 
replication of HIV-1 in the MOLT3 system are enough to suggest a possible 
mechanism, additional experiments will need to be undertaken to verify these 
theories.  The expression of Nef from Group N and SIV viruses induced a 
reduction in the cell surface levels of the CXCR4 viral coreceptor, confounding 
our interpretation of their effects on replication.  In order to get a clearer 
understanding of whether these Nefs are capable of supporting replication of 
Nef-deficient HIV-1 we intend to generate cell lines that stably express the 
specific Nef proteins as well stably express CXCR4, and then determine their 
activity in our Nef in trans system.  It is our hope that increased levels of this 
receptor will enable us to obtain clearer results regarding the activity of these 
viral proteins.   
In addition, we would like to better characterize the Nef K92A mutation, 
which showed a significant defect in replication enhancement when compared to 
the Nef WT protein, despite showing WT levels of activity with regard to CD4 and 
MHC-I downregulation.  At this time, no other publications have reported a 
function for this residue in any Nef-induced effect, e.g. enhanced replication, 
infectivity increase, or interaction with any cell protein.  Interestingly, mutation of 
the neighboring residue in Nef (E93) had shown a robust enhancement of 
replication in our system and exceeded even that of WT Nef (data not shown), 
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suggesting that the effect of the K92A mutation is specific.  Using flow cytometry 
and antibodies directed against CD4 and MHC-I molecules we have shown that 
this mutant is active in both regards (data not shown), again further indicating a 
defect in a specific function rather than a defect in activity due to improper folding 
or expression.  We intend to investigate the activity of this Nef mutant in actin 
rearrangement using an assay similar to that published by Haller (106).  Jurkat T-
cells will be transfected with a GFP vector, as well as vectors expressing specific 
Nef proteins, and their adherence to fibronectin will be used as an indication of 
actin cytoskeletal stability.  Further analysis of actin structure can be undertaken 
using the actin specific dye phalloidin.  In addition to determining the activity of 
the K92A mutation, we also plan on investigating the activities of both the 
membrane-binding defective G2A mutant and the PP69,72AA mutant in this assay. 
In order to test whether the increase in replication efficiency in the MOLT3 
system is dependent on an increase in cell to cell transfer two separate 
experimental methods can be undertaken.  The first would separate the infected 
producer cells from the target cells by the insertion of a transwell insert that will 
allow for the free diffusion of viral particles while preventing contact between the 
two cell populations.  Target cells can then be assayed for presence of viral 
genomes or viral protein expression (p24).  The second method requires the 
gentle agitation of the infected cells to prevent the formation of cell to cell 
contacts, although what effect this method has on virus to cell transmission is 
questionable. 
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  Lastly, the massive defect in replication enhancement observed in Nef 
mutants disrupting the hydrophobic pocket/dimerization domain suggest that 
interaction with a cellular protein may play a significant role in this process.  In an 
effort to identify potential cell proteins involved in this process we have opted to 
immunoprecipitate HA-tagged Nef proteins from MOLT3 cells which stably 
express either WT Nef or Nef mutants that have been shown to abrogate the 
replication enhancement.  Towards this end we have created cell lines 
expressing codon-optimized, HA-tagged versions of the Group M, Clade C Nef of 
96ZM651, which displayed a robust effect in our Nef in trans assay system.  The 
cell lines generated thus far include the WT version of the Nef 96ZM651, as well 
as a D123A and K92A version of this construct as potential negative controls, as 
well as cell lines containing the Groups N and O Nefs and the ARF6 protein as a 
non-Nef control.  Cell proteins that interact with the respective Nefs will be 
determined by MudPit analysis of the complete precipitate. 
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Materials and Methods 
Virus production and infections.  Replication competent virus was generated 
by transfection of HEK293T cell with 2 µg of WT HIV-1 proviral vector using a 
calcium phosphate technique.  Infectious particles of Nef-deficient HIV-1 (NefFS), 
HIV-1 encoding a portion of the MLV Glyco-Gag in place of Nef, or HIV-1 
containing the indicated Nef mutant were generated similarly.  Cells were 
washed six hours after transfection and fed with fresh DMEM+10% FBS.  
Twenty-four hours after transfection, supernatant was removed, cells were 
pelleted with low speed centrifugation, and supernatant was filtered through 2µm 
filter.  Titer of released virus was determined using a p24 sandwich plate ELISA 
(prepared on site by CFAR).  Equivalent levels of virus, as determined by ELISA 
were used to inoculate target cells.  Twenty-four hours post-infection, infected 
cells were washed with RPMI +10% FBS and resuspended in fresh media.  
Samples of supernatant were removed from infections periodically, spun to 
remove suspended cells, and frozen for future quantification of virus release 
using p24 ELISA.   
Generation of stable cell lines.  The pCX4bsr-CD4ΔCT retroviral vector was 
generated by PCR cloning of CD4 from a previously described vector and 
inserting the sequence into the BamHI and NotI sites of pCX4bsr (Acc. No. 
AB086384).  Infectious VSV-G pseudotyped virus was made in 293T cells with 
calcium phosphate technique using 2 µg of pCX4pur-CD4ΔCT as well as 2 µg 
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MLV Gag-pol, and 0.2 µg of VSV-G envelope.  Twenty-four hrs after transfection, 
the supernatant was removed and cleared by low speed centrifugation (1,200 
rpm, 5 mins, 4ºC) followed by passage through a 0.2 µm syringe filter.  Five-
hundred microliters of cleared supernatant was used to infect 5.0x105 MOLT3 
cells.  Twenty-four hrs after infection, cells were washed to remove unbound 
virus and resuspended in RPMI + 10% FBS containing blasticidine ( 0.5 µg/ml) 
for selection of cells containing a successfully integrated gene.    
Vectors used to stably express HA-tagged Nef proteins were cloned from 
their respective vectors by PCR using primers contain restriction sites for BamHI 
and EcoRI and inserted in the pCX4pur (Acc. No. AB08386)  at the BamHI and 
EcoRI sites.  The Nefs used in these experiments were: LAI and SF2 (subtype B, 
Acc. No. K02013 and K02007, respectively), 96ZM651 and 97ZA012 (subtype C, 
Acc. No. AF286224 and AF286227, resp.), 93BRO020 (subtype F, Acc. No. 
005494) and 90CF056 (subtype H, Acc. No. 005496).  Plasmids containing 
codon optimized, HA-tagged versions of Group N (YBF30, Acc. No. AJ006022) 
and Group O (MVP8161 Acc. No. AY536905) were ordered from Genewiz.  
These genes were used as templates for PCR and insertion into the same 
pCX4pur vector.   
Generation of HIV-1 proviral constructs:  Proviral vectors expressing full-
length HIV-1 (NL4-3), HIV-1 NefFS (containing a FS mutation in the Nef gene 
resulting in a premature stop codon at residue 35 of Nef), and HIV-1ΔNef-Glyco-
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Gag (containing the gene for an active portion of Glycosylated Gag from the MLV 
in place of the endogenous Nef gene) have been described previously (236).  
Full length proviral constructs containing Nef point mutations were generated 
from a series of NefLAI expression vectors previously made as follows.  The 
portion of full length NL4-3 genome contained between the XhoI and NcoI 
restriction sites were inserted in the pTZ18U polylinker plasmid.  The region of 
the NL4-3 Nef gene contained between the KpnI and BspEI was replaced by the 
corresponding region from the expression vector encoding the point mutation in 
HIV-1LAI Nef.  Following sequence verification, the XhoI-NcoI fragment 
containing the NL4-3/LAI hybrid Nef was inserted back into full-length NL4-3.  
This strategy was used to generate full-length NL4-3-based vectors for all Nef 
point mutations. 
Derivation of NL4-3 envelope mutants:     
 Vectors expressing the NL4-3 proviral clone of HIV-1 containing the D368R 
mutation in Env were generated using the Stratagene QuickChange XL Site-
Directed Mutagenesis kit (Cat# 200516, Stratagene, La Jolla, CA) and the NL4-3 
Env protein as a template.  Following sequence verification, the region from NheI 
to BamHI of Env was transferred into the corresponding restriction sites of the full 
length plasmids encoding wild type NL4-3 and NL4-3 containing the Nef frame-
shift previously described. 
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Flow Cytometry: 
Cell surface expression of CD4 and CXCR4 was determined by staining target 
cells with anti-CD4 (BD Biosciences ) or anti-CXCR4 (BD Biosciences ).  Isotype 
controls were used to determine cross-reactivity (IgG1a for CD4-BD Bio and 
IgG2κ for CXCR4 – BD Bio).  Cell were stained in 0.5% BSA in PBS at 4ºC for 1 
hr, washed and then stained with the fluorophore-conjugated secondary (PE-
mouse and human Jackson) for one hour.  Data was collected by UMASS 
Medical School FACS core, and analyzed using the FlowJo software suite 
(version 7.6.5). 
 
Infectivity assay: 
 Infectious virions were generated by expressing proviral constructs 
encoding either NL4-3 WT, NL4-3 Nef FS, or NL4-3 Glyco-Gag in HEK293T cells 
using a calcium phosphate transfection technique.  Viral titers were quantified by 
determination of soluble p24 in supernatants using sandwich ELISA to detect that 
protein.  MOLT3 cells were inoculated with either 10 ng of supernatant from NL4-
3 WT or 100 ng of supernatant from NL4-3 Nef FS or NL4-3 Glyco-Gag 
producing cells.  Virus released from the MOLT3 cells was collected and p24 
levels determined by ELISA.  This virus was introduced to 5.0x104 TZM-bl cells, a 
HeLa derived reporter cell line that expresses CD4, CCR5 and CXCR4 and will 
express β-galactosidase upon infection with HIV-1 in a Tat-dependent manner.  
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Following infection, the cells were washed to remove unbound virus and treated 
with the protease inhibitor Saquinavir (1 µM/ml) to limit infection to a single 
round.  Cells were lysed and the β-gal expression was quantified using an ONPG 
reporter system (Promega E2000).  All sample conditions were done in triplicate 
and means +/- SEM are reported. 
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Chapter IV 
General Discussion 
 In this thesis I have presented data from my research into the mechanism 
of NEDD4 stimulated release of HIV-1 particles.  I have shown that NEDD4 
activity is dependent on the presence of the partial C2 domain of the ubiquitin 
ligase which serves as a Gag targeting module sufficient to drive interaction of 
divergent HECT domains with viral particles.  I have also demonstrated that the 
ability of NEDD4 family members to rescue release of HIV-1 particles requires 
the ability of these HECT domains to form K63-polyubiquitin chains.  In addition, I 
have presented data from on-going research investigating the activities of Nef on 
HIV-1 replication in the MOLT3 system.  To date, my findings demonstrate that 
Nef-induced downregulation of surface CD4 levels does not account for the 
enhancement of HIV-1 replication observed in the presence of Nef.  I have also 
shown that a range of lentiviral Nef proteins retain the ability to enhance HIV-1 
replication in this cell line, indicating the observed enhancement is a function 
conserved in Group M  and N Nef proteins.  In addition, I report the observation 
that equally infectious HIV-1 particles display different replication efficiencies in 
MOLT3 cells, demonstrating that these two functions of Nef are separable.  This 
finding, coupled with the apparently narrow window of viral gene expression, 
suggests that the observed enhancement of HIV-1 replication induced by Nef 
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expression is due to an increase in cell-to cell-spread in culture early after the 
initial infection.    
In the introduction I presented a brief overview of important events in the 
replication cycle of HIV-1 in an effort to impress upon the reader the manner in 
which this relatively small virus is able to manipulate its host cell to replicate.  In 
the microcosm that is the host cell the virus will come into contact with all manner 
of proteins and pathways that may positively or negatively impact the ability of 
the virus to replicate.  A successful virus must adapt to ensure that the majority of 
these interactions have a net positive effect on its own replication cycle.  HIV-1 
has gone to extraordinary lengths to achieve this, as evidenced by the reported 
activities of NEDD4 and Nef presented here.     
Although addressed separately in this thesis, the roles of Nef and ESCRT 
in the formation and release of virus particles may overlap significantly to 
cooperatively enhance the assembly and infectivity of HIV-1 virions.  In 
increasing the lipid raft content of the plasma membrane, either through 
increasing the number of lipid rafts or their size (37, 237, 323), Nef expression 
could have the added effect of increasing the efficiency of ESCRT-mediated 
particle release.  The mechanism of ESCRT mediated membrane scission is still 
unknown (118), and although recruitment of enzymatically active VPS4 is 
required (116), the current literature suggests that its function is primarily to 
disassemble ESCRT-III complexes into component subunits (164).  Release of 
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enveloped viral particles that are not reliant on ESCRT recruitment may provide 
some insight into ESCRT function.  In contrast to HIV-1, release of Influenza 
virus is not dependent on the ESCRT machinery (35).  A recent report by 
Rossman et al describing the budding of Influenza virus suggested that the M2 
protein of Influenza was able to induce particle release by altering the line 
tension of the membrane from which it budded (256).  In light of the findings of 
this group the question has risen as to whether membrane line tension plays a 
role in ESCRT-mediated membrane scission (118).  In order to address this 
topic, an understanding of the chemistry and biophysics of lipid rafts must first be 
considered. 
 Lipid rafts are nano-scale membrane domains (10-200 nm) found 
dispersed throughout the plasma membrane (232).  The existence of lipid rafts, 
or detergent-resistant microdomains (DRM), has remained somewhat 
controversial due to intensive purification strategies required to isolate them 
(303).  However, more recent microscopic studies have provided evidence of 
their existence in living cells, and have also helped in further indentifying their 
components (232, 303).   
 Containing a higher concentration of cholesterol and sphingomyelin 
relative to the surrounding plasma membrane (232), lipid rafts are enriched in 
transmembrane proteins such as GM1, and tetraspanins (232, 303).  
Additionally, proteins such as actin and cofilin have also been shown to be 
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enriched on the cytosolic leaflet of these domains, indicating a specific 
connection with the cell cytoskeleton (232).  Some researchers have questioned 
whether interaction with the cell cytoskeleton prevents aberrant formation of large 
clusters, and thus protects PM integrity (316).  For example, in giant unilamellar 
vesicles (GUVs) containing phospholipid concentrations similar to those 
observed with authentic lipid rafts, clustering of raft-phospholipids can lead to 
spontaneous budding and fission of the membrane (15). 
This spontaneous fission process is thought to be driven by the 
energetically favorable release of line tension that exists between the lipid raft 
and the surrounding membrane (15).  As the existence of lipid rafts has become 
increasingly accepted, and the apparent importance of these domains in 
membrane mediated processes in the cell becomes clearer, biophysical theories 
have been generated to explain experimental observations.  One such theory 
addresses the physical ordering of the lipids present in both rafts and the 
surrounding plasma membrane (174).  The increased levels of cholesterol and 
sphingomyelin present in lipid rafts impart a more structured orientation of the 
lipid tails prompting these microdomains to be referred to as liquid ordered (Lo), 
while the unsaturated fatty acid chains of the surrounding membrane are termed 
liquid disordered (Ld) (232). 
This difference in order also presents a difference in membrane thickness 
at these sites, with Lo regions being thicker than Ld regions due to the ability of 
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the tails of unsaturated fatty acids in the Ld phase to interact across the bilayer 
(232).  Line tension between the two disparate domains is created by the 
interaction of the hydrophilic head groups of the Ld phase with the hydrophobic 
tails of the lipid rafts (Lo), with the resulting line tension being proportional to the 
circumference of the lipid raft.  If the raft approaches an appreciable size, in the 
micrometer scale, it is more energetically favorable for the raft to deform and 
bud, reducing the line tension by decreasing the circumference of the raft(15, 
300).  It has been suggested that interaction of lipid rafts with the cytoskeleton 
helps protect against this spontaneous action by preventing clustering of rafts. 
Interestingly, several biological functions are thought to make use of this 
difference in line tension in generating membrane bound vesicles in the cell.  For 
example, it has been suggested that formation of transport vesicles in the trans-
Golgi network is the result of protein mediated generation of line tension, and a 
similar process has been proposed to explain the activity of dynamin in 
endocytosis (258).  A recent paper has suggested that dynamin serves to both 
constrict the membrane to form a bud neck while simultaneously inducing lipid 
domain segregation, resulting in the enrichment of Lo domains in the forming 
vesicle, and Ld regions in the bud neck (174).  This induction of line tension 
between the vesicle and bud neck may cause scission of the membrane at the 
interphase between ordered and disordered regions, resulting in vesicle release 
(174).  One wonders if a similar process can account for the ESCRT mediated 
scission of membranes observed in the release of HIV-1.  In contrast to dynamin, 
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which supports the bud neck from the outside of the membrane (174), ESCRT-III 
proteins support the bud neck from the inside (77).  Otherwise, the actions of 
these proteins appear quite similar, which is to support the Ld membrane during 
the process of membrane budding.  
In addition to mediating membrane scission it has also been suggested 
that recruitment of ESCRT proteins may also play a significant role in deforming 
the plasma membrane, particularly at sites of negative membrane curvature 
(313).  While an effect on membrane deformation has been shown in GUVs 
treated with purified ESCRT proteins (313), one wonders what role they play in 
the lipid raft rich membrane associated with HIV-1 nef expression.  Research into 
the composition of the viral envelope indicates that it is enriched for lipid raft 
components (36, 324), suggesting also that this membrane composition is 
present during the process of particle assembly (303).  This has also been 
demonstrated in studies reporting that Gag associates with and clusters lipid rafts 
during virus formation (210, 211, 217).  Interestingly, it has recently been 
published that ESCRT-II also clusters lipid rafts prior to formation of MVB through 
recognition of ubiquitinated cargo (28).  Thus, although HIV-1 does not utilize 
ESCRT-II proteins for release, a similar action is still required, in this case one 
accomplished by the viral protein, further illustrating the conserved relationship 
between lipid rafts and ESCRT-mediated activity.   
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Clustering of rafts large enough to support the formation of a single virus 
particle could generate significant line tension between the Lo and Ld regions of 
the membrane, encouraging membrane deformation and formation of the viral 
bud .  This curvature is no doubt further enhanced by the presence of the Gag 
lattice itself, which also promotes positive membrane curvature of the membrane 
bud (31).  Perhaps more important than this positive membrane curvature, is the 
zone of negative curvature referred to as the bud neck (313).  Years of study into 
the role of ESCRT proteins in the formation and release of MVBs has resulted in 
the theory that the bud neck is formed through stepwise recruitment of ESCRT-0, 
ESCRT-I and ESCRT-II complexes, which localize to the bud neck and may act 
to impart the negative membrane curvature observed (313).  However, this may 
not be the case.  Again, recent studies into the activities of other vesicle-forming 
events in the cell provide an insight into potential alternative theories.   
Mechanically formed vesicles generated by pulling a microbead bound to 
a cellular membrane results in the separation of the heterogeneous membrane 
into Lo and Ld regions, with the portion attached to the bead (the vesicle) 
composed predominantly of Lo lipids and the connecting membrane tube (bud 
neck) composed of Ld lipids (258).  Interestingly, formation of a vesicle in the 
absence of segregation of Lo and Ld domains not only fails to release but will 
eventually resolve back into heterogeneous membrane (121, 152), suggesting 
that more than just mechanical manipulation of membranes is necessary for 
membrane scission and vesicle release.  While similar studies have not been 
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reported for ESCRT-mediated vesicle formation, it is possible that ESCRT-III 
proteins perform a similar function and stabilize Gag-induced lipid segregation at 
the bud neck, rather than directly imposing the observed negative membrane 
curvature.   
An additional consideration is the role that ESCRT protein recruitment 
may play not only in stimulating the release of virus particles, but also in 
determining the concentration of Gag present in the budding virus.  Moloney 
Murine Leukemia Virus (MoMLV) lacking all three of its late domains was 
recently shown to be capable of low levels of release and replication in an 
ESCRT-independent manner (260).  Indeed, despite a reliance on ESCRT 
proteins for release from most cell lines, infectious HIV-1 particles lacking a 
functional Late-domain are able to release from certain T-cell lines (i.e. Jurkat) 
although at lower levels than WT HIV-1 (118).  Interestingly, the reliance on 
ESCRT mediated release by HIV-1 also seems to depend on the presence of 
cholesterol in the host cell membrane (118), as L-domain deficient HIV-1 was 
able to assemble and release from T-cells deprived of cholesterol by MβCD or 
statin treatment, but not from untreated cells (218).  Thus, a decrease in lipid raft 
content in the plasma membrane also decreases retroviral reliance on the 
ESCRT machinery for release.  These findings may suggest that the ability of 
retroviruses to recruit ESCRT proteins provides more than just a way for the virus 
to exit infected cells, and instead may indicate a functional role for ESCRT 
recruitment in particle assembly.    
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A series of cryoelectron tomography studies is illustrative in this regard.  
These studies, which were mentioned before in Chapter I, used cET to image 
immature HIV-1 viruses as they budded from the host cell membrane (42, 67, 
68).  One study in particular imaged budding of HIV-1 particles in MT-4 cells, 
from HIV-1 genomes expressed at physiological levels (42).  The authors found 
that the overall structure of the mature HIV-1Gag lattice was formed during 
assembly and maintained during budding, indicating authentic viral particle 
formation (42). Interestingly, they also observed a subset of budding viruses that 
appeared to lack the density corresponding to the condensed NC-RNA core, 
which also contained a higher concentration of Gag compared to productively 
budding virus (42).  The authors reasoned that this structure arose from 
prematurely activated viral protease, which is often observed in L-domain 
phenotypes (42).  As the L-domain containing region of HIV-1 is present in the p6 
fragment of Gag, downstream of NC, premature cleavage at the NC site removes 
the ability of Gag to recruit ESCRT proteins (68).  Thus, the increase in nascent 
viral Gag content in this subset of budding virus may indicate that recruitment of 
the ESCRT proteins are important not just for release of the viral particle, but 
also for determining the number of HIV-1 Gag molecules present in the virus, 
possibly by formation of the structure referred to as the bud neck which is an 
area of negative membrane curvature localized the region between the positively 
curving virus bud and the surrounding plasma membrane.  
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The previous findings that Late-domain deficient HIV-1 and MoMLV virus 
can bud and release in the absence of ESCRT recruitment (260), albeit at 
significantly reduced levels, further suggest that ESCRT recruitment is not 
specifically required for virus release per se.  Analysis of data from the Moloney 
Murine Leukemia Virus study may provide insight into understanding a potential 
second role for ESCRT recruitment.  In this study, MoMLV was shown to 
assemble and release low levels of replication competent virus in the absence of 
all functional L-domains, and therefore ESCRT complex recruitment (260).  
Investigating the contents of the released viruses, the authors reported a 
significant increase in the levels of viral capsid present in the L-domain deficient 
viruses compared to WT virus capable of recruiting ESCRT proteins (260).  
These findings may indicate that more Gag molecules were incorporated into the 
particles released from the cells infected with MoMLV lacking a functional L-
domain compared to WT MoMLV (260), and suggest that recruitment of ESCRT 
machinery may play a role in particle assembly by limiting the amount of Gag 
able to associate with the nascent virus.  This theory is supported by the results 
of a live-imaging study of infected cells by Jouvenet et al. (138).  Using GFP-Gag 
fusion proteins, the authors observed consistent recruitment of Gag to sites of 
particle assembly, followed by a short time during which no new Gag was 
recruited prior to release (138).  Again, this may imply that formation of the bud 
neck may limit Gag recruitment to the nascent virus by sealing it off from the host 
cell cytoplasm.  Assuming that formation of the bud neck limits HIV-1 virus 
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recruitment of Gag to some optimal level for the formation of infectious virus, one 
wonders whether formation of this bud neck is benefited by an increase in the 
lipid raft content of the membrane.  Again, formation of large lipid rafts is believed 
to induce significant membrane curvature away from the cytoplasm in an effort to 
reduce line tension (31).  Reduction in line tension, through formation of the 
budding membrane, would result in a smaller area of contact between the Ld and 
Lo domains (15), and the formation of bud neck-like structure.  This structure, 
although likely larger than an authentic bud neck, would still have less surface 
area than the inner membrane of the budding virus and should in principle slow 
recruitment of Gag to the virus.  Thus, it is conceivable that expression of Nef, 
which stimulates a commensurate increase in lipid raft content in the host cell 
membrane (323), may positively affect HIV-1 particle assembly by inducing the 
formation of a bud neck-like structure which limits Gag recruitment to an optimal 
level.  Subsequent recruitment of ESCRT proteins may further narrow the bud 
neck and definitively stop Gag recruitment to virus assembly sites (138).  
Recruitment of ESCRT proteins to the bud neck may then stabilize the 
segregation of Lo and Ld regions stimulating membrane scission (77).   
   This idea is not specifically novel, as several labs have investigated the 
relative levels of Gag and Gag-subunit proteins in viruses produced in the 
presence or absence of Nef biochemically (37, 79, 250, 266).  However, if there 
is a difference in the levels of Gag and Gag-pol proteins present in a optimally 
infectious virus particle compared to other particles, the difference is likely to be 
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slight.  A number of reports have indicated that little or no difference exists in the 
protein content of particles generated under these conditions (37, 79, 250, 266).  
In addition, these studies have reported no difference in the association of Gag 
with lipid rafts regardless of Nef expression (37, 250, 266).  However, these 
studies are limited by several fundamental flaws, not the least of which is a major 
logical tautology. 
In an effort to determine the relative levels of Gag- and Gag-pol-related 
proteins present in particles generated in the presence or absence of Nef, 
several of these studies have equalized the amount of input virus based on the 
either the reverse transcriptase activity or concentration of p24 in the respective 
samples (4, 37, 192, 266).  Not surprisingly, after equalizing the amount of p24 
containing particles, no difference in the relative levels of viral proteins was 
observed when samples were separated via SDS-PAGE, in either released 
particles or in DRM (4, 37, 266).  While these findings are important in 
demonstrating that there are no significant disparities in the composition of 
virions-meaning disproportionately more reverse transcriptase to nucleocapsid, 
for example- the method fails to take into account the overall amount of Gag and 
Gag-pol present in each particle.  The recent imaging studies of budding particles 
are particularly illustrative in this regard, and suggest that the partial lattice of 
Gag observed in these structures may denote a specific concentration of Gag 
required for membrane deformation and thus affect the formation of an infectious 
particle (42, 68).  Some undetermined minimal amount of Gag must be 
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necessary to induce membrane curvature, and likewise, to form the bud neck.  
Thus, viral particles containing too much or too little of Gag and Gag-pol in total 
may still show the same ratio of viral elements, but not the appropriate 
concentration for assembly of a virus with optimal infectivity.  In this regard it may 
be beneficial to consider what role lipid rafts play in determining the overall 
concentration of Gag in the budding virus.  However, due to the relationship 
between membrane lipid raft content and Gag assembly a different method of 
sample standardization will be required. 
The current literature supports a model in which two copies of the 
retroviral genome are contained within the HIV-1 core (7).  Assuming this to be 
accurate, then a strict quantification of HIV-1 genomes in a given preparation of 
virus should be sufficient to standardize samples prior to comparison of viral 
protein content.  A previous study, investigating the relationship between Nef and 
virus content compared both the Gag levels and genome numbers in virus 
generated in the presence and absence of Nef, reported no difference in either 
component (266).  Again, this group first standardized their samples by 
determining p24 levels in the virus samples prior to separation via SDS-PAGE 
(266).  Interestingly, when analyzing the RNA content of these samples by 
hybridization with a probe against the HIV-1 genome, this group also reported no 
difference despite observing a significant disparity in probe signal at lower 
concentrations, with a greater signal coming from the Nef+ virus; no suitable 
explanation for this interpretation was presented in that manuscript (266).  The 
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difference in genome content would have accounted for the modest effects (7-10 
fold increase in the presence of Nef) in Nef-induced infectivity they reported after 
standardizing input samples for p24 level (266).  A separate investigation by 
Aiken and Trono presented hybridization signals more closely matched in 
intensity than the previous study (266), but also a narrower range of genome 
dilution (0 ng, 10 ng and 25 ng of p24-standardized virus)(4).  Certainly, a more 
exacting quantification of viral genomes, such as a Taqman assay, is necessary 
to determine what may be a very subtle difference in HIV-1 viral proteins.  If a 
difference in the ratio of viral genomes to p24 is determined this would provide a 
suitable standard for the comparison virus produced in Nef expressing and Nef 
deficient cells, and allow for more direct comparison of the associated viral 
proteins.   
Unfortunately, no single virus assay exists to specifically determine the 
components of a given particle using standard biochemical techniques.  Lacking 
this type of assay the field is forced to study particles in the aggregate making 
assumptions of individual particles based on the observations of the whole viral 
population.  In order to overcome this deficiency a larger number of parameters 
will need to be assessed to make comparisons between different populations.  
Absent a reliable standard, biochemically determining the effects of Nef on the 
assembly of viral particles will remain a question yet to be completely answered. 
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However, if Nef expression impacts particle assembly by acting like 
ESCRT proteins to form a bud neck to limit Gag recruitment, then data could 
conceivably be obtained using imaging strategies similar to those of Jouvenet et 
al (138).  Total internal reflection microscopy (TIRF) would allow for the 
observation of GFP-Gag fusion assembly at the plasma membrane under a 
variety of experimental conditions.  Using the fluorescence intensity of viral 
particles assembled in the absence of Nef as a baseline, the effects of Nef 
expression in the presence and absence of ESCRT proteins could easily be 
determined.  An increase in the fluorescence signal above that observed from the 
baseline sample (i.e. assembly of “WT” GFP-Gag particles) would indicate an 
increase in GFP-Gag recruitment, while a decrease would suggest the opposite, 
reduced recruitment of Gag.  Using these parameters the effects of Nef 
expression, ESCRT participation, and cholesterol on Gag recruitment could be 
directly determined.  These experiments have the potential to add insight into 
finally determining the role that Nef expression may play in the assembly and 
release of infectious HIV-1 particles. 
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Appendix 
 
Regulation of CHMP4/ESCRT-III Function in Human Immunodeficiency Virus 
Type I Budding by CC2D1A(293) 
 
Yoshiko Usami, Sergei Popov, Eric R. Weiss, Christie Vriesema-Magnuson, 
Arianna Calistri, and Heinrich G. Gottlinger. 
Journal of Virology.  2012, 86(7) 
 
 Release of HIV-1 virions by the host cell requires the recruitment of 
proteins of the ESCRT pathway which promote scission of the viral envelope 
from the plasma membrane.  Scission is accomplished through the recruitment 
and activation of the ESCRT-III subunit proteins known as CHMPs which 
associate with the inner leaflet of the plasma membrane at bud sites.  A recent 
siRNA based study has found that release of HIV-1 particles relies predominantly 
on the actions of two ESCRT-III subunits, CHMP2 and CHMP4. 
 In this paper, our lab addressed the function of CC2D1A and CC2D1B 
proteins on release of HIV-1 through the regulation of the ESCRT-III subunit 
CHMP4B .  Both proteins, CC2D1A and CC2D1B, were identified as potential 
targets of investigation based on microsequencing analysis of proteins that 
specifically interacted with CHMP4B.  Subsequent experiments demonstrated 
that CCD21A overexpression inhibits HIV-1 release; more specifically, 
overexpression of this protein inhibited ALIX-mediated of HIV-1, a process known 
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to be reliant on interaction between ALIX and CHMP4B.  In contrast, siRNA 
mediated knock down of CC2D1A and CC2D1B were shown to increase HIV-1 
budding, as would be expected if CC2D1A/B played a negative role in CHMP4B 
regulation.  Also, a series of immunoprecipitation experiments indicated that the 
interaction between CC2D1A and CHMP4B relies heavily on the presence of the 
DM14 domains of CC2D1A, specifically the third of four linear domains.  In 
addition, it was shown that CC2D1A interacts with the N-terminal helical hairpin 
of the CHMP4B protein, and not the C-terminal site that has been shown to play 
a role in ALIX recruitment.       
 
 My contributions to the paper involved creating N-terminal truncation 
mutants for constructs based on the CHMP4B1-153 core fragment.  These 
constructs were used to investigate the minimal region of CHMP4B required to 
behave as an inhibitor to virus release.  In addition, I performed an experiment 
designed to test whether co-expression of CCD21A with ALIX led to inhibition of 
particle release.  As mentioned, ALIX-mediated release of the HIV-1ΔPTAPP 
construct requires recruitment of CHMP4B by the Bro1 domain of ALIX.  The 
data I generated indicated that expression of ALIX alone was sufficient to rescue 
release of HIV-1ΔPTAPP particles, but co-expression of both ALIX and CC2D1A 
vectors failed to stimulate release of viral particles to any extent greater than that 
observed with empty vector alone.  Lastly, I analyzed the release of HIV-1 
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particles from 293T cells that had been treated with siRNA directed against either 
CC2D1A or CC2D1B or both.  This experiment, which was performed in tandem 
with the lead author of this paper and returned the same results, demonstrated 
that the knockdown of endogenous levels of CC2D1A or CC2D1B increased the 
release of HIV-1 particles.  These results confirmed the previous findings in the 
paper that these proteins behave as regulators of CHMP4B activity in the release 
of HIV-1. 
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